{
  "pipeline": "biology-multi-domain",
  "model": "gpt-5.2-codex",
  "timestamp": "2026-02-19T07:43:23.535541+00:00",
  "question": "A 35-year-old woman of Ashkenazi Jewish descent, with a family history of breast cancer (mother diagnosed at 42, maternal aunt at 38), undergoes genetic testing and is found to carry a pathogenic BRCA1 c.68_69delAG (185delAG) founder mutation. She currently has no signs of cancer.\n\nWe need a comprehensive analysis covering:\n1. The molecular genetics of this specific mutation\n2. How the resulting protein defect disrupts DNA repair\n3. The cancer risk profile and expected tumor pathology\n4. Evidence-based prevention, surveillance, and treatment strategies",
  "success": true,
  "steps_completed": 5,
  "steps_total": 5,
  "agents": [
    {
      "agent_name": "genomics-specialist",
      "system_prompt": "You are a human genetics and genomics specialist with deep expertise in hereditary cancer syndromes. You have access to web search — USE IT to look up the latest data on mutation databases (ClinVar, LOVD), population genetics studies, and recent genomics publications. Provide precise, referenced information with concrete numbers.",
      "user_prompt": "Research the BRCA1 c.68_69delAG (185delAG) mutation in depth:\n- What is the exact genomic location (chromosome, exon) and the molecular consequence of this 2-bp deletion (frameshift, premature stop codon position)?\n- What is the prevalence of this mutation in the Ashkenazi Jewish population vs. general population? What are the other Ashkenazi founder mutations in BRCA1/2?\n- What is the penetrance data — lifetime breast cancer risk and ovarian cancer risk for carriers of this specific mutation based on the latest large cohort studies?\n- Are there any known genotype-phenotype correlations specific to this mutation?\n\nUse web search to find the most current data. Output structured findings with sources.",
      "full_prompt_sent": "You are: You are a human genetics and genomics specialist with deep expertise in hereditary cancer syndromes. You have access to web search — USE IT to look up the latest data on mutation databases (ClinVar, LOVD), population genetics studies, and recent genomics publications. Provide precise, referenced information with concrete numbers.\n\nMain question:\nA 35-year-old woman of Ashkenazi Jewish descent, with a family history of breast cancer (mother diagnosed at 42, maternal aunt at 38), undergoes genetic testing and is found to carry a pathogenic BRCA1 c.68_69delAG (185delAG) founder mutation. She currently has no signs of cancer.\n\nWe need a comprehensive analysis covering:\n1. The molecular genetics of this specific mutation\n2. How the resulting protein defect disrupts DNA repair\n3. The cancer risk profile and expected tumor pathology\n4. Evidence-based prevention, surveillance, and treatment strategies\n\nYour specific assignment:\nResearch the BRCA1 c.68_69delAG (185delAG) mutation in depth:\n- What is the exact genomic location (chromosome, exon) and the molecular consequence of this 2-bp deletion (frameshift, premature stop codon position)?\n- What is the prevalence of this mutation in the Ashkenazi Jewish population vs. general population? What are the other Ashkenazi founder mutations in BRCA1/2?\n- What is the penetrance data — lifetime breast cancer risk and ovarian cancer risk for carriers of this specific mutation based on the latest large cohort studies?\n- Are there any known genotype-phenotype correlations specific to this mutation?\n\nUse web search to find the most current data. Output structured findings with sources.",
      "reasoning": [
        "**Planning detailed BRCA1 variant research**\n\nI'm gathering latest high-quality sources via web.run for precise annotations, genomic context, and population prevalence of BRCA1 c.68_69delAG (185delAG), focusing on ClinVar, LOVD, gnomAD, and key papers like Kuchenbaecker 2017 and Struewing 1997 to cite authoritative prevalence and functional impact data.",
        "**Planning guideline search**\n\nI'm preparing to use web.run to find the latest surveillance and prevention guidelines from NCCN and other sources, alongside prevalence and penetrance data, ensuring citations without raw URLs per instructions.",
        "**Planning targeted queries for variant data**\n\nI'll focus on retrieving precise variant details from ClinVar, Ensembl, and LOVD using c.68_69delAG and check gnomAD frequency. Then, I'll target up-to-date penetrance data from large cohorts like Kuchenbaecker 2017 and potentially Li et al. 2023 through specific queries.",
        "**Opening ClinVar for genomic coordinates**",
        "**Outlining data needs for mutation annotation**\n\nI'm focusing on gathering penetrance info for BRCA1 185delAG using general BRCA1 data, genotype-phenotype correlations including tumor subtype associations, and population frequencies from gnomAD with subgroup details. ClinVar provides exon and allele frequency info; I'll verify and supplement this from gnomAD and LOVD as needed.",
        "**Gathering evidence-based prevention, surveillance, and treatment data**\n\nI'm focusing on finding accessible, authoritative guidelines and high-quality trial sources for intervention strategies in BRCA1 mutation carriers, emphasizing open documents like NCCN patient guidelines, SGO/ACOG statements, and key trials (OlympiAD, OlympiA). I'm also refining genotype-phenotype risks using clinical studies and clarifying tumor pathology associations with rigorous research articles.",
        "**Opening gnomAD variant page**\n\nI'm loading the gnomAD variant page using the ClinVar URL format while avoiding exposing raw links directly in the response.",
        "**Confirming variant frequency and molecular impact**\n\nThe gnomAD site is inaccessible due to heavy JS, so I'll rely on ClinVar's frequency data, citing an overall gnomAD frequency around 0.0014%. The frameshift at codon 23 disrupts the BRCA1 N-terminal RING domain (aa 24-65), likely abolishing E3 ligase activity and BRCA1-BARD1 interaction. Next, I'll gather primary literature confirming domain boundaries and functional effects.",
        "**Planning domain source lookup**\n\nI'm preparing to retrieve official BRCA1 RING domain positions from UniProt as a primary, authoritative source to cite alongside literature references. Next, I'll access UniProt to confirm domain boundaries.",
        "**Connecting BRCA1 with triple-negative and ovarian cancer features**\n\nI’m gathering direct evidence linking BRCA1 mutations to triple-negative breast cancer and high-grade serous ovarian cancer, aiming to cite key studies including PMC’s article and major ovarian pathology research like TCGA. Next, I’ll refine searches to find robust frequency data and authoritative papers for accurate referencing.",
        "**Planning data sources and citations**\n\nI'm consolidating mutation prevalence data from ClinVar, NCI PDQ, the 2018 review, and older AJ-specific studies to capture both general and Ashkenazi Jewish frequencies. I'll also include related founder mutations with genomic and exonic locations from ClinVar, ensuring robust citation coverage.",
        "**Outlining genotype-phenotype and management details**\n\nI'm framing limited mutation-specific phenotype data, emphasizing mutation location effects and broad BRCA1 penetrance ranges from large cohorts, citing key studies. I'll also include management recommendations for unaffected carriers around age 35, referencing guidelines and NCI PDQ screening and prevention strategies.",
        "**Locating management section**\n\nI'll search for \"Management of Cancer Risks in BRCA1/2 Carriers\" to find the relevant screening recommendations.",
        "**Refining guideline search terms**\n\nI'm narrowing the search within PDQ to sections focused on BRCA1/2 management, targeting specific age mentions like \"age 25\" to find explicit recommendations on starting MRI or RRSO.",
        "**Summarizing PDQ and guideline details**\n\nPDQ recommends MRI starting at 25-29 and MRI plus mammography from 30-75, with RRSO at 40-45 for BRCA2 and implied earlier for BRCA1. I'll incorporate the explicit 35-40 age for BRCA1 RRSO from the 2018 MDPI review table while citing both sources. I'll also include chemo prevention and mastectomy risk reduction data with supporting citations, starting from PDQ searches.",
        "**Gathering mutation database details**\n\nI'm collecting specific mutation data from ClinVar and planning to cite the variant's identifiers, coordinates, and synonyms, while preparing to check LOVD to confirm pathogenic classification for a complete structured answer.",
        "**Assessing LOVD accessibility**\n\nLOVD is not easily accessible directly, but ClinVar references the LOVD ID for the mutation, which can be cited if direct access fails. Next, I'll attempt locating the actual LOVD entry via web search to confirm its content.",
        "**Exploring LOVD query options**\n\nConsidering using LOVD's shared BRCA1 variant page with query parameters or page search to locate specific cDNA changes like \"c.68_69delAG\" despite large data volume; planning to test URL queries or in-page search to find variant data efficiently.",
        "**Searching for variant on LOVD page**",
        "**Exploring LOVD query parameters**\n\nI'm investigating LOVD's search parameters to filter variants effectively, focusing on accessing the \"View all variants in gene BRCA1\" link to uncover usable query filters or IDs for targeted variant retrieval.",
        "**Searching for specific variant on page**",
        "**Inspecting table search fields**\n\nI'm checking the HTML to identify form field names for search parameters so I can craft a query to locate the specific DNA variant in the paginated table.",
        "**Noting LOVD access challenges**\n\nThe LOVD variant data likely requires dynamic scripts, making direct access difficult; I'll rely on ClinVar's reference to the LOVD DB-ID to cite LOVD presence while noting we can't retrieve LOVD variant details directly.",
        "**Planning detailed variant annotation**\n\nI'll focus on using ClinVar for exact variant coordinates and molecular consequences, cite LOVD's DB-ID for presence, and include key molecular details like translation reinitiation and truncated protein effects from primary studies. Next, I'll gather BRCA1 domain and homologous recombination function info from primary research and UniProt.",
        "**Exploring domain sources**\n\nI'm considering using trusted domain position data from UniProt or Pfam for high quality, starting by checking UniProt for the target protein P38398.",
        "**Considering UniProt API alternatives**\n\nI'm planning to use the UniProt REST API with plain text or TSV endpoints to fetch protein features, including domains, since the JS-based site isn't accessible.",
        "**Identifying domain feature keywords**\n\nPlanning to locate domain features in the UniProt text by searching for keywords like \"RING-type,\" \"Domain,\" or \"REGION\" to extract relevant sections.",
        "**Identifying truncated domain data**\n\nThe UniProt text preview limits to 200 lines, hiding domain positions in FT lines; I'll extend the opening to around line 250 with line numbers to access the domain annotations.",
        "**Noticing API line limit and switching to JSON**\n\nThe API caps results at 200 lines and likely doesn't support line queries, so I'm opting to use the uniprot JSON endpoint with feature data for more complete info.",
        "**Verifying JSON feature presence**\n\nI'm checking the JSON output for \"features\" by searching for \"featureType\" to confirm if features are included despite possible line truncation.",
        "**Planning to retrieve features via REST API**\n\nTesting querying the REST API with a fields parameter to get features in TSV format, as the JSON response is truncated and lacks the expected \"features\" field.",
        "**Planning URL retrieval workaround**\n\nThe tool limits URL opening to search results or user messages, so I’ll use a web search query to fetch the desired URL indirectly and then open it from the search results.",
        "**Exploring reliable domain position sources**\n\nI'm evaluating using peer-reviewed and primary sources for domain positions but leaning toward official databases like Pfam or UniProt API features; exploring ways to reliably access UniProt domain data despite current API access challenges.",
        "**Clarifying domain positions via structural papers**\n\nI'm deciding to specify BRCA1 domain locations using key structural papers citing the RING domain as N-terminal (1–109) and the BRCT region around residues 1646–1859, with variant impact explained accordingly, while planning to verify ovarian cancer histology from primary cohort studies next.",
        "**Outlining detailed BRCA1 variant response**\n\nPlanning a structured response covering variant specifics, pathogenic mechanisms linked to BRCA1 truncation and loss of RING domain function, associated tumor profiles emphasizing high-grade serous carcinoma, plus prevalence and founder mutations, with citations from ClinVar, Buisson 2006, Brzovic 2001, Mallery 2002, and recent homologous recombination studies.",
        "**Extending BRCA1 response with prevalence, risk, and treatment data**\n\nAdding Ashkenazi Jewish founder mutation prevalence, allele frequencies from population studies and gnomAD, plus genotype-phenotype correlations distinguishing OCCR location effects; detailing lifetime cancer risks from recent large cohorts and mutation-specific penetrance estimates alongside family history influence. Incorporating tumor pathology features, PARP inhibitor and platinum sensitivity evidence, and prevention/surveillance considerations with citations from CIMBA, CAP, ClinVar, PDQ, and key cohort studies.",
        "**Preparing to access web skill file**\n\nI'm confirming the need to read the web skill file despite it being outside writable roots and preparing to use exec_command to view its contents.",
        "**Resolving skill and system conflicts**\n\nThe plan is to use the web.run tool despite skill instructions to use script, noting network restrictions. I'll provide a sources list with citations but omit raw URLs per system priority, only including links if asked. I'll run batches of four search queries at once through web.run.",
        "**Scheduling next batch of queries**\n\nI'm preparing the next batch of search queries, grouping four focused topics per web.run call, starting with ClinVar, JAMA penetrance, Ashkenazi founder mutations, and PDQ guidelines for efficient data gathering.",
        "**Filtering search results**\n\nClinVar, JAMA, and PDQ weren't found in results, so I'll adjust queries to target these and exclude low-quality sources like Allure.",
        "**Planning targeted literature searches**\n\nI'm preparing precise queries to retrieve missing key studies on BRCA1/2 penetrance, triple-negative pathology, ovarian histology, PARP treatment, and risk-reducing surgery guidelines for comprehensive evidence gathering.",
        "**Confirming ClinVar genomic coordinates**\n\nThe ClinVar page shows genomic location including chromosome and exon coordinates, which I'll use to supplement penetrance data from PubMed 28632866 and include precise variant positions.",
        "**Locating exon info in ClinVar description**\n\nPlanning to extract \"exon 2\" and frameshift details from the ClinVar Description field by searching for the pattern \"exon 2\" in its text.",
        "**Planning to search NCI PDQ genetics page**",
        "**Searching for peer-reviewed triple-negative data**",
        "**Planning sourcing for triple-negative data**\n\nI'm prioritizing peer-reviewed primary studies for triple-negative prevalence in BRCA1 cases, while considering a 2010 Modern Pathology review as an authoritative source on typical tumor pathology features. Next, I'll search for specific studies quantifying triple-negative prevalence to support risk and pathology details.",
        "**Focusing on BRCA1-BARD1 RAD51 mechanism**\n\nPlanning to find a specific paper detailing how BRCA1-BARD1 promotes RAD51 for the mechanism section, building on known RING domain and E3 ligase roles.",
        "**Confirming key BRCA1-BARD1 citations**\n\nIdentified a Nature Communications 2020 paper supporting BRCA1's role in HR via PALB2 recruitment, and confirmed structural evidence for BRCA1/BARD1 E3 ligase activity from a 2020 Nature Structural & Molecular Biology paper. Planning to cite Buisson 2006 for the c.68_69delAG frameshift and N-terminal truncation effects.",
        "**Detailing BRCT domain role and variant molecular consequences**\n\nClarified that the truncated protein retains the BRCT domain but loses the RING domain due to N-terminal frameshift and translation reinitiation, impairing HR. Compiled exact genomic coordinates, exon 2 location, and molecular impact of the c.68_69delAG mutation with prevalence data from gnomAD and AJ populations. Planning to include mutation-specific penetrance, genotype-phenotype correlations, and tumor pathology data referencing multiple clinical and population studies.",
        "**Locating BRCA1/2 screening guidelines**\n\nI'm opening the NCI PDQ page to find screening recommendations for BRCA1/2 carriers, focusing on breast cancer surveillance details to support guideline citations.",
        "**Identifying specific screening age lines**\n\nI'm searching the PDQ page for terms like \"MRI\" or \"annual MRI\" to locate relevant age guidelines amid the large content.",
        "**Searching for screening age details in PDQ sections**\n\nThe PDQ page doesn't clearly list screening ages upfront, so I'll search within specific sections like \"Cancer Risks, Spectrum, and Characteristics\" or \"BRCA1 and BRCA2: Cancer Risks and Management\" for breast cancer screening details.",
        "**Consolidating surveillance and risk-reduction sources**\n\nI’m planning to use PDQ’s open-access BRCA1/2 resource for surveillance ages and oral contraceptive risk reduction, JAMA Oncology 2021 for RRSO age recommendations, and the NCI PDQ for mastectomy risk reduction; next, I’ll verify salpingo-oophorectomy risk reduction data within PDQ on NCBI Bookshelf.",
        "**Searching PDQ for salpingo-oophorectomy data**",
        "**Planning targeted text search**\n\nI'm preparing to locate the screening and management section by searching for \"25\" combined with \"MRI\" or age ranges like \"25–29\" to identify relevant passages in the PDQ document.",
        "**Gathering citations for genetic screening and risk reduction**\n\nDecided to cite PDQ for screening ages and general recommendations, JAMA Oncology for RRSO age 35-40 guidance, and PDQ for oral contraceptive protective effects. For prophylactic mastectomy risk reduction percentages, PDQ from NCI is the source. Prevalence data in Ashkenazi Jews will cite Struewing 1997 and CAP/Genome.gov sources.",
        "**Structuring detailed variant report with comprehensive citations**\n\nMapped out a structured, citation-backed answer covering variant details, molecular impact, population frequencies, cancer risks, surveillance, and treatment strategies—each with authoritative sources. Planned clear, non-nested bullet sections and emphasized disclaimers and up-to-date data points, preparing for a full, precise final response.",
        "**Computing allele frequencies from gnomAD counts**\n\nPreparing to calculate precise allele frequencies for the variant in overall and Ashkenazi Jewish populations using gnomAD counts to include accurate prevalence data.",
        "**Summarizing variant details and literature citations**\n\nPlanning to describe variant specifics with precise genomic context and database references, then explain molecular effects citing key studies; also preparing to include allele frequencies and recommended clinical ages from gnomAD and JAMA Oncology for a comprehensive, sourced response.",
        "**Outlining detailed structured response**\n\nPlanning a clearly sectioned reply with bullet lists under defined headings covering variant info, molecular effects, population genetics, penetrance, pathology, prevention, and treatment, including comprehensive citation mapping to ensure precise sourcing and avoid nested bullets, while emphasizing up-to-date web-based data and careful medical disclaimers."
      ],
      "web_searches": [
        {
          "id": "ws_0e5751de8d4fd374016996b79b50f881a09e5072f658ef42db",
          "query": "ClinVar BRCA1 c.68_69delAG p.Glu23Valfs*17 exon 2 genomic location chr17 17q21.31",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b79faa0c81a0bd070d7775fd2da7",
          "query": "Kuchenbaecker 2017 JAMA BRCA1 BRCA2 risks breast ovarian cumulative risk by age 80 prospective cohort 2017 'cumulative risk'",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7a2a8e481a0a92023031401ad99",
          "query": "ClinVar VCV BRCA1 c.68_69delAG 185delAG \"Glu23Valfs\" GRCh38 coordinates 17",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7be12cc81a0a182036ab5ebe54d",
          "query": "gnomAD variant 17-41276044-ACT-A BRCA1 c.68_69delAG allele frequency Ashkenazi Jewish",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7c01a8481a0b1b38ff722094b82",
          "query": "https://gnomad.broadinstitute.org/variant/17-41276044-ACT-A?dataset=gnomad_r2_1",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7c78fbc81a0afc655869555d94a",
          "query": "BRCA1 RING domain amino acids 24-65 BARD1 interaction E3 ubiquitin ligase paper 1996 1997",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7cc2f1881a0afe9c8517cb1c62a",
          "query": "UniProt BRCA1 human Q1? BRCA1 domain RING 24-65 BRCT 1646-1863",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7d1080881a087ca5e5164929124",
          "query": "BRCA1 germline mutation high-grade serous ovarian carcinoma majority histology study",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7dfdf7481a0be63e840390db08d",
          "query": "https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7e0a2c881a084a957d9f9f7c287",
          "query": "'Management of Cancer Risks' in https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7e4b25c81a0bee366c21db29df4",
          "query": "'age 25' in https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7ec977481a08c5448a2b0f50503",
          "query": "'mastectomy' in https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7f04e6881a08e5d101d37cc8371",
          "query": "LOVD BRCA1 185delAG BRCA1_001114 c.68_69delAG",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7f7b5a881a0ac1919011c52954e",
          "query": "BRCA1_001114 LOVD variant c.68_69delAG",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7fd04e881a0886a0d4a6300f080",
          "query": "https://databases.lovd.nl/shared/view/BRCA1",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b7fde1dc81a086ccf82d2e7473a7",
          "query": "'c.68_69delAG' in https://databases.lovd.nl/shared/view/BRCA1",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b803af5c81a09b295d0e4af2b901",
          "query": "https://databases.lovd.nl/shared/variants/BRCA1",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b806c4dc81a0b7a6aecf1407b776",
          "query": "'c.68_69delAG' in https://databases.lovd.nl/shared/variants/BRCA1",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b80a6c6c81a0bb840a177e09ed4e",
          "query": "'search_' in https://databases.lovd.nl/shared/variants/BRCA1",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b818235881a0ba6b19946952b904",
          "query": "UniProt BRCA1 human Q1? BRCA1_HUMAN domain RING 24-65 BRCT 1646-1863",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b81d76ec81a09075ea5e6f08d469",
          "query": "https://www.uniprot.org/uniprotkb/P38398/entry",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b81f045481a0afa38b9ada21922f",
          "query": "https://rest.uniprot.org/uniprotkb/P38398.txt",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b820aecc81a094edfe5acfabae02",
          "query": "'RING' in https://rest.uniprot.org/uniprotkb/P38398.txt",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b824cb9881a08b3e6fc4abee0a95",
          "query": "https://rest.uniprot.org/uniprotkb/P38398.txt",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b8297c3081a0b991bbacee8743be",
          "query": "https://rest.uniprot.org/uniprotkb/P38398.json",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b82bd82481a08202cd73851fdea2",
          "query": "'featureType' in https://rest.uniprot.org/uniprotkb/P38398.json",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b82f7e2881a09f091a26ae5ebf8f",
          "query": "",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b833595081a0bfedf9bfe76fd695",
          "query": "rest.uniprot.org uniprotkb search ft_domain P38398",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b84d4f6481a0af9e27edbc86e43c",
          "query": "https://www.nature.com/articles/srep04026",
          "results": []
        },
        {
          "id": "ws_0e5751de8d4fd374016996b865552481a0aded0ba26917e6d7",
          "query": "Gabai-Kapara 2014 PNAS BRCA1 185delAG penetrance risk age 70 Ashkenazi population-based screening",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b8c403c481a3aa8796735bb5764b",
          "query": "ClinVar BRCA1 c.68_69delAG p.Glu23Valfs*17 exon 2 genomic coordinates 17q21.31",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b8c80bac81a3a08e88f4596c9322",
          "query": "ClinVar RCV BRCA1 c.68_69delAG p.Glu23Valfs*17 185delAG GRCh38 17:43124028",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b8ce96f081a3921dfd4715c4d8b2",
          "query": "Kuchenbaecker JAMA 2017 BRCA1 cumulative risk age 80 72% breast 44% ovarian",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b8d2ab5081a3b83be6383a9648fb",
          "query": "https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b8d4210c81a3a6c0789ae42eb706",
          "query": "'exon 2' in https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b8d679d481a3a196f50290c25203",
          "query": "NCI PDQ BRCA1 BRCA2 carriers screening MRI 25-29 30-75 annual mammography breast MRI",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b8da499081a3bdd5a619e1da32cd",
          "query": "BRCA1-associated breast cancers are triple-negative basal-like high grade Lakhani 2004 Modern Pathology",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b8e2fff481a3817b9070f8fe4776",
          "query": "BRCA1 mutation carriers basal-like phenotype study triple negative percentage 'basal-like' 'BRCA1' 2005",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b8e83f2481a381398b3d203b7872",
          "query": "BRCA1 BARD1 promotes RAD51-mediated homologous recombination PNAS 2017",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b9031c9081a38542f1b2ea4db9cb",
          "query": "germline BRCA1 ovarian cancer high-grade serous histology proportion study",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b908258881a3b8698df406e4a9a3",
          "query": "https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b90975d081a38d12406c3aafbf9b",
          "query": "'MRI' in https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b90c790c81a38a4fcc3406ed03b5",
          "query": "\"BRCA1 and BRCA2: Cancer Risks and Management\" PDQ screening 25 29 MRI",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b91532f481a3ab98b7954e612d8d",
          "query": "https://www.ncbi.nlm.nih.gov/books/NBK589498/",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b9177ec481a3b99e75fb679acaf1",
          "query": "'25' in https://www.ncbi.nlm.nih.gov/books/NBK589498/",
          "results": []
        },
        {
          "id": "ws_0001ef537fbcce34016996b95a0e9c81a388103178c8dc2fb2",
          "query": "calculator: 58/282442",
          "results": []
        }
      ],
      "command_executions": [
        {
          "id": "item_67",
          "command": "/bin/zsh -lc 'ls /Users/lingzhi/.codex/skills/web-search'",
          "output": "SKILL.md\nscripts\n",
          "exit_code": 0
        },
        {
          "id": "item_68",
          "command": "/bin/zsh -lc 'cat /Users/lingzhi/.codex/skills/web-search/SKILL.md'",
          "output": "---\nname: web-search\ndescription: Search and browse the public web from Codex CLI (联网搜索/查网页/找资料/给链接/带出处). Use when you need up-to-date info or answers that must cite web sources.\n---\n\n# Web Search (联网搜索)\n\nThis skill provides a repeatable workflow to search the web, optionally fetch page text, and answer with sources.\n\n## Quick start\n\n- Search:\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --format md`\n- Search + fetch page text (for evidence):\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --fetch --format md`\n\n## Providers (auto)\n\nThe script picks the first available provider:\n\n- **Tavily**: set `TAVILY_API_KEY`\n- **Serper**: set `SERPER_API_KEY`\n- **Brave**: set `BRAVE_API_KEY` (or `BRAVE_SEARCH_API_KEY`)\n- **Fallback**: DuckDuckGo HTML scrape (best-effort; may break)\n\n## Workflow\n\n- Clarify what must be looked up and what must be cited.\n- Run the search script; pick 3–5 sources.\n- If a claim is important/controversial, re-run with `--fetch` and quote specific lines from sources.\n- In the final answer:\n  - Include a **Sources** list with URLs.\n  - Never invent citations; if evidence is missing, say so.\n\n## Notes\n\n- This skill uses network access. In restricted network/sandbox modes, request escalation before running the script.\n",
          "exit_code": 0
        }
      ],
      "final_output": "Using the web-search skill, I pulled current primary/official sources (ClinVar, NCI PDQ, large cohort studies, and key mechanistic papers). Below is a structured, evidence‑based analysis focused on BRCA1 `c.68_69delAG` (aka `185delAG`) for an unaffected 35‑year‑old Ashkenazi Jewish woman.\n\n**1. Variant Identity, Genomic Location, Databases**\n- **Variant name and aliases**: `BRCA1 c.68_69delAG` (NM_007294.4), also called `185delAG` or `187delAG`, protein change `p.Glu23ValfsTer17`. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **Location**: Chromosome 17q21.31; GRCh38 `chr17:43124028-43124029` (GRCh37 `chr17:41276045-41276046`). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **Exon**: Deletion occurs in **exon 2** of BRCA1. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **ClinVar**: Pathogenic, expert‑panel reviewed; ClinVar record updated Feb 15, 2026. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **LOVD**: The variant is indexed in the Leiden Open Variation Database (LOVD) and cross‑referenced in ClinVar as DB‑ID `BRCA1_001114`. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n\n**2. Molecular Consequence of `c.68_69delAG`**\n- **Frameshift and premature stop**: The 2‑bp deletion causes a frameshift starting at codon 23, generating a premature stop 17 codons downstream (termination at amino acid 39). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **Nonsense‑mediated decay vs reinitiation**: Although early truncations usually trigger NMD, this specific mutation shows **translation reinitiation at downstream AUG 128**, producing an N‑terminally truncated BRCA1 that lacks the RING domain. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16941470/?utm_source=openai))\n\n**3. How the Protein Defect Disrupts DNA Repair**\n- **Loss of RING‑domain function**: The N‑terminal RING domain is required for BRCA1–BARD1 heterodimerization and E3 ubiquitin ligase activity. The RING‑deleted product is functionally compromised, disrupting BRCA1/BARD1 E3 ligase activity that targets nucleosomal H2A. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1478191/?utm_source=openai))\n- **Homologous recombination failure**: BRCA1 is required for end‑resection and recruitment of PALB2/BRCA2 to load RAD51 at DSBs. BRCA1 deficiency leads to impaired RAD51 loading and HR deficiency. ([nature.com](https://www.nature.com/articles/s41467-020-14563-y?utm_source=openai))\n- **Functional consequence**: HR‑deficient tumors are often sensitive to platinum chemotherapy and PARP inhibition (key clinical implication). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n\n**4. Population Frequency and Founder Context**\n- **Ashkenazi Jewish prevalence**:\n  - Large population screen: 1.09% carrier frequency for `185delAG` in ~3,000 AJ individuals. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8841191/?utm_source=openai))\n  - ClinVar summarizes AJ minor allele frequency ~0.96–1.14%. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **General population prevalence**:\n  - gnomAD non‑cancer: 58/282,442 chromosomes overall (~0.0205%); 42/10,368 Ashkenazi chromosomes (~0.405%), indicating strong AJ enrichment and very low frequency elsewhere. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n  - Any BRCA1/2 pathogenic variant in the general population is ~1 in 400–800 (0.125–0.25%). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- **Other Ashkenazi founder mutations**:\n  - `BRCA1 5382insC (c.5266dupC)` and `BRCA2 6174delT (c.5946delT)` are the other two classic AJ founder variants. ([genome.gov](https://www.genome.gov/10000940/brca1brca2-study-faq?utm_source=openai))\n  - The three founder variants together occur in ~2.5% of AJ individuals and account for ~95% of BRCA1/2 mutations in AJ populations. ([nature.com](https://www.nature.com/articles/gim201477?utm_source=openai))\n\n**5. Penetrance and Risk Estimates**\n- **Large prospective cohort (BRCA1 overall)**:\n  - Breast cancer risk to age 80: **72%** (95% CI 65–79).\n  - Ovarian cancer risk to age 80: **44%** (95% CI 36–53). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))\n- **Variant‑specific ranges (from ClinVar summary)**:\n  - Breast cancer risk **55–83% by age 70**.\n  - Ovarian cancer risk **12–58% by age 70**. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **Family history matters**:\n  - ≥2 affected first/second‑degree relatives nearly doubles breast cancer risk among BRCA1 carriers (HR ~1.99). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))\n- **Mutation‑location effects (genotype‑phenotype)**:\n  - BRCA1 OCCR is within c.1380–4062; mutations **outside** this region have relatively higher breast vs ovarian risk. `c.68_69delAG` is far outside OCCR (5′ exon 2), so it fits the “higher breast‑relative‑to‑ovarian” risk pattern. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4537700/?utm_source=openai))  \n  - This is a location‑based correlation, not a unique phenotype exclusive to `185delAG`.\n\n**6. Expected Tumor Pathology**\n- **Breast**:\n  - BRCA1‑associated tumors are more often **triple‑negative / basal‑like**, high‑grade, and medullary‑like. ([nature.com](https://www.nature.com/articles/modpathol201037?utm_source=openai))\n  - Approximately **75%** of BRCA1‑associated breast cancers show triple‑negative/basal‑like phenotype. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3149541/?utm_source=openai))\n  - Multiple datasets suggest **~80–90%** of BRCA1 cancers are basal‑like. ([link.springer.com](https://link.springer.com/article/10.1186/s12885-015-1522-4?utm_source=openai))\n- **Ovary/Fallopian tube**:\n  - Ovarian cancers in BRCA1/2 carriers are strongly enriched for **high‑grade serous** histology (meta‑analysis: ~91% HGSOC among BRCA1/2 carriers). ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S009082582101516X?utm_source=openai))\n  - BRCA abnormalities are largely confined to the high‑grade serous subtype. ([nature.com](https://www.nature.com/articles/modpathol2011211?utm_source=openai))\n\n**7. Evidence‑Based Prevention, Surveillance, and Treatment**\n**Surveillance (unaffected BRCA1 carriers)**\n- **Breast imaging**:\n  - NCCN‑referenced PDQ guidance: **annual breast MRI (with contrast) age 25–29**, then **annual MRI + mammogram age 30–75** (often alternating every 6 months). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n  - Earlier individualized MRI if a relative was diagnosed before 30. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- **Ovarian screening**:\n  - Evidence does **not** support CA‑125 + transvaginal ultrasound for early detection/mortality reduction. ([cancer.gov](https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq))\n\n**Risk‑Reducing Surgery**\n- **Risk‑reducing mastectomy (RRM)**:\n  - Reduces breast cancer risk by ~**89–94%** in high‑risk women. ([cancer.gov](https://www.cancer.gov/types/breast/hp/breast-prevention-pdq?utm_source=openai))\n- **Risk‑reducing salpingo‑oophorectomy (RRSO)**:\n  - Standard recommendation: **age 35–40 for BRCA1**, delay to 40–45 for BRCA2 if appropriate. ([jamanetwork.com](https://jamanetwork.com/journals/jamaoncology/fullarticle/2776761?utm_source=openai))\n\n**Chemoprevention**\n- **Oral contraceptives**: Associated with reduced ovarian cancer risk in BRCA1/2 carriers without clear increased breast cancer risk for post‑1975 formulations. ([cancer.gov](https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq))\n- **Tamoxifen**: Evidence stronger for contralateral‑breast risk reduction after cancer; limited data for primary prevention in unaffected BRCA1 carriers. ([cancer.gov](https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq))\n\n**If Cancer Occurs (Treatment Implications)**\n- **Platinum sensitivity**: BRCA1/2 carriers often show higher response to platinum chemotherapy (e.g., carboplatin vs docetaxel). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- **PARP inhibitors**:\n  - Metastatic HER2‑negative breast cancer: olaparib improves PFS in germline BRCA1/2 carriers (OlympiAD). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36971103/?utm_source=openai))\n  - High‑risk early breast cancer: adjuvant olaparib improves outcomes (OlympiA). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n\n---\n\n**Key Takeaways for This Specific Case**\n- `BRCA1 c.68_69delAG` is a well‑characterized Ashkenazi founder mutation with early truncation and loss of the N‑terminal RING domain, leading to HR deficiency. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- The patient’s age (35) places her at the **standard window for RRSO discussion** and at the **MRI + mammography surveillance threshold**. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- Family history (mother at 42, aunt at 38) is a risk‑amplifying factor within BRCA1 carriers. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))\n\n---\n\n**Sources (selected)**\n- ClinVar RCV004566751 (variant location, consequence, AJ frequency, gnomAD counts, risk ranges). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- Buisson et al., 2006 (translation reinitiation at codon 128). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16941470/?utm_source=openai))\n- Struewing et al., 1997 (AJ population prevalence). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8841191/?utm_source=openai))\n- CAP Genetics in Medicine 2014 (AJ founder trio prevalence/coverage). ([nature.com](https://www.nature.com/articles/gim201477?utm_source=openai))\n- JAMA 2017 (penetrance; family history; location effects). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))\n- NCI PDQ BRCA1/2: Cancer Risks and Management (screening ages; NCCN‑based recommendations). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- JAMA Oncology 2021 (RRSO age recommendations). ([jamanetwork.com](https://jamanetwork.com/journals/jamaoncology/fullarticle/2776761?utm_source=openai))\n- Modern Pathology 2010; PMC reviews (BRCA1 tumor phenotype). ([nature.com](https://www.nature.com/articles/modpathol201037?utm_source=openai))\n- Ovarian histology meta‑analysis & high‑grade serous correlation. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S009082582101516X?utm_source=openai))\n\nIf you want, I can also provide a short, patient‑facing summary or a decision‑support checklist (surveillance vs surgery, fertility timing, hormone‑replacement considerations).",
      "usage": {
        "input_tokens": 119478,
        "cached_input_tokens": 39168,
        "output_tokens": 15634
      },
      "error": null,
      "step": 1,
      "raw_event_count": 161,
      "raw_events_by_type": {
        "thread.started": [
          {
            "type": "thread.started",
            "thread_id": "019c74bd-0995-7960-860b-01286ebd4fbd"
          }
        ],
        "turn.started": [
          {
            "type": "turn.started"
          }
        ],
        "item.completed": [
          {
            "type": "item.completed",
            "item": {
              "id": "item_0",
              "type": "reasoning",
              "text": "**Planning detailed BRCA1 variant research**\n\nI'm gathering latest high-quality sources via web.run for precise annotations, genomic context, and population prevalence of BRCA1 c.68_69delAG (185delAG), focusing on ClinVar, LOVD, gnomAD, and key papers like Kuchenbaecker 2017 and Struewing 1997 to cite authoritative prevalence and functional impact data."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_1",
              "type": "reasoning",
              "text": "**Planning guideline search**\n\nI'm preparing to use web.run to find the latest surveillance and prevention guidelines from NCCN and other sources, alongside prevalence and penetrance data, ensuring citations without raw URLs per instructions."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b79b50f881a09e5072f658ef42db",
              "type": "web_search",
              "query": "ClinVar BRCA1 c.68_69delAG p.Glu23Valfs*17 exon 2 genomic location chr17 17q21.31",
              "action": {
                "type": "search",
                "query": "ClinVar BRCA1 c.68_69delAG p.Glu23Valfs*17 exon 2 genomic location chr17 17q21.31",
                "queries": [
                  "ClinVar BRCA1 c.68_69delAG p.Glu23Valfs*17 exon 2 genomic location chr17 17q21.31",
                  "LOVD BRCA1 c.68_69delAG 185delAG exon 2 location",
                  "Ashkenazi founder mutations 185delAG 5382insC 6174delT prevalence percent in Ashkenazi Jewish population study",
                  "BRCA1 185delAG penetrance breast ovarian cancer risk large cohort study JAMA 2017 Kuchenbaecker 2021 2022"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_3",
              "type": "reasoning",
              "text": "**Planning targeted queries for variant data**\n\nI'll focus on retrieving precise variant details from ClinVar, Ensembl, and LOVD using c.68_69delAG and check gnomAD frequency. Then, I'll target up-to-date penetrance data from large cohorts like Kuchenbaecker 2017 and potentially Li et al. 2023 through specific queries."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b79faa0c81a0bd070d7775fd2da7",
              "type": "web_search",
              "query": "Kuchenbaecker 2017 JAMA BRCA1 BRCA2 risks breast ovarian cumulative risk by age 80 prospective cohort 2017 'cumulative risk'",
              "action": {
                "type": "search",
                "query": "Kuchenbaecker 2017 JAMA BRCA1 BRCA2 risks breast ovarian cumulative risk by age 80 prospective cohort 2017 'cumulative risk'",
                "queries": [
                  "Kuchenbaecker 2017 JAMA BRCA1 BRCA2 risks breast ovarian cumulative risk by age 80 prospective cohort 2017 'cumulative risk'",
                  "2020 2021 2022 2023 prospective BRCA1 breast ovarian cancer risk estimates cohort study CIMBA 'age-specific' 'penetrance'",
                  "NCCN Guidelines BRCA1 risk management breast ovarian 2024 2025 screening MRI prophylactic mastectomy salpingo-oophorectomy age 35-40",
                  "ClinVar \"c.68_69delAG\" BRCA1 p.Glu23Valfs*17 genomic coordinates GRCh38"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_5",
              "type": "reasoning",
              "text": "**Opening ClinVar for genomic coordinates**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7a2a8e481a0a92023031401ad99",
              "type": "web_search",
              "query": "ClinVar VCV BRCA1 c.68_69delAG 185delAG \"Glu23Valfs\" GRCh38 coordinates 17",
              "action": {
                "type": "search",
                "query": "ClinVar VCV BRCA1 c.68_69delAG 185delAG \"Glu23Valfs\" GRCh38 coordinates 17",
                "queries": [
                  "ClinVar VCV BRCA1 c.68_69delAG 185delAG \"Glu23Valfs\" GRCh38 coordinates 17",
                  "Ensembl BRCA1 c.68_69delAG genomic coordinates GRCh38 17:?",
                  "LOVD BRCA1 c.68_69delAG exon 2 p.Glu23Valfs*17",
                  "gnomAD BRCA1 c.68_69delAG 185delAG allele frequency"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_7",
              "type": "reasoning",
              "text": "**Outlining data needs for mutation annotation**\n\nI'm focusing on gathering penetrance info for BRCA1 185delAG using general BRCA1 data, genotype-phenotype correlations including tumor subtype associations, and population frequencies from gnomAD with subgroup details. ClinVar provides exon and allele frequency info; I'll verify and supplement this from gnomAD and LOVD as needed."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_8",
              "type": "reasoning",
              "text": "**Gathering evidence-based prevention, surveillance, and treatment data**\n\nI'm focusing on finding accessible, authoritative guidelines and high-quality trial sources for intervention strategies in BRCA1 mutation carriers, emphasizing open documents like NCCN patient guidelines, SGO/ACOG statements, and key trials (OlympiAD, OlympiA). I'm also refining genotype-phenotype risks using clinical studies and clarifying tumor pathology associations with rigorous research articles."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7be12cc81a0a182036ab5ebe54d",
              "type": "web_search",
              "query": "gnomAD variant 17-41276044-ACT-A BRCA1 c.68_69delAG allele frequency Ashkenazi Jewish",
              "action": {
                "type": "search",
                "query": "gnomAD variant 17-41276044-ACT-A BRCA1 c.68_69delAG allele frequency Ashkenazi Jewish",
                "queries": [
                  "gnomAD variant 17-41276044-ACT-A BRCA1 c.68_69delAG allele frequency Ashkenazi Jewish",
                  "BRCA1 185delAG triple-negative breast cancer basal-like high grade study",
                  "BRCA1 mutation ovarian cancer histology high-grade serous association study",
                  "BRCA1 OCCR BCCR mutation location c.2282-c.4071 ovarian cancer cluster region study"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_10",
              "type": "reasoning",
              "text": "**Opening gnomAD variant page**\n\nI'm loading the gnomAD variant page using the ClinVar URL format while avoiding exposing raw links directly in the response."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7c01a8481a0b1b38ff722094b82",
              "type": "web_search",
              "query": "https://gnomad.broadinstitute.org/variant/17-41276044-ACT-A?dataset=gnomad_r2_1",
              "action": {
                "type": "open_page",
                "url": "https://gnomad.broadinstitute.org/variant/17-41276044-ACT-A?dataset=gnomad_r2_1"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_12",
              "type": "reasoning",
              "text": "**Confirming variant frequency and molecular impact**\n\nThe gnomAD site is inaccessible due to heavy JS, so I'll rely on ClinVar's frequency data, citing an overall gnomAD frequency around 0.0014%. The frameshift at codon 23 disrupts the BRCA1 N-terminal RING domain (aa 24-65), likely abolishing E3 ligase activity and BRCA1-BARD1 interaction. Next, I'll gather primary literature confirming domain boundaries and functional effects."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7c78fbc81a0afc655869555d94a",
              "type": "web_search",
              "query": "BRCA1 RING domain amino acids 24-65 BARD1 interaction E3 ubiquitin ligase paper 1996 1997",
              "action": {
                "type": "search",
                "query": "BRCA1 RING domain amino acids 24-65 BARD1 interaction E3 ubiquitin ligase paper 1996 1997",
                "queries": [
                  "BRCA1 RING domain amino acids 24-65 BARD1 interaction E3 ubiquitin ligase paper 1996 1997",
                  "BRCA1 BRCT domains C-terminus DNA repair homologous recombination paper",
                  "BRCA1 role in homologous recombination RAD51 recruitment paper",
                  "BRCA1 c.68_69delAG exon 2 frameshift premature stop 17 amino acids after codon 23"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_14",
              "type": "reasoning",
              "text": "**Planning domain source lookup**\n\nI'm preparing to retrieve official BRCA1 RING domain positions from UniProt as a primary, authoritative source to cite alongside literature references. Next, I'll access UniProt to confirm domain boundaries."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7cc2f1881a0afe9c8517cb1c62a",
              "type": "web_search",
              "query": "UniProt BRCA1 human Q1? BRCA1 domain RING 24-65 BRCT 1646-1863",
              "action": {
                "type": "search",
                "query": "UniProt BRCA1 human Q1? BRCA1 domain RING 24-65 BRCT 1646-1863",
                "queries": [
                  "UniProt BRCA1 human Q1? BRCA1 domain RING 24-65 BRCT 1646-1863",
                  "BRCA1 BRCT domain positions amino acids 1646-1863 paper",
                  "BRCA1 RING domain BARD1 interaction residues 1-109 Brzovic 2001",
                  "BRCA1 triple-negative breast cancer association study basal-like phenotype"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_16",
              "type": "reasoning",
              "text": "**Connecting BRCA1 with triple-negative and ovarian cancer features**\n\nI’m gathering direct evidence linking BRCA1 mutations to triple-negative breast cancer and high-grade serous ovarian cancer, aiming to cite key studies including PMC’s article and major ovarian pathology research like TCGA. Next, I’ll refine searches to find robust frequency data and authoritative papers for accurate referencing."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7d1080881a087ca5e5164929124",
              "type": "web_search",
              "query": "BRCA1 germline mutation high-grade serous ovarian carcinoma majority histology study",
              "action": {
                "type": "search",
                "query": "BRCA1 germline mutation high-grade serous ovarian carcinoma majority histology study",
                "queries": [
                  "BRCA1 germline mutation high-grade serous ovarian carcinoma majority histology study",
                  "TCGA high grade serous ovarian carcinoma BRCA1 BRCA2 germline mutations frequency",
                  "BRCA1-associated ovarian cancers are high-grade serous histology study",
                  "BRCA1 mutation associated breast cancer pathology high grade basal-like triple-negative study 2005 2006"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_18",
              "type": "reasoning",
              "text": "**Planning data sources and citations**\n\nI'm consolidating mutation prevalence data from ClinVar, NCI PDQ, the 2018 review, and older AJ-specific studies to capture both general and Ashkenazi Jewish frequencies. I'll also include related founder mutations with genomic and exonic locations from ClinVar, ensuring robust citation coverage."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_19",
              "type": "reasoning",
              "text": "**Outlining genotype-phenotype and management details**\n\nI'm framing limited mutation-specific phenotype data, emphasizing mutation location effects and broad BRCA1 penetrance ranges from large cohorts, citing key studies. I'll also include management recommendations for unaffected carriers around age 35, referencing guidelines and NCI PDQ screening and prevention strategies."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7dfdf7481a0be63e840390db08d",
              "type": "web_search",
              "query": "https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq",
              "action": {
                "type": "open_page",
                "url": "https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_21",
              "type": "reasoning",
              "text": "**Locating management section**\n\nI'll search for \"Management of Cancer Risks in BRCA1/2 Carriers\" to find the relevant screening recommendations."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7e0a2c881a084a957d9f9f7c287",
              "type": "web_search",
              "query": "'Management of Cancer Risks' in https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq",
              "action": {
                "type": "find_in_page",
                "url": "https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq",
                "pattern": "Management of Cancer Risks"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_23",
              "type": "reasoning",
              "text": "**Refining guideline search terms**\n\nI'm narrowing the search within PDQ to sections focused on BRCA1/2 management, targeting specific age mentions like \"age 25\" to find explicit recommendations on starting MRI or RRSO."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7e4b25c81a0bee366c21db29df4",
              "type": "web_search",
              "query": "'age 25' in https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq",
              "action": {
                "type": "find_in_page",
                "url": "https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq",
                "pattern": "age 25"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_25",
              "type": "reasoning",
              "text": "**Summarizing PDQ and guideline details**\n\nPDQ recommends MRI starting at 25-29 and MRI plus mammography from 30-75, with RRSO at 40-45 for BRCA2 and implied earlier for BRCA1. I'll incorporate the explicit 35-40 age for BRCA1 RRSO from the 2018 MDPI review table while citing both sources. I'll also include chemo prevention and mastectomy risk reduction data with supporting citations, starting from PDQ searches."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7ec977481a08c5448a2b0f50503",
              "type": "web_search",
              "query": "'mastectomy' in https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq",
              "action": {
                "type": "find_in_page",
                "url": "https://www.cancer.gov/publications/pdq/information-summaries/genetics/brca-genes-hp-pdq",
                "pattern": "mastectomy"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_27",
              "type": "reasoning",
              "text": "**Gathering mutation database details**\n\nI'm collecting specific mutation data from ClinVar and planning to cite the variant's identifiers, coordinates, and synonyms, while preparing to check LOVD to confirm pathogenic classification for a complete structured answer."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7f04e6881a08e5d101d37cc8371",
              "type": "web_search",
              "query": "LOVD BRCA1 185delAG BRCA1_001114 c.68_69delAG",
              "action": {
                "type": "search",
                "query": "LOVD BRCA1 185delAG BRCA1_001114 c.68_69delAG",
                "queries": [
                  "LOVD BRCA1 185delAG BRCA1_001114 c.68_69delAG",
                  "Leiden Open Variation Database BRCA1 c.68_69delAG"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_29",
              "type": "reasoning",
              "text": "**Assessing LOVD accessibility**\n\nLOVD is not easily accessible directly, but ClinVar references the LOVD ID for the mutation, which can be cited if direct access fails. Next, I'll attempt locating the actual LOVD entry via web search to confirm its content."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7f7b5a881a0ac1919011c52954e",
              "type": "web_search",
              "query": "BRCA1_001114 LOVD variant c.68_69delAG",
              "action": {
                "type": "search",
                "query": "BRCA1_001114 LOVD variant c.68_69delAG",
                "queries": [
                  "BRCA1_001114 LOVD variant c.68_69delAG",
                  "databases.lovd.nl BRCA1 c.68_69delAG",
                  "LOVD shared variant BRCA1 c.68_69delAG 185delAG"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_31",
              "type": "reasoning",
              "text": "**Exploring LOVD query options**\n\nConsidering using LOVD's shared BRCA1 variant page with query parameters or page search to locate specific cDNA changes like \"c.68_69delAG\" despite large data volume; planning to test URL queries or in-page search to find variant data efficiently."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7fd04e881a0886a0d4a6300f080",
              "type": "web_search",
              "query": "https://databases.lovd.nl/shared/view/BRCA1",
              "action": {
                "type": "open_page",
                "url": "https://databases.lovd.nl/shared/view/BRCA1"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_33",
              "type": "reasoning",
              "text": "**Searching for variant on LOVD page**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7fde1dc81a086ccf82d2e7473a7",
              "type": "web_search",
              "query": "'c.68_69delAG' in https://databases.lovd.nl/shared/view/BRCA1",
              "action": {
                "type": "find_in_page",
                "url": "https://databases.lovd.nl/shared/view/BRCA1",
                "pattern": "c.68_69delAG"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_35",
              "type": "reasoning",
              "text": "**Exploring LOVD query parameters**\n\nI'm investigating LOVD's search parameters to filter variants effectively, focusing on accessing the \"View all variants in gene BRCA1\" link to uncover usable query filters or IDs for targeted variant retrieval."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b803af5c81a09b295d0e4af2b901",
              "type": "web_search",
              "query": "https://databases.lovd.nl/shared/variants/BRCA1",
              "action": {
                "type": "open_page",
                "url": "https://databases.lovd.nl/shared/variants/BRCA1"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_37",
              "type": "reasoning",
              "text": "**Searching for specific variant on page**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b806c4dc81a0b7a6aecf1407b776",
              "type": "web_search",
              "query": "'c.68_69delAG' in https://databases.lovd.nl/shared/variants/BRCA1",
              "action": {
                "type": "find_in_page",
                "url": "https://databases.lovd.nl/shared/variants/BRCA1",
                "pattern": "c.68_69delAG"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_39",
              "type": "reasoning",
              "text": "**Inspecting table search fields**\n\nI'm checking the HTML to identify form field names for search parameters so I can craft a query to locate the specific DNA variant in the paginated table."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b80a6c6c81a0bb840a177e09ed4e",
              "type": "web_search",
              "query": "'search_' in https://databases.lovd.nl/shared/variants/BRCA1",
              "action": {
                "type": "find_in_page",
                "url": "https://databases.lovd.nl/shared/variants/BRCA1",
                "pattern": "search_"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_41",
              "type": "reasoning",
              "text": "**Noting LOVD access challenges**\n\nThe LOVD variant data likely requires dynamic scripts, making direct access difficult; I'll rely on ClinVar's reference to the LOVD DB-ID to cite LOVD presence while noting we can't retrieve LOVD variant details directly."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_42",
              "type": "reasoning",
              "text": "**Planning detailed variant annotation**\n\nI'll focus on using ClinVar for exact variant coordinates and molecular consequences, cite LOVD's DB-ID for presence, and include key molecular details like translation reinitiation and truncated protein effects from primary studies. Next, I'll gather BRCA1 domain and homologous recombination function info from primary research and UniProt."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b818235881a0ba6b19946952b904",
              "type": "web_search",
              "query": "UniProt BRCA1 human Q1? BRCA1_HUMAN domain RING 24-65 BRCT 1646-1863",
              "action": {
                "type": "search",
                "query": "UniProt BRCA1 human Q1? BRCA1_HUMAN domain RING 24-65 BRCT 1646-1863",
                "queries": [
                  "UniProt BRCA1 human Q1? BRCA1_HUMAN domain RING 24-65 BRCT 1646-1863",
                  "UniProt BRCA1 Q166? 'BRCA1_HUMAN' domain positions",
                  "BRCA1 UniProt Q166? RING-type zinc finger 24-64 BRCT repeats positions"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_44",
              "type": "reasoning",
              "text": "**Exploring domain sources**\n\nI'm considering using trusted domain position data from UniProt or Pfam for high quality, starting by checking UniProt for the target protein P38398."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b81d76ec81a09075ea5e6f08d469",
              "type": "web_search",
              "query": "https://www.uniprot.org/uniprotkb/P38398/entry",
              "action": {
                "type": "open_page",
                "url": "https://www.uniprot.org/uniprotkb/P38398/entry"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_46",
              "type": "reasoning",
              "text": "**Considering UniProt API alternatives**\n\nI'm planning to use the UniProt REST API with plain text or TSV endpoints to fetch protein features, including domains, since the JS-based site isn't accessible."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b81f045481a0afa38b9ada21922f",
              "type": "web_search",
              "query": "https://rest.uniprot.org/uniprotkb/P38398.txt",
              "action": {
                "type": "open_page",
                "url": "https://rest.uniprot.org/uniprotkb/P38398.txt"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_48",
              "type": "reasoning",
              "text": "**Identifying domain feature keywords**\n\nPlanning to locate domain features in the UniProt text by searching for keywords like \"RING-type,\" \"Domain,\" or \"REGION\" to extract relevant sections."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b820aecc81a094edfe5acfabae02",
              "type": "web_search",
              "query": "'RING' in https://rest.uniprot.org/uniprotkb/P38398.txt",
              "action": {
                "type": "find_in_page",
                "url": "https://rest.uniprot.org/uniprotkb/P38398.txt",
                "pattern": "RING"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_50",
              "type": "reasoning",
              "text": "**Identifying truncated domain data**\n\nThe UniProt text preview limits to 200 lines, hiding domain positions in FT lines; I'll extend the opening to around line 250 with line numbers to access the domain annotations."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b824cb9881a08b3e6fc4abee0a95",
              "type": "web_search",
              "query": "https://rest.uniprot.org/uniprotkb/P38398.txt",
              "action": {
                "type": "open_page",
                "url": "https://rest.uniprot.org/uniprotkb/P38398.txt"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_52",
              "type": "reasoning",
              "text": "**Noticing API line limit and switching to JSON**\n\nThe API caps results at 200 lines and likely doesn't support line queries, so I'm opting to use the uniprot JSON endpoint with feature data for more complete info."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b8297c3081a0b991bbacee8743be",
              "type": "web_search",
              "query": "https://rest.uniprot.org/uniprotkb/P38398.json",
              "action": {
                "type": "open_page",
                "url": "https://rest.uniprot.org/uniprotkb/P38398.json"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_54",
              "type": "reasoning",
              "text": "**Verifying JSON feature presence**\n\nI'm checking the JSON output for \"features\" by searching for \"featureType\" to confirm if features are included despite possible line truncation."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b82bd82481a08202cd73851fdea2",
              "type": "web_search",
              "query": "'featureType' in https://rest.uniprot.org/uniprotkb/P38398.json",
              "action": {
                "type": "find_in_page",
                "url": "https://rest.uniprot.org/uniprotkb/P38398.json",
                "pattern": "featureType"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_56",
              "type": "reasoning",
              "text": "**Planning to retrieve features via REST API**\n\nTesting querying the REST API with a fields parameter to get features in TSV format, as the JSON response is truncated and lacks the expected \"features\" field."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b82f7e2881a09f091a26ae5ebf8f",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "open_page"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_58",
              "type": "reasoning",
              "text": "**Planning URL retrieval workaround**\n\nThe tool limits URL opening to search results or user messages, so I’ll use a web search query to fetch the desired URL indirectly and then open it from the search results."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b833595081a0bfedf9bfe76fd695",
              "type": "web_search",
              "query": "rest.uniprot.org uniprotkb search ft_domain P38398",
              "action": {
                "type": "search",
                "query": "rest.uniprot.org uniprotkb search ft_domain P38398",
                "queries": [
                  "rest.uniprot.org uniprotkb search ft_domain P38398",
                  "UniProt API ft_domain P38398 tsv"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_60",
              "type": "reasoning",
              "text": "**Exploring reliable domain position sources**\n\nI'm evaluating using peer-reviewed and primary sources for domain positions but leaning toward official databases like Pfam or UniProt API features; exploring ways to reliably access UniProt domain data despite current API access challenges."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_61",
              "type": "reasoning",
              "text": "**Clarifying domain positions via structural papers**\n\nI'm deciding to specify BRCA1 domain locations using key structural papers citing the RING domain as N-terminal (1–109) and the BRCT region around residues 1646–1859, with variant impact explained accordingly, while planning to verify ovarian cancer histology from primary cohort studies next."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b84d4f6481a0af9e27edbc86e43c",
              "type": "web_search",
              "query": "https://www.nature.com/articles/srep04026",
              "action": {
                "type": "open_page",
                "url": "https://www.nature.com/articles/srep04026"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_63",
              "type": "reasoning",
              "text": "**Outlining detailed BRCA1 variant response**\n\nPlanning a structured response covering variant specifics, pathogenic mechanisms linked to BRCA1 truncation and loss of RING domain function, associated tumor profiles emphasizing high-grade serous carcinoma, plus prevalence and founder mutations, with citations from ClinVar, Buisson 2006, Brzovic 2001, Mallery 2002, and recent homologous recombination studies."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_64",
              "type": "reasoning",
              "text": "**Extending BRCA1 response with prevalence, risk, and treatment data**\n\nAdding Ashkenazi Jewish founder mutation prevalence, allele frequencies from population studies and gnomAD, plus genotype-phenotype correlations distinguishing OCCR location effects; detailing lifetime cancer risks from recent large cohorts and mutation-specific penetrance estimates alongside family history influence. Incorporating tumor pathology features, PARP inhibitor and platinum sensitivity evidence, and prevention/surveillance considerations with citations from CIMBA, CAP, ClinVar, PDQ, and key cohort studies."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b865552481a0aded0ba26917e6d7",
              "type": "web_search",
              "query": "Gabai-Kapara 2014 PNAS BRCA1 185delAG penetrance risk age 70 Ashkenazi population-based screening",
              "action": {
                "type": "search",
                "query": "Gabai-Kapara 2014 PNAS BRCA1 185delAG penetrance risk age 70 Ashkenazi population-based screening",
                "queries": [
                  "Gabai-Kapara 2014 PNAS BRCA1 185delAG penetrance risk age 70 Ashkenazi population-based screening",
                  "Struewing 1997 NEJM risk of cancer associated with specific mutations BRCA1 185delAG 5382insC 6174delT",
                  "BRCA1 185delAG penetrance study age 70 80 Ashkenazi"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_66",
              "type": "reasoning",
              "text": "**Preparing to access web skill file**\n\nI'm confirming the need to read the web skill file despite it being outside writable roots and preparing to use exec_command to view its contents."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_67",
              "type": "command_execution",
              "command": "/bin/zsh -lc 'ls /Users/lingzhi/.codex/skills/web-search'",
              "aggregated_output": "SKILL.md\nscripts\n",
              "exit_code": 0,
              "status": "completed"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_68",
              "type": "command_execution",
              "command": "/bin/zsh -lc 'cat /Users/lingzhi/.codex/skills/web-search/SKILL.md'",
              "aggregated_output": "---\nname: web-search\ndescription: Search and browse the public web from Codex CLI (联网搜索/查网页/找资料/给链接/带出处). Use when you need up-to-date info or answers that must cite web sources.\n---\n\n# Web Search (联网搜索)\n\nThis skill provides a repeatable workflow to search the web, optionally fetch page text, and answer with sources.\n\n## Quick start\n\n- Search:\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --format md`\n- Search + fetch page text (for evidence):\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --fetch --format md`\n\n## Providers (auto)\n\nThe script picks the first available provider:\n\n- **Tavily**: set `TAVILY_API_KEY`\n- **Serper**: set `SERPER_API_KEY`\n- **Brave**: set `BRAVE_API_KEY` (or `BRAVE_SEARCH_API_KEY`)\n- **Fallback**: DuckDuckGo HTML scrape (best-effort; may break)\n\n## Workflow\n\n- Clarify what must be looked up and what must be cited.\n- Run the search script; pick 3–5 sources.\n- If a claim is important/controversial, re-run with `--fetch` and quote specific lines from sources.\n- In the final answer:\n  - Include a **Sources** list with URLs.\n  - Never invent citations; if evidence is missing, say so.\n\n## Notes\n\n- This skill uses network access. In restricted network/sandbox modes, request escalation before running the script.\n",
              "exit_code": 0,
              "status": "completed"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_69",
              "type": "reasoning",
              "text": "**Resolving skill and system conflicts**\n\nThe plan is to use the web.run tool despite skill instructions to use script, noting network restrictions. I'll provide a sources list with citations but omit raw URLs per system priority, only including links if asked. I'll run batches of four search queries at once through web.run."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_70",
              "type": "reasoning",
              "text": "**Scheduling next batch of queries**\n\nI'm preparing the next batch of search queries, grouping four focused topics per web.run call, starting with ClinVar, JAMA penetrance, Ashkenazi founder mutations, and PDQ guidelines for efficient data gathering."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8c403c481a3aa8796735bb5764b",
              "type": "web_search",
              "query": "ClinVar BRCA1 c.68_69delAG p.Glu23Valfs*17 exon 2 genomic coordinates 17q21.31",
              "action": {
                "type": "search",
                "query": "ClinVar BRCA1 c.68_69delAG p.Glu23Valfs*17 exon 2 genomic coordinates 17q21.31",
                "queries": [
                  "ClinVar BRCA1 c.68_69delAG p.Glu23Valfs*17 exon 2 genomic coordinates 17q21.31",
                  "Kuchenbaecker 2017 JAMA BRCA1 lifetime risk 72% breast 44% ovarian age 80",
                  "Ashkenazi Jewish BRCA1 185delAG frequency 1% founder mutation 5382insC 6174delT 2.5%",
                  "NCI PDQ BRCA1 BRCA2 management screening MRI age 25 mammography 30 risk-reducing mastectomy 90%"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_72",
              "type": "reasoning",
              "text": "**Filtering search results**\n\nClinVar, JAMA, and PDQ weren't found in results, so I'll adjust queries to target these and exclude low-quality sources like Allure."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8c80bac81a3a08e88f4596c9322",
              "type": "web_search",
              "query": "ClinVar RCV BRCA1 c.68_69delAG p.Glu23Valfs*17 185delAG GRCh38 17:43124028",
              "action": {
                "type": "search",
                "query": "ClinVar RCV BRCA1 c.68_69delAG p.Glu23Valfs*17 185delAG GRCh38 17:43124028",
                "queries": [
                  "ClinVar RCV BRCA1 c.68_69delAG p.Glu23Valfs*17 185delAG GRCh38 17:43124028",
                  "NCI PDQ BRCA1 BRCA2 risk management MRI 25-29 mammography 30 75 risk-reducing mastectomy 90%",
                  "BRCA1 mutation location ovarian cancer cluster region c.1380-4062 2015 CIMBA breast ovarian risk location",
                  "Buisson 2006 BRCA1 185delAG translation reinitiation downstream AUG 128 RING domain"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_74",
              "type": "reasoning",
              "text": "**Planning targeted literature searches**\n\nI'm preparing precise queries to retrieve missing key studies on BRCA1/2 penetrance, triple-negative pathology, ovarian histology, PARP treatment, and risk-reducing surgery guidelines for comprehensive evidence gathering."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8ce96f081a3921dfd4715c4d8b2",
              "type": "web_search",
              "query": "Kuchenbaecker JAMA 2017 BRCA1 cumulative risk age 80 72% breast 44% ovarian",
              "action": {
                "type": "search",
                "query": "Kuchenbaecker JAMA 2017 BRCA1 cumulative risk age 80 72% breast 44% ovarian",
                "queries": [
                  "Kuchenbaecker JAMA 2017 BRCA1 cumulative risk age 80 72% breast 44% ovarian",
                  "BRCA1 mutation carriers triple-negative basal-like breast cancer percentage study Lakhani 2002 2005",
                  "BRCA1 germline ovarian cancer high-grade serous histology study BRCA1 2014",
                  "risk-reducing salpingo-oophorectomy age 35 40 BRCA1 guideline NCCN patient hereditary breast ovarian"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_76",
              "type": "reasoning",
              "text": "**Confirming ClinVar genomic coordinates**\n\nThe ClinVar page shows genomic location including chromosome and exon coordinates, which I'll use to supplement penetrance data from PubMed 28632866 and include precise variant positions."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8d2ab5081a3b83be6383a9648fb",
              "type": "web_search",
              "query": "https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/",
              "action": {
                "type": "open_page",
                "url": "https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_78",
              "type": "reasoning",
              "text": "**Locating exon info in ClinVar description**\n\nPlanning to extract \"exon 2\" and frameshift details from the ClinVar Description field by searching for the pattern \"exon 2\" in its text."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8d4210c81a3a6c0789ae42eb706",
              "type": "web_search",
              "query": "'exon 2' in https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/",
              "action": {
                "type": "find_in_page",
                "url": "https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/",
                "pattern": "exon 2"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_80",
              "type": "reasoning",
              "text": "**Planning to search NCI PDQ genetics page**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8d679d481a3a196f50290c25203",
              "type": "web_search",
              "query": "NCI PDQ BRCA1 BRCA2 carriers screening MRI 25-29 30-75 annual mammography breast MRI",
              "action": {
                "type": "search",
                "query": "NCI PDQ BRCA1 BRCA2 carriers screening MRI 25-29 30-75 annual mammography breast MRI",
                "queries": [
                  "NCI PDQ BRCA1 BRCA2 carriers screening MRI 25-29 30-75 annual mammography breast MRI",
                  "NCI PDQ Genetics of Breast and Gynecologic Cancers BRCA1 management risk reducing salpingo-oophorectomy",
                  "BRCA1 triple-negative basal-like breast cancer 70% 80% carriers study",
                  "olaparib germline BRCA1 breast cancer trial OlympiAD talazoparib EMBRACA"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_82",
              "type": "reasoning",
              "text": "**Searching for peer-reviewed triple-negative data**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8da499081a3bdd5a619e1da32cd",
              "type": "web_search",
              "query": "BRCA1-associated breast cancers are triple-negative basal-like high grade Lakhani 2004 Modern Pathology",
              "action": {
                "type": "search",
                "query": "BRCA1-associated breast cancers are triple-negative basal-like high grade Lakhani 2004 Modern Pathology",
                "queries": [
                  "BRCA1-associated breast cancers are triple-negative basal-like high grade Lakhani 2004 Modern Pathology",
                  "BRCA1 mutation carriers triple-negative breast cancer proportion study 70% 80%",
                  "BRCA1 BARD1 RING domain E3 ubiquitin ligase heterodimer structure 2001",
                  "BRCA1 BARD1 promotes RAD51-mediated homologous recombination PNAS 2017"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_84",
              "type": "reasoning",
              "text": "**Planning sourcing for triple-negative data**\n\nI'm prioritizing peer-reviewed primary studies for triple-negative prevalence in BRCA1 cases, while considering a 2010 Modern Pathology review as an authoritative source on typical tumor pathology features. Next, I'll search for specific studies quantifying triple-negative prevalence to support risk and pathology details."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8e2fff481a3817b9070f8fe4776",
              "type": "web_search",
              "query": "BRCA1 mutation carriers basal-like phenotype study triple negative percentage 'basal-like' 'BRCA1' 2005",
              "action": {
                "type": "search",
                "query": "BRCA1 mutation carriers basal-like phenotype study triple negative percentage 'basal-like' 'BRCA1' 2005",
                "queries": [
                  "BRCA1 mutation carriers basal-like phenotype study triple negative percentage 'basal-like' 'BRCA1' 2005",
                  "BRCAness triple negative BRCA1 carriers proportion estrogen receptor negative study 2004",
                  "BRCA1 breast cancer pathology medullary-like high grade estrogen receptor negative study 2000 Lakhani",
                  "Kuchenbaecker JAMA 2017 28632866 breast cancer risk age 80 72%"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_86",
              "type": "reasoning",
              "text": "**Focusing on BRCA1-BARD1 RAD51 mechanism**\n\nPlanning to find a specific paper detailing how BRCA1-BARD1 promotes RAD51 for the mechanism section, building on known RING domain and E3 ligase roles."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8e83f2481a381398b3d203b7872",
              "type": "web_search",
              "query": "BRCA1 BARD1 promotes RAD51-mediated homologous recombination PNAS 2017",
              "action": {
                "type": "search",
                "query": "BRCA1 BARD1 promotes RAD51-mediated homologous recombination PNAS 2017",
                "queries": [
                  "BRCA1 BARD1 promotes RAD51-mediated homologous recombination PNAS 2017",
                  "BRCA1 PALB2 BRCA2 RAD51 recruitment homologous recombination 2019 Nature Communications",
                  "BRCA1 deficiency homologous recombination repair double strand breaks study",
                  "BRCA1 BRCT domain phosphopeptide binding structure 2001"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_88",
              "type": "reasoning",
              "text": "**Confirming key BRCA1-BARD1 citations**\n\nIdentified a Nature Communications 2020 paper supporting BRCA1's role in HR via PALB2 recruitment, and confirmed structural evidence for BRCA1/BARD1 E3 ligase activity from a 2020 Nature Structural & Molecular Biology paper. Planning to cite Buisson 2006 for the c.68_69delAG frameshift and N-terminal truncation effects."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_89",
              "type": "reasoning",
              "text": "**Detailing BRCT domain role and variant molecular consequences**\n\nClarified that the truncated protein retains the BRCT domain but loses the RING domain due to N-terminal frameshift and translation reinitiation, impairing HR. Compiled exact genomic coordinates, exon 2 location, and molecular impact of the c.68_69delAG mutation with prevalence data from gnomAD and AJ populations. Planning to include mutation-specific penetrance, genotype-phenotype correlations, and tumor pathology data referencing multiple clinical and population studies."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b9031c9081a38542f1b2ea4db9cb",
              "type": "web_search",
              "query": "germline BRCA1 ovarian cancer high-grade serous histology proportion study",
              "action": {
                "type": "search",
                "query": "germline BRCA1 ovarian cancer high-grade serous histology proportion study",
                "queries": [
                  "germline BRCA1 ovarian cancer high-grade serous histology proportion study",
                  "BRCA1 mutation ovarian cancer predominantly high-grade serous study 'histology'",
                  "BRCA1-associated ovarian cancer high-grade serous carcinoma study 2013 2014",
                  "BRCA1 BARD1 RAD51 homologous recombination 2017 PNAS 114 2017"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_91",
              "type": "reasoning",
              "text": "**Locating BRCA1/2 screening guidelines**\n\nI'm opening the NCI PDQ page to find screening recommendations for BRCA1/2 carriers, focusing on breast cancer surveillance details to support guideline citations."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b908258881a3b8698df406e4a9a3",
              "type": "web_search",
              "query": "https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq",
              "action": {
                "type": "open_page",
                "url": "https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_93",
              "type": "reasoning",
              "text": "**Identifying specific screening age lines**\n\nI'm searching the PDQ page for terms like \"MRI\" or \"annual MRI\" to locate relevant age guidelines amid the large content."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b90975d081a38d12406c3aafbf9b",
              "type": "web_search",
              "query": "'MRI' in https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq",
              "action": {
                "type": "find_in_page",
                "url": "https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq",
                "pattern": "MRI"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_95",
              "type": "reasoning",
              "text": "**Searching for screening age details in PDQ sections**\n\nThe PDQ page doesn't clearly list screening ages upfront, so I'll search within specific sections like \"Cancer Risks, Spectrum, and Characteristics\" or \"BRCA1 and BRCA2: Cancer Risks and Management\" for breast cancer screening details."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b90c790c81a38a4fcc3406ed03b5",
              "type": "web_search",
              "query": "\"BRCA1 and BRCA2: Cancer Risks and Management\" PDQ screening 25 29 MRI",
              "action": {
                "type": "search",
                "query": "\"BRCA1 and BRCA2: Cancer Risks and Management\" PDQ screening 25 29 MRI",
                "queries": [
                  "\"BRCA1 and BRCA2: Cancer Risks and Management\" PDQ screening 25 29 MRI",
                  "\"BRCA1 and BRCA2: Cancer Risks and Management\" NCI PDQ breast MRI age 25 29 mammography 30",
                  "BRCA1 BRCA2 cancer risks and management PDQ breast MRI 25 29",
                  "NCCN patient guidelines hereditary breast ovarian screening MRI 25 30"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_97",
              "type": "reasoning",
              "text": "**Consolidating surveillance and risk-reduction sources**\n\nI’m planning to use PDQ’s open-access BRCA1/2 resource for surveillance ages and oral contraceptive risk reduction, JAMA Oncology 2021 for RRSO age recommendations, and the NCI PDQ for mastectomy risk reduction; next, I’ll verify salpingo-oophorectomy risk reduction data within PDQ on NCBI Bookshelf."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_98",
              "type": "reasoning",
              "text": "**Searching PDQ for salpingo-oophorectomy data**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b91532f481a3ab98b7954e612d8d",
              "type": "web_search",
              "query": "https://www.ncbi.nlm.nih.gov/books/NBK589498/",
              "action": {
                "type": "open_page",
                "url": "https://www.ncbi.nlm.nih.gov/books/NBK589498/"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_100",
              "type": "reasoning",
              "text": "**Planning targeted text search**\n\nI'm preparing to locate the screening and management section by searching for \"25\" combined with \"MRI\" or age ranges like \"25–29\" to identify relevant passages in the PDQ document."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b9177ec481a3b99e75fb679acaf1",
              "type": "web_search",
              "query": "'25' in https://www.ncbi.nlm.nih.gov/books/NBK589498/",
              "action": {
                "type": "find_in_page",
                "url": "https://www.ncbi.nlm.nih.gov/books/NBK589498/",
                "pattern": "25"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_102",
              "type": "reasoning",
              "text": "**Gathering citations for genetic screening and risk reduction**\n\nDecided to cite PDQ for screening ages and general recommendations, JAMA Oncology for RRSO age 35-40 guidance, and PDQ for oral contraceptive protective effects. For prophylactic mastectomy risk reduction percentages, PDQ from NCI is the source. Prevalence data in Ashkenazi Jews will cite Struewing 1997 and CAP/Genome.gov sources."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_103",
              "type": "reasoning",
              "text": "**Structuring detailed variant report with comprehensive citations**\n\nMapped out a structured, citation-backed answer covering variant details, molecular impact, population frequencies, cancer risks, surveillance, and treatment strategies—each with authoritative sources. Planned clear, non-nested bullet sections and emphasized disclaimers and up-to-date data points, preparing for a full, precise final response."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_104",
              "type": "reasoning",
              "text": "**Computing allele frequencies from gnomAD counts**\n\nPreparing to calculate precise allele frequencies for the variant in overall and Ashkenazi Jewish populations using gnomAD counts to include accurate prevalence data."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0001ef537fbcce34016996b95a0e9c81a388103178c8dc2fb2",
              "type": "web_search",
              "query": "calculator: 58/282442",
              "action": {
                "type": "search",
                "query": "calculator: 58/282442",
                "queries": [
                  "calculator: 58/282442"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_106",
              "type": "reasoning",
              "text": "**Summarizing variant details and literature citations**\n\nPlanning to describe variant specifics with precise genomic context and database references, then explain molecular effects citing key studies; also preparing to include allele frequencies and recommended clinical ages from gnomAD and JAMA Oncology for a comprehensive, sourced response."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_107",
              "type": "reasoning",
              "text": "**Outlining detailed structured response**\n\nPlanning a clearly sectioned reply with bullet lists under defined headings covering variant info, molecular effects, population genetics, penetrance, pathology, prevention, and treatment, including comprehensive citation mapping to ensure precise sourcing and avoid nested bullets, while emphasizing up-to-date web-based data and careful medical disclaimers."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_108",
              "type": "agent_message",
              "text": "Using the web-search skill, I pulled current primary/official sources (ClinVar, NCI PDQ, large cohort studies, and key mechanistic papers). Below is a structured, evidence‑based analysis focused on BRCA1 `c.68_69delAG` (aka `185delAG`) for an unaffected 35‑year‑old Ashkenazi Jewish woman.\n\n**1. Variant Identity, Genomic Location, Databases**\n- **Variant name and aliases**: `BRCA1 c.68_69delAG` (NM_007294.4), also called `185delAG` or `187delAG`, protein change `p.Glu23ValfsTer17`. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **Location**: Chromosome 17q21.31; GRCh38 `chr17:43124028-43124029` (GRCh37 `chr17:41276045-41276046`). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **Exon**: Deletion occurs in **exon 2** of BRCA1. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **ClinVar**: Pathogenic, expert‑panel reviewed; ClinVar record updated Feb 15, 2026. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **LOVD**: The variant is indexed in the Leiden Open Variation Database (LOVD) and cross‑referenced in ClinVar as DB‑ID `BRCA1_001114`. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n\n**2. Molecular Consequence of `c.68_69delAG`**\n- **Frameshift and premature stop**: The 2‑bp deletion causes a frameshift starting at codon 23, generating a premature stop 17 codons downstream (termination at amino acid 39). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **Nonsense‑mediated decay vs reinitiation**: Although early truncations usually trigger NMD, this specific mutation shows **translation reinitiation at downstream AUG 128**, producing an N‑terminally truncated BRCA1 that lacks the RING domain. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16941470/?utm_source=openai))\n\n**3. How the Protein Defect Disrupts DNA Repair**\n- **Loss of RING‑domain function**: The N‑terminal RING domain is required for BRCA1–BARD1 heterodimerization and E3 ubiquitin ligase activity. The RING‑deleted product is functionally compromised, disrupting BRCA1/BARD1 E3 ligase activity that targets nucleosomal H2A. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1478191/?utm_source=openai))\n- **Homologous recombination failure**: BRCA1 is required for end‑resection and recruitment of PALB2/BRCA2 to load RAD51 at DSBs. BRCA1 deficiency leads to impaired RAD51 loading and HR deficiency. ([nature.com](https://www.nature.com/articles/s41467-020-14563-y?utm_source=openai))\n- **Functional consequence**: HR‑deficient tumors are often sensitive to platinum chemotherapy and PARP inhibition (key clinical implication). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n\n**4. Population Frequency and Founder Context**\n- **Ashkenazi Jewish prevalence**:\n  - Large population screen: 1.09% carrier frequency for `185delAG` in ~3,000 AJ individuals. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8841191/?utm_source=openai))\n  - ClinVar summarizes AJ minor allele frequency ~0.96–1.14%. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **General population prevalence**:\n  - gnomAD non‑cancer: 58/282,442 chromosomes overall (~0.0205%); 42/10,368 Ashkenazi chromosomes (~0.405%), indicating strong AJ enrichment and very low frequency elsewhere. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n  - Any BRCA1/2 pathogenic variant in the general population is ~1 in 400–800 (0.125–0.25%). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- **Other Ashkenazi founder mutations**:\n  - `BRCA1 5382insC (c.5266dupC)` and `BRCA2 6174delT (c.5946delT)` are the other two classic AJ founder variants. ([genome.gov](https://www.genome.gov/10000940/brca1brca2-study-faq?utm_source=openai))\n  - The three founder variants together occur in ~2.5% of AJ individuals and account for ~95% of BRCA1/2 mutations in AJ populations. ([nature.com](https://www.nature.com/articles/gim201477?utm_source=openai))\n\n**5. Penetrance and Risk Estimates**\n- **Large prospective cohort (BRCA1 overall)**:\n  - Breast cancer risk to age 80: **72%** (95% CI 65–79).\n  - Ovarian cancer risk to age 80: **44%** (95% CI 36–53). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))\n- **Variant‑specific ranges (from ClinVar summary)**:\n  - Breast cancer risk **55–83% by age 70**.\n  - Ovarian cancer risk **12–58% by age 70**. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **Family history matters**:\n  - ≥2 affected first/second‑degree relatives nearly doubles breast cancer risk among BRCA1 carriers (HR ~1.99). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))\n- **Mutation‑location effects (genotype‑phenotype)**:\n  - BRCA1 OCCR is within c.1380–4062; mutations **outside** this region have relatively higher breast vs ovarian risk. `c.68_69delAG` is far outside OCCR (5′ exon 2), so it fits the “higher breast‑relative‑to‑ovarian” risk pattern. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4537700/?utm_source=openai))  \n  - This is a location‑based correlation, not a unique phenotype exclusive to `185delAG`.\n\n**6. Expected Tumor Pathology**\n- **Breast**:\n  - BRCA1‑associated tumors are more often **triple‑negative / basal‑like**, high‑grade, and medullary‑like. ([nature.com](https://www.nature.com/articles/modpathol201037?utm_source=openai))\n  - Approximately **75%** of BRCA1‑associated breast cancers show triple‑negative/basal‑like phenotype. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3149541/?utm_source=openai))\n  - Multiple datasets suggest **~80–90%** of BRCA1 cancers are basal‑like. ([link.springer.com](https://link.springer.com/article/10.1186/s12885-015-1522-4?utm_source=openai))\n- **Ovary/Fallopian tube**:\n  - Ovarian cancers in BRCA1/2 carriers are strongly enriched for **high‑grade serous** histology (meta‑analysis: ~91% HGSOC among BRCA1/2 carriers). ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S009082582101516X?utm_source=openai))\n  - BRCA abnormalities are largely confined to the high‑grade serous subtype. ([nature.com](https://www.nature.com/articles/modpathol2011211?utm_source=openai))\n\n**7. Evidence‑Based Prevention, Surveillance, and Treatment**\n**Surveillance (unaffected BRCA1 carriers)**\n- **Breast imaging**:\n  - NCCN‑referenced PDQ guidance: **annual breast MRI (with contrast) age 25–29**, then **annual MRI + mammogram age 30–75** (often alternating every 6 months). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n  - Earlier individualized MRI if a relative was diagnosed before 30. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- **Ovarian screening**:\n  - Evidence does **not** support CA‑125 + transvaginal ultrasound for early detection/mortality reduction. ([cancer.gov](https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq))\n\n**Risk‑Reducing Surgery**\n- **Risk‑reducing mastectomy (RRM)**:\n  - Reduces breast cancer risk by ~**89–94%** in high‑risk women. ([cancer.gov](https://www.cancer.gov/types/breast/hp/breast-prevention-pdq?utm_source=openai))\n- **Risk‑reducing salpingo‑oophorectomy (RRSO)**:\n  - Standard recommendation: **age 35–40 for BRCA1**, delay to 40–45 for BRCA2 if appropriate. ([jamanetwork.com](https://jamanetwork.com/journals/jamaoncology/fullarticle/2776761?utm_source=openai))\n\n**Chemoprevention**\n- **Oral contraceptives**: Associated with reduced ovarian cancer risk in BRCA1/2 carriers without clear increased breast cancer risk for post‑1975 formulations. ([cancer.gov](https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq))\n- **Tamoxifen**: Evidence stronger for contralateral‑breast risk reduction after cancer; limited data for primary prevention in unaffected BRCA1 carriers. ([cancer.gov](https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq))\n\n**If Cancer Occurs (Treatment Implications)**\n- **Platinum sensitivity**: BRCA1/2 carriers often show higher response to platinum chemotherapy (e.g., carboplatin vs docetaxel). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- **PARP inhibitors**:\n  - Metastatic HER2‑negative breast cancer: olaparib improves PFS in germline BRCA1/2 carriers (OlympiAD). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36971103/?utm_source=openai))\n  - High‑risk early breast cancer: adjuvant olaparib improves outcomes (OlympiA). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n\n---\n\n**Key Takeaways for This Specific Case**\n- `BRCA1 c.68_69delAG` is a well‑characterized Ashkenazi founder mutation with early truncation and loss of the N‑terminal RING domain, leading to HR deficiency. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- The patient’s age (35) places her at the **standard window for RRSO discussion** and at the **MRI + mammography surveillance threshold**. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- Family history (mother at 42, aunt at 38) is a risk‑amplifying factor within BRCA1 carriers. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))\n\n---\n\n**Sources (selected)**\n- ClinVar RCV004566751 (variant location, consequence, AJ frequency, gnomAD counts, risk ranges). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- Buisson et al., 2006 (translation reinitiation at codon 128). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16941470/?utm_source=openai))\n- Struewing et al., 1997 (AJ population prevalence). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8841191/?utm_source=openai))\n- CAP Genetics in Medicine 2014 (AJ founder trio prevalence/coverage). ([nature.com](https://www.nature.com/articles/gim201477?utm_source=openai))\n- JAMA 2017 (penetrance; family history; location effects). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))\n- NCI PDQ BRCA1/2: Cancer Risks and Management (screening ages; NCCN‑based recommendations). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- JAMA Oncology 2021 (RRSO age recommendations). ([jamanetwork.com](https://jamanetwork.com/journals/jamaoncology/fullarticle/2776761?utm_source=openai))\n- Modern Pathology 2010; PMC reviews (BRCA1 tumor phenotype). ([nature.com](https://www.nature.com/articles/modpathol201037?utm_source=openai))\n- Ovarian histology meta‑analysis & high‑grade serous correlation. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S009082582101516X?utm_source=openai))\n\nIf you want, I can also provide a short, patient‑facing summary or a decision‑support checklist (surveillance vs surgery, fertility timing, hormone‑replacement considerations)."
            }
          }
        ],
        "item.started": [
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b79b50f881a09e5072f658ef42db",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b79faa0c81a0bd070d7775fd2da7",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7a2a8e481a0a92023031401ad99",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7be12cc81a0a182036ab5ebe54d",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7c01a8481a0b1b38ff722094b82",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7c78fbc81a0afc655869555d94a",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7cc2f1881a0afe9c8517cb1c62a",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7d1080881a087ca5e5164929124",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7dfdf7481a0be63e840390db08d",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7e0a2c881a084a957d9f9f7c287",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7e4b25c81a0bee366c21db29df4",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7ec977481a08c5448a2b0f50503",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7f04e6881a08e5d101d37cc8371",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7f7b5a881a0ac1919011c52954e",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7fd04e881a0886a0d4a6300f080",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b7fde1dc81a086ccf82d2e7473a7",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b803af5c81a09b295d0e4af2b901",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b806c4dc81a0b7a6aecf1407b776",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b80a6c6c81a0bb840a177e09ed4e",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b818235881a0ba6b19946952b904",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b81d76ec81a09075ea5e6f08d469",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b81f045481a0afa38b9ada21922f",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b820aecc81a094edfe5acfabae02",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b824cb9881a08b3e6fc4abee0a95",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b8297c3081a0b991bbacee8743be",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b82bd82481a08202cd73851fdea2",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b82f7e2881a09f091a26ae5ebf8f",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b833595081a0bfedf9bfe76fd695",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b84d4f6481a0af9e27edbc86e43c",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e5751de8d4fd374016996b865552481a0aded0ba26917e6d7",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "item_67",
              "type": "command_execution",
              "command": "/bin/zsh -lc 'ls /Users/lingzhi/.codex/skills/web-search'",
              "aggregated_output": "",
              "exit_code": null,
              "status": "in_progress"
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "item_68",
              "type": "command_execution",
              "command": "/bin/zsh -lc 'cat /Users/lingzhi/.codex/skills/web-search/SKILL.md'",
              "aggregated_output": "",
              "exit_code": null,
              "status": "in_progress"
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8c403c481a3aa8796735bb5764b",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8c80bac81a3a08e88f4596c9322",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8ce96f081a3921dfd4715c4d8b2",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8d2ab5081a3b83be6383a9648fb",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8d4210c81a3a6c0789ae42eb706",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8d679d481a3a196f50290c25203",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8da499081a3bdd5a619e1da32cd",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8e2fff481a3817b9070f8fe4776",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b8e83f2481a381398b3d203b7872",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b9031c9081a38542f1b2ea4db9cb",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b908258881a3b8698df406e4a9a3",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b90975d081a38d12406c3aafbf9b",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b90c790c81a38a4fcc3406ed03b5",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b91532f481a3ab98b7954e612d8d",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b9177ec481a3b99e75fb679acaf1",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0001ef537fbcce34016996b95a0e9c81a388103178c8dc2fb2",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          }
        ],
        "error": [
          {
            "type": "error",
            "message": "Reconnecting... 1/5 (stream disconnected before completion: Transport error: network error: error decoding response body)"
          }
        ],
        "turn.completed": [
          {
            "type": "turn.completed",
            "usage": {
              "input_tokens": 119478,
              "cached_input_tokens": 39168,
              "output_tokens": 15634
            }
          }
        ]
      }
    },
    {
      "agent_name": "molecular-biology-expert",
      "system_prompt": "You are a molecular biologist specializing in DNA damage response and repair pathways. You have expertise in protein structure-function relationships and the BRCA1/BRCA2 repair axis. You have access to web search — USE IT to look up recent research on BRCA1 protein domains, interaction partners, and mechanistic studies. Build upon the genomics findings provided.",
      "user_prompt": "Based on the genomics research provided, explain the molecular consequences:\n- How does the truncated BRCA1 protein (from 185delAG) affect the RING domain, BRCT domains, and key functional regions?\n- How does loss of functional BRCA1 impair homologous recombination repair (HRR)? Describe the BRCA1-PALB2-BRCA2-RAD51 axis.\n- What happens to the BRCA1-BARD1 E3 ubiquitin ligase complex?\n- Explain the concept of 'BRCAness' and synthetic lethality with PARP inhibition at the molecular level.\n- What compensatory or reversion mutations have been documented?\n\nUse web search for the latest mechanistic research. Be precise about protein domains and molecular interactions.",
      "full_prompt_sent": "You are: You are a molecular biologist specializing in DNA damage response and repair pathways. You have expertise in protein structure-function relationships and the BRCA1/BRCA2 repair axis. You have access to web search — USE IT to look up recent research on BRCA1 protein domains, interaction partners, and mechanistic studies. Build upon the genomics findings provided.\n\nContext from previous work:\nUsing the web-search skill, I pulled current primary/official sources (ClinVar, NCI PDQ, large cohort studies, and key mechanistic papers). Below is a structured, evidence‑based analysis focused on BRCA1 `c.68_69delAG` (aka `185delAG`) for an unaffected 35‑year‑old Ashkenazi Jewish woman.\n\n**1. Variant Identity, Genomic Location, Databases**\n- **Variant name and aliases**: `BRCA1 c.68_69delAG` (NM_007294.4), also called `185delAG` or `187delAG`, protein change `p.Glu23ValfsTer17`. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **Location**: Chromosome 17q21.31; GRCh38 `chr17:43124028-43124029` (GRCh37 `chr17:41276045-41276046`). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **Exon**: Deletion occurs in **exon 2** of BRCA1. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **ClinVar**: Pathogenic, expert‑panel reviewed; ClinVar record updated Feb 15, 2026. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **LOVD**: The variant is indexed in the Leiden Open Variation Database (LOVD) and cross‑referenced in ClinVar as DB‑ID `BRCA1_001114`. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n\n**2. Molecular Consequence of `c.68_69delAG`**\n- **Frameshift and premature stop**: The 2‑bp deletion causes a frameshift starting at codon 23, generating a premature stop 17 codons downstream (termination at amino acid 39). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **Nonsense‑mediated decay vs reinitiation**: Although early truncations usually trigger NMD, this specific mutation shows **translation reinitiation at downstream AUG 128**, producing an N‑terminally truncated BRCA1 that lacks the RING domain. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16941470/?utm_source=openai))\n\n**3. How the Protein Defect Disrupts DNA Repair**\n- **Loss of RING‑domain function**: The N‑terminal RING domain is required for BRCA1–BARD1 heterodimerization and E3 ubiquitin ligase activity. The RING‑deleted product is functionally compromised, disrupting BRCA1/BARD1 E3 ligase activity that targets nucleosomal H2A. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1478191/?utm_source=openai))\n- **Homologous recombination failure**: BRCA1 is required for end‑resection and recruitment of PALB2/BRCA2 to load RAD51 at DSBs. BRCA1 deficiency leads to impaired RAD51 loading and HR deficiency. ([nature.com](https://www.nature.com/articles/s41467-020-14563-y?utm_source=openai))\n- **Functional consequence**: HR‑deficient tumors are often sensitive to platinum chemotherapy and PARP inhibition (key clinical implication). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n\n**4. Population Frequency and Founder Context**\n- **Ashkenazi Jewish prevalence**:\n  - Large population screen: 1.09% carrier frequency for `185delAG` in ~3,000 AJ individuals. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8841191/?utm_source=openai))\n  - ClinVar summarizes AJ minor allele frequency ~0.96–1.14%. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **General population prevalence**:\n  - gnomAD non‑cancer: 58/282,442 chromosomes overall (~0.0205%); 42/10,368 Ashkenazi chromosomes (~0.405%), indicating strong AJ enrichment and very low frequency elsewhere. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n  - Any BRCA1/2 pathogenic variant in the general population is ~1 in 400–800 (0.125–0.25%). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- **Other Ashkenazi founder mutations**:\n  - `BRCA1 5382insC (c.5266dupC)` and `BRCA2 6174delT (c.5946delT)` are the other two classic AJ founder variants. ([genome.gov](https://www.genome.gov/10000940/brca1brca2-study-faq?utm_source=openai))\n  - The three founder variants together occur in ~2.5% of AJ individuals and account for ~95% of BRCA1/2 mutations in AJ populations. ([nature.com](https://www.nature.com/articles/gim201477?utm_source=openai))\n\n**5. Penetrance and Risk Estimates**\n- **Large prospective cohort (BRCA1 overall)**:\n  - Breast cancer risk to age 80: **72%** (95% CI 65–79).\n  - Ovarian cancer risk to age 80: **44%** (95% CI 36–53). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))\n- **Variant‑specific ranges (from ClinVar summary)**:\n  - Breast cancer risk **55–83% by age 70**.\n  - Ovarian cancer risk **12–58% by age 70**. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- **Family history matters**:\n  - ≥2 affected first/second‑degree relatives nearly doubles breast cancer risk among BRCA1 carriers (HR ~1.99). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))\n- **Mutation‑location effects (genotype‑phenotype)**:\n  - BRCA1 OCCR is within c.1380–4062; mutations **outside** this region have relatively higher breast vs ovarian risk. `c.68_69delAG` is far outside OCCR (5′ exon 2), so it fits the “higher breast‑relative‑to‑ovarian” risk pattern. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4537700/?utm_source=openai))  \n  - This is a location‑based correlation, not a unique phenotype exclusive to `185delAG`.\n\n**6. Expected Tumor Pathology**\n- **Breast**:\n  - BRCA1‑associated tumors are more often **triple‑negative / basal‑like**, high‑grade, and medullary‑like. ([nature.com](https://www.nature.com/articles/modpathol201037?utm_source=openai))\n  - Approximately **75%** of BRCA1‑associated breast cancers show triple‑negative/basal‑like phenotype. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3149541/?utm_source=openai))\n  - Multiple datasets suggest **~80–90%** of BRCA1 cancers are basal‑like. ([link.springer.com](https://link.springer.com/article/10.1186/s12885-015-1522-4?utm_source=openai))\n- **Ovary/Fallopian tube**:\n  - Ovarian cancers in BRCA1/2 carriers are strongly enriched for **high‑grade serous** histology (meta‑analysis: ~91% HGSOC among BRCA1/2 carriers). ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S009082582101516X?utm_source=openai))\n  - BRCA abnormalities are largely confined to the high‑grade serous subtype. ([nature.com](https://www.nature.com/articles/modpathol2011211?utm_source=openai))\n\n**7. Evidence‑Based Prevention, Surveillance, and Treatment**\n**Surveillance (unaffected BRCA1 carriers)**\n- **Breast imaging**:\n  - NCCN‑referenced PDQ guidance: **annual breast MRI (with contrast) age 25–29**, then **annual MRI + mammogram age 30–75** (often alternating every 6 months). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n  - Earlier individualized MRI if a relative was diagnosed before 30. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- **Ovarian screening**:\n  - Evidence does **not** support CA‑125 + transvaginal ultrasound for early detection/mortality reduction. ([cancer.gov](https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq))\n\n**Risk‑Reducing Surgery**\n- **Risk‑reducing mastectomy (RRM)**:\n  - Reduces breast cancer risk by ~**89–94%** in high‑risk women. ([cancer.gov](https://www.cancer.gov/types/breast/hp/breast-prevention-pdq?utm_source=openai))\n- **Risk‑reducing salpingo‑oophorectomy (RRSO)**:\n  - Standard recommendation: **age 35–40 for BRCA1**, delay to 40–45 for BRCA2 if appropriate. ([jamanetwork.com](https://jamanetwork.com/journals/jamaoncology/fullarticle/2776761?utm_source=openai))\n\n**Chemoprevention**\n- **Oral contraceptives**: Associated with reduced ovarian cancer risk in BRCA1/2 carriers without clear increased breast cancer risk for post‑1975 formulations. ([cancer.gov](https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq))\n- **Tamoxifen**: Evidence stronger for contralateral‑breast risk reduction after cancer; limited data for primary prevention in unaffected BRCA1 carriers. ([cancer.gov](https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq))\n\n**If Cancer Occurs (Treatment Implications)**\n- **Platinum sensitivity**: BRCA1/2 carriers often show higher response to platinum chemotherapy (e.g., carboplatin vs docetaxel). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- **PARP inhibitors**:\n  - Metastatic HER2‑negative breast cancer: olaparib improves PFS in germline BRCA1/2 carriers (OlympiAD). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36971103/?utm_source=openai))\n  - High‑risk early breast cancer: adjuvant olaparib improves outcomes (OlympiA). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n\n---\n\n**Key Takeaways for This Specific Case**\n- `BRCA1 c.68_69delAG` is a well‑characterized Ashkenazi founder mutation with early truncation and loss of the N‑terminal RING domain, leading to HR deficiency. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- The patient’s age (35) places her at the **standard window for RRSO discussion** and at the **MRI + mammography surveillance threshold**. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- Family history (mother at 42, aunt at 38) is a risk‑amplifying factor within BRCA1 carriers. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))\n\n---\n\n**Sources (selected)**\n- ClinVar RCV004566751 (variant location, consequence, AJ frequency, gnomAD counts, risk ranges). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV004566751/))\n- Buisson et al., 2006 (translation reinitiation at codon 128). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16941470/?utm_source=openai))\n- Struewing et al., 1997 (AJ population prevalence). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8841191/?utm_source=openai))\n- CAP Genetics in Medicine 2014 (AJ founder trio prevalence/coverage). ([nature.com](https://www.nature.com/articles/gim201477?utm_source=openai))\n- JAMA 2017 (penetrance; family history; location effects). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))\n- NCI PDQ BRCA1/2: Cancer Risks and Management (screening ages; NCCN‑based recommendations). ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK589498/))\n- JAMA Oncology 2021 (RRSO age recommendations). ([jamanetwork.com](https://jamanetwork.com/journals/jamaoncology/fullarticle/2776761?utm_source=openai))\n- Modern Pathology 2010; PMC reviews (BRCA1 tumor phenotype). ([nature.com](https://www.nature.com/articles/modpathol201037?utm_source=openai))\n- Ovarian histology meta‑analysis & high‑grade serous correlation. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S009082582101516X?utm_source=openai))\n\nIf you want, I can also provide a short, patient‑facing summary or a decision‑support checklist (surveillance vs surgery, fertility timing, hormone‑replacement considerations).\n\nMain question:\nA 35-year-old woman of Ashkenazi Jewish descent, with a family history of breast cancer (mother diagnosed at 42, maternal aunt at 38), undergoes genetic testing and is found to carry a pathogenic BRCA1 c.68_69delAG (185delAG) founder mutation. She currently has no signs of cancer.\n\nWe need a comprehensive analysis covering:\n1. The molecular genetics of this specific mutation\n2. How the resulting protein defect disrupts DNA repair\n3. The cancer risk profile and expected tumor pathology\n4. Evidence-based prevention, surveillance, and treatment strategies\n\nYour specific assignment:\nBased on the genomics research provided, explain the molecular consequences:\n- How does the truncated BRCA1 protein (from 185delAG) affect the RING domain, BRCT domains, and key functional regions?\n- How does loss of functional BRCA1 impair homologous recombination repair (HRR)? Describe the BRCA1-PALB2-BRCA2-RAD51 axis.\n- What happens to the BRCA1-BARD1 E3 ubiquitin ligase complex?\n- Explain the concept of 'BRCAness' and synthetic lethality with PARP inhibition at the molecular level.\n- What compensatory or reversion mutations have been documented?\n\nUse web search for the latest mechanistic research. Be precise about protein domains and molecular interactions.",
      "reasoning": [
        "**Preparing to read skill file**\n\nI'm running a command to read the web-search skill's SKILL.md file first before using the web.run tool for searches.",
        "**Planning targeted web searches**\n\nI'm preparing to run up to four web searches focused on primary, authoritative sources like PubMed and top journals to collect recent mechanistic research on BRCA1 domains, interactions, and reversion mutations for accurate, cited answers.",
        "**Executing focused literature searches**\n\nI'm initiating four targeted web.run queries on BRCA1 domain mechanisms, protein interactions, homologous recombination pathways, and recent reviews on reversion mutations linked to therapy resistance.",
        "**Refining literature search strategy**\n\nI'm prioritizing primary research from key journals for technical accuracy and focusing on curated sources like Uniprot for domain architecture. Next, I'll run targeted searches on BRCA1-PALB2 interactions and reversion mutations using precise keywords to gather detailed mechanistic data.",
        "**Confirming domain boundaries from Uniprot**",
        "**Planning domain boundary search**\n\nI'm preparing to extract domain boundaries for BRCA1 using explicit UniProt queries focusing on domains like RING, BRCT, and coiled-coil.",
        "**Planning direct UniProt search**\n\nI'll perform a direct UniProt search for the given protein and domain ranges to locate domain positions. If results are insufficient, I'll open UniProt manually to verify details.",
        "**Searching UniProt for domain data**\n\nPlanning to obtain domain positions from the authoritative UniProt source, focusing on UniProt entries filtered by domains.",
        "**Opening Uniprot entry directly**\n\nI'm opening the specific Uniprot entry URL directly since the search didn't yield results, ensuring accurate access to the needed data.",
        "**Choosing Uniprot REST API**\n\nDecided to use the Uniprot REST API with open requests to fetch data in text or JSON format for fallback instead of JS-rendered content.",
        "**Planning domain feature search**\n\nI'm preparing to use the find tool with a pattern like \"RING\" or \"BRCT\" on the Uniprot text to locate specific domain features efficiently.",
        "**Adjusting file read start for features**\n\nThe file preview of 200 lines misses the features section, so I'll open the file further down, around line 800–1200, to locate the \"FT\" lines and relevant domain features.",
        "**Switching to Uniprot JSON API**\n\nOpening the local file with line numbers is limited by a 200-line truncate, blocking feature inspection. I'll use the Uniprot REST JSON API instead to get full feature data and parse it within the tool.",
        "**Searching for JSON data URL**\n\nI'm searching for a JSON or TSV endpoint for the given UniProt ID to locate an allowed URL for opening and further data extraction.",
        "**Clarifying URL opening constraints**\n\nThe REST API JSON URL isn't directly from search results or user message, so opening it violates URL safety rules; the .txt URL was allowed likely because it matched a previous context. Next, I'll explore ways to retrieve allowed URLs from search results or user input to access the JSON data safely.",
        "**Pivoting to primary literature for domain positions**\n\nSince opening new UniProt API URLs is restricted, I'll rely on primary studies to specify domain positions precisely, citing key papers for RING, BRCT, and coiled-coil regions. Next, I'll search specifically for primary sources on the BRCA1 coiled-coil domain in Sy et al. 2009/2010 to confirm exact residue ranges.",
        "**Identifying primary sources for PALB2 mapping**\n\nPlanning to locate primary papers for PALB2 coiled-coil region mapping, focusing on Sy et al. 2009 to precisely define residues 1367-1437 and complement Zhang et al. 2009, ensuring technical accuracy beyond review citations.",
        "**Identifying primary source for PALB2-BRCA1**\n\nI'm focusing on a primary PMC article, likely Xia et al. 2007, that details the BRCA1 coiled-coil region and residues 1364-1437 relevant for PALB2 interaction to confirm and cite accurately.",
        "**Searching page for residue references**",
        "**Specifying precise domain boundaries**\n\nDecided on precise BRCA1 domain ranges: RING domain at amino acids 1–100/110 supported by Brzovic 2001 NMR structure, coiled-coil at 1364–1437 from PNAS 2009, and BRCT domain at 1646–1859 per Williams 2001 Nat Struct Biol. These targeted citations support detailed domain and interaction mapping as requested.",
        "**Planning precise functional domain citations**\n\nPreparing to cite primary sources linking truncated BRCA1 from 185delAG to loss of RING domain (aa 1–110) using Buisson 2006, with RING domain functions and E3 activity detailed via Brzovic 2001 and Witus 2021. Also gathering structural evidence for BRCT domain phospho-peptide binding from Clapperton 2004 NSMB to meet the requirement for primary structural citations.",
        "**Synthesizing key BRCA and PARPi literature**\n\nIdentified primary papers on BRCT domain phospho-recognition, BRCAness, and synthetic lethality with PARP inhibitors, prioritizing Bryant et al. 2005 and Farmer et al. 2005. Planning to include reversion mutations conferring PARPi resistance, highlighting classic and recent studies, including a 2024 Molecular Cancer paper on BRCA1 splice-site mutations causing exon 11 skipping as a novel resistance mechanism.",
        "**Detailing reversion and compensatory mutations**\n\nPlanning to summarize secondary BRCA1/2 mutations restoring reading frame causing PARPi/platinum resistance, citing foundational 2008 studies and the 2024 Molecular Cancer paper on exon 11 skipping as compensatory. Also including compensatory loss-of-function mutations in 53BP1/Shieldin complex restoring homologous recombination, supported by primary research like Bouwman et al. 2010.",
        "**Identifying key citations**\n\nI found a 2008 study on secondary BRCA1 mutations related to platinum resistance to use as a primary reference, and noted that 2005 Nature papers cover PARP synthetic lethality; I'll search to include these appropriately.",
        "**Mapping core literature for synthetic lethality explanation**\n\nThe plan is to primarily cite Bryant 2005 for PARP inhibitor synthetic lethality, possibly supplemented by Farmer 2005, though we may rely on Bryant alone. To illustrate PARP1 trapping, a primary mechanistic paper like Murai 2012 is suitable. Recent key papers on BRCA1-BARD1 in DNA end resection and RNF168-BARD1 recruitment from 2024 and 2021 will also be incorporated, ensuring primary research supports the molecular details.",
        "**Outlining detailed BRCA1 domain functions and repair axis**\n\nI'm structuring the mechanistic explanation to cover key BRCA1 domains—RING, coiled-coil, BRCT—with their precise positions and functions, including mutation effects like 185delAG truncation. The plan integrates primary studies on BRCA1-BARD1 complex recruitment, PALB2 bridging, BRCA2-RAD51 interactions, and recent papers on ubiquitin-mediated recruitment and resection. I'll also address BRCAness as an HR deficiency phenotype linked to PARP sensitivity and cover known compensatory/reversion mutations restoring HR, ensuring all key claims are tightly cited and organized into clear sections.",
        "**Summarizing key citations for BRCT and RING domains**\n\nI'm compiling foundational citations for BRCT pSXXF interactions, RING domain boundaries and activity, BARD1-E2 binding, nucleosomal H2A ubiquitination, recruitment mechanisms, and PARP inhibitor resistance, ensuring key structural and biochemical studies are properly referenced.",
        "**Clarifying BRCA1 domains, HR disruption, and resistance mechanisms**\n\nI'm organizing detailed domain mappings for the 185delAG frameshift with citation-backed positions and effects on protein function, outlining the BRCA1-PALB2-BRCA2-RAD51 HR axis disruption and recruitment steps, defining BRCAness including related gene defects, and summarizing reversion and compensatory resistance mechanisms with precise source attributions.",
        "**Finalizing resistance and domain impact citations**\n\nI'm outlining a clear bullet list of tumor-acquired resistance mutations restoring BRCA1 function with primary research citations, confirming BARD1's recognition of RNF168-ubiquitinated H2A via BUDR, emphasizing the loss of RING-mediated E3 ligase activity in 185delAG truncations, and structuring the final response with domain maps, HR disruption steps, and mechanism overviews fully backed by primary sources."
      ],
      "web_searches": [
        {
          "id": "ws_08b7f638efd06faa016996b9b3923c81a389c4ee36e9c0f462",
          "query": "BRCA1 RING domain BARD1 heterodimer E3 ubiquitin ligase nucleosome H2A mechanistic study",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9b95a4081a3b7e543e77a7db09b",
          "query": "BRCA1 PALB2 coiled-coil interaction structural basis 2014 2015 2017",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9bda37481a3999e4238ffdd664a",
          "query": "UniProt BRCA1 human Q5O- domain RING coiled-coil BRCT boundaries",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9c1604081a3877e29b962829187",
          "query": "UniProt P38398 BRCA1 domain RING BRCT coiled-coil aa positions",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9c5f29081a3a5bec80a20a06164",
          "query": "UniProt P38398 BRCA1 RING-type zinc finger 24-65 BRCT 1646-1863 coiled-coil 1364-1437",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9ca1ce481a3b3b54f60cb3b70af",
          "query": "site:uniprot.org BRCA1 P38398 domain RING BRCT coiled-coil positions",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9cf440c81a38e6126331c2079aa",
          "query": "https://www.uniprot.org/uniprotkb/P38398/entry",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9d2226081a3b5ebbaeb99457dfc",
          "query": "https://rest.uniprot.org/uniprotkb/P38398.txt",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9d4a8d081a3b2f60053c2e884c0",
          "query": "'RING' in https://rest.uniprot.org/uniprotkb/P38398.txt",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9d895b881a3a6bc44274e16dca2",
          "query": "https://rest.uniprot.org/uniprotkb/P38398.txt",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9ddcfc481a396c7b9128bcc2547",
          "query": "",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9e0c0d481a3bcf215c2abffee01",
          "query": "rest.uniprot.org/uniprotkb/P38398?format=json",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9f2fb2c81a3b87371e529a7ec44",
          "query": "BRCA1 coiled-coil 1367 1437 PALB2 binding Sy 2009 2010 paper",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996b9f9f02c81a38671cc56225b1c9f",
          "query": "Sy PALB2 BRCA1 coiled-coil 1364 1437 2009 BRCA1 interaction residues",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996ba000dec81a3a211c7a11782ef81",
          "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996ba00f8b481a3afbd837cd0397eef",
          "query": "'1364' in https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996ba0f6df081a3977e819880ea6a98",
          "query": "BRCA1 BRCT BACH1 phosphopeptide structure 2004 PubMed 15133502",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996ba20b9c481a398020808e1b10ca6",
          "query": "loss of 53BP1 rescues BRCA1 deficiency homologous recombination 2010 Nature",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996ba25016c81a3b08e858c354e6365",
          "query": "PARP inhibitor synthetic lethality BRCA2 2005 Nature Bryant 2005",
          "results": []
        },
        {
          "id": "ws_08b7f638efd06faa016996ba535c4081a3961c03e77061538e",
          "query": "15133502 BRCA1 BRCT BACH1 phosphopeptide PubMed",
          "results": []
        }
      ],
      "command_executions": [
        {
          "id": "item_1",
          "command": "/bin/zsh -lc \"sed -n '1,200p' /Users/lingzhi/.codex/skills/web-search/SKILL.md\"",
          "output": "---\nname: web-search\ndescription: Search and browse the public web from Codex CLI (联网搜索/查网页/找资料/给链接/带出处). Use when you need up-to-date info or answers that must cite web sources.\n---\n\n# Web Search (联网搜索)\n\nThis skill provides a repeatable workflow to search the web, optionally fetch page text, and answer with sources.\n\n## Quick start\n\n- Search:\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --format md`\n- Search + fetch page text (for evidence):\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --fetch --format md`\n\n## Providers (auto)\n\nThe script picks the first available provider:\n\n- **Tavily**: set `TAVILY_API_KEY`\n- **Serper**: set `SERPER_API_KEY`\n- **Brave**: set `BRAVE_API_KEY` (or `BRAVE_SEARCH_API_KEY`)\n- **Fallback**: DuckDuckGo HTML scrape (best-effort; may break)\n\n## Workflow\n\n- Clarify what must be looked up and what must be cited.\n- Run the search script; pick 3–5 sources.\n- If a claim is important/controversial, re-run with `--fetch` and quote specific lines from sources.\n- In the final answer:\n  - Include a **Sources** list with URLs.\n  - Never invent citations; if evidence is missing, say so.\n\n## Notes\n\n- This skill uses network access. In restricted network/sandbox modes, request escalation before running the script.\n",
          "exit_code": 0
        }
      ],
      "final_output": "Below is a focused mechanistic analysis of the **BRCA1 c.68_69delAG (185delAG)** allele, emphasizing domain-level impact, HRR axis disruption, BRCA1–BARD1 E3 ligase behavior, BRCAness/PARP synthetic lethality, and documented compensatory or reversion mechanisms. I’ve prioritized **primary mechanistic studies** and recent work.\n\n**Domain-Level Consequences of 185delAG**\n- **Early truncation with translation reinitiation**: The frameshift introduces a premature stop near codon 39, and translation can reinitiate at a downstream AUG (~128), producing an N‑terminally truncated BRCA1. This removes the N‑terminal segment that contains the RING domain. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16941470/?utm_source=openai))  \n- **RING domain loss**: The RING domain is an N‑terminal (~1–110) zinc‑binding module that heterodimerizes with BARD1; losing this region abolishes the BRCA1–BARD1 RING–RING interface and its E3 ligase activity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11573085/?utm_source=openai))  \n- **Coiled‑coil region remains but cannot be productively used**: The BRCA1 coiled‑coil domain that binds PALB2 lies in residues ~1364–1437; it is intact in the reinitiated protein, but **recruitment and function are compromised** without the N‑terminal BRCA1–BARD1 module that anchors BRCA1 at damage sites. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/))  \n- **BRCT tandem domains remain**: The C‑terminal tandem BRCT domains (approx. 1651–1863) are intact in the reinitiated protein and still recognize phosphorylated pSXXF motifs (e.g., CtIP/BACH1/Abraxas), but their DNA‑damage recruitment context is disrupted because the upstream BRCA1–BARD1 axis is lost. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S002192581960058X?utm_source=openai))  \n\n**How Loss of Functional BRCA1 Impairs HRR (BRCA1–PALB2–BRCA2–RAD51 Axis)**\n1. **Damage-site recruitment**: RNF168‑dependent H2A ubiquitin marks promote BARD1‑mediated recruitment of BRCA1–PALB2 to DNA breaks; without BRCA1’s N‑terminal RING/BARD1 module, this recruitment is impaired. ([nature.com](https://www.nature.com/articles/s41467-021-25346-4?utm_source=openai))  \n2. **DNA end resection**: BRCA1–BARD1 works with CtIP/MRN and long‑range resection machinery (WRN/BLM–DNA2–RPA) to stimulate resection. Loss of BRCA1–BARD1 reduces productive resection and HR entry. ([nature.com](https://www.nature.com/articles/s41586-024-07909-9?utm_source=openai))  \n3. **PALB2 bridging**: BRCA1’s coiled‑coil region binds PALB2 (BRCA1 residues ~1364–1437), enabling PALB2 to bridge BRCA1 with BRCA2 and organize BRCA2/RAD51 loading at breaks. Disruption of BRCA1–PALB2 binding compromises HR. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/))  \n4. **BRCA2-mediated RAD51 loading**: BRCA2’s BRC repeats and C‑terminal RAD51‑binding region load and stabilize RAD51 filaments on RPA‑coated ssDNA; this step fails when BRCA1 cannot recruit PALB2/BRCA2. ([nature.com](https://www.nature.com/articles/s41467-023-36211-x?utm_source=openai))  \n5. **RAD51‑driven strand invasion**: BRCA1–BARD1 also directly enhances RAD51‑mediated homologous pairing and synaptic complex formation, a late HR step that is lost when BRCA1–BARD1 is absent. ([nature.com](https://www.nature.com/articles/nature24060?utm_source=openai))  \n\n**BRCA1–BARD1 E3 Ubiquitin Ligase Complex**\n- The BRCA1 RING domain binds BARD1 to form an active E3 ligase; the E2 enzyme UbcH5c binds **BRCA1’s** RING and is required for ligase activity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11573085/?utm_source=openai))  \n- Structural and biochemical studies show BRCA1–BARD1 ubiquitinates nucleosomal H2A specifically at K125/127/129, with BARD1 providing key nucleosome‑recognition surfaces. Loss of the BRCA1 RING abolishes this activity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33589814/?utm_source=openai))  \n\n**BRCAness and Synthetic Lethality with PARP Inhibition**\n- **BRCAness** is a functional state of **HR deficiency** that phenocopies BRCA1/2 loss, including defects in PALB2 or RAD51 paralogs; such tumors show HR impairment and PARP‑inhibitor sensitivity. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/))  \n- **Synthetic lethality (PARP inhibition + HR deficiency)**: PARP inhibitors cause lesions that convert into DSBs during replication; BRCA‑deficient cells cannot repair these DSBs by HR and die, establishing the synthetic lethal interaction. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15829966/?utm_source=openai))  \n\n**Documented Compensatory or Reversion Mechanisms**\n1. **BRCA1 reversion mutations**: Secondary BRCA1 mutations restoring the reading frame appear in platinum‑resistant ovarian tumors, re‑establishing BRCA1 protein expression and HR. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18413725/?utm_source=openai))  \n2. **Secondary splice‑site changes (exon 11 skipping)**: Acquired BRCA1 splice‑site mutations can increase Δ11/Δ11q isoforms and promote PARP‑inhibitor resistance in BRCA1 exon‑11 mutant tumors. ([link.springer.com](https://link.springer.com/article/10.1186/s12943-024-02048-1?utm_source=openai))  \n3. **Reversion in other HR genes**: Secondary mutations restoring RAD51C/D have been observed after PARP‑inhibitor treatment, consistent with regained HR and drug resistance. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28588062/?utm_source=openai))  \n4. **Compensatory pathway shifts**: Loss of 53BP1 (or its pathway) can partially restore HR in BRCA1‑deficient cells by allowing resection and PALB2‑dependent recruitment, reducing PARP‑inhibitor sensitivity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20362325/?utm_source=openai))  \n\nIf you want, I can extend this with a compact **protein‑domain schematic** that annotates all interaction partners (BARD1, CtIP, Abraxas, BRIP1, PALB2, BRCA2, RAD51) mapped onto residue ranges, or I can integrate these mechanisms into a patient‑facing or clinician‑facing decision summary.",
      "usage": {
        "input_tokens": 106038,
        "cached_input_tokens": 17664,
        "output_tokens": 17160
      },
      "error": null,
      "step": 2,
      "raw_event_count": 75,
      "raw_events_by_type": {
        "thread.started": [
          {
            "type": "thread.started",
            "thread_id": "019c74c5-2390-7511-91a3-239a1027c4bd"
          }
        ],
        "turn.started": [
          {
            "type": "turn.started"
          }
        ],
        "item.completed": [
          {
            "type": "item.completed",
            "item": {
              "id": "item_0",
              "type": "reasoning",
              "text": "**Preparing to read skill file**\n\nI'm running a command to read the web-search skill's SKILL.md file first before using the web.run tool for searches."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_1",
              "type": "command_execution",
              "command": "/bin/zsh -lc \"sed -n '1,200p' /Users/lingzhi/.codex/skills/web-search/SKILL.md\"",
              "aggregated_output": "---\nname: web-search\ndescription: Search and browse the public web from Codex CLI (联网搜索/查网页/找资料/给链接/带出处). Use when you need up-to-date info or answers that must cite web sources.\n---\n\n# Web Search (联网搜索)\n\nThis skill provides a repeatable workflow to search the web, optionally fetch page text, and answer with sources.\n\n## Quick start\n\n- Search:\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --format md`\n- Search + fetch page text (for evidence):\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --fetch --format md`\n\n## Providers (auto)\n\nThe script picks the first available provider:\n\n- **Tavily**: set `TAVILY_API_KEY`\n- **Serper**: set `SERPER_API_KEY`\n- **Brave**: set `BRAVE_API_KEY` (or `BRAVE_SEARCH_API_KEY`)\n- **Fallback**: DuckDuckGo HTML scrape (best-effort; may break)\n\n## Workflow\n\n- Clarify what must be looked up and what must be cited.\n- Run the search script; pick 3–5 sources.\n- If a claim is important/controversial, re-run with `--fetch` and quote specific lines from sources.\n- In the final answer:\n  - Include a **Sources** list with URLs.\n  - Never invent citations; if evidence is missing, say so.\n\n## Notes\n\n- This skill uses network access. In restricted network/sandbox modes, request escalation before running the script.\n",
              "exit_code": 0,
              "status": "completed"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_2",
              "type": "reasoning",
              "text": "**Planning targeted web searches**\n\nI'm preparing to run up to four web searches focused on primary, authoritative sources like PubMed and top journals to collect recent mechanistic research on BRCA1 domains, interactions, and reversion mutations for accurate, cited answers."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_3",
              "type": "reasoning",
              "text": "**Executing focused literature searches**\n\nI'm initiating four targeted web.run queries on BRCA1 domain mechanisms, protein interactions, homologous recombination pathways, and recent reviews on reversion mutations linked to therapy resistance."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9b3923c81a389c4ee36e9c0f462",
              "type": "web_search",
              "query": "BRCA1 RING domain BARD1 heterodimer E3 ubiquitin ligase nucleosome H2A mechanistic study",
              "action": {
                "type": "search",
                "query": "BRCA1 RING domain BARD1 heterodimer E3 ubiquitin ligase nucleosome H2A mechanistic study",
                "queries": [
                  "BRCA1 RING domain BARD1 heterodimer E3 ubiquitin ligase nucleosome H2A mechanistic study",
                  "BRCA1 BRCT domains phosphopeptide binding ABRAXAS BRIP1 CtIP interaction structure",
                  "BRCA1 PALB2 BRCA2 RAD51 axis homologous recombination end resection mechanistic study",
                  "BRCA1 reversion mutations PARP inhibitor resistance 2022 2024 review"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_5",
              "type": "reasoning",
              "text": "**Refining literature search strategy**\n\nI'm prioritizing primary research from key journals for technical accuracy and focusing on curated sources like Uniprot for domain architecture. Next, I'll run targeted searches on BRCA1-PALB2 interactions and reversion mutations using precise keywords to gather detailed mechanistic data."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9b95a4081a3b7e543e77a7db09b",
              "type": "web_search",
              "query": "BRCA1 PALB2 coiled-coil interaction structural basis 2014 2015 2017",
              "action": {
                "type": "search",
                "query": "BRCA1 PALB2 coiled-coil interaction structural basis 2014 2015 2017",
                "queries": [
                  "BRCA1 PALB2 coiled-coil interaction structural basis 2014 2015 2017",
                  "BRCA1 BRCA2 RAD51 loading mediator PALB2 mechanistic study homologous recombination",
                  "BRCA1 reversion mutation PARP inhibitor resistance clinical study 2020 2024",
                  "BRCA1 185delAG translation reinitiation AUG 128 Buisson 2006"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_7",
              "type": "reasoning",
              "text": "**Confirming domain boundaries from Uniprot**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9bda37481a3999e4238ffdd664a",
              "type": "web_search",
              "query": "UniProt BRCA1 human Q5O- domain RING coiled-coil BRCT boundaries",
              "action": {
                "type": "search",
                "query": "UniProt BRCA1 human Q5O- domain RING coiled-coil BRCT boundaries",
                "queries": [
                  "UniProt BRCA1 human Q5O- domain RING coiled-coil BRCT boundaries",
                  "BRCA1 coiled-coil PALB2 interaction domain 1364 1437 study",
                  "BRCA1 BARD1 RING heterodimer structure 2001 Brzovic",
                  "BRCA1 reversion mutations c.68_69delAG PARP inhibitor resistance clinical case"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_9",
              "type": "reasoning",
              "text": "**Planning domain boundary search**\n\nI'm preparing to extract domain boundaries for BRCA1 using explicit UniProt queries focusing on domains like RING, BRCT, and coiled-coil."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9c1604081a3877e29b962829187",
              "type": "web_search",
              "query": "UniProt P38398 BRCA1 domain RING BRCT coiled-coil aa positions",
              "action": {
                "type": "search",
                "query": "UniProt P38398 BRCA1 domain RING BRCT coiled-coil aa positions",
                "queries": [
                  "UniProt P38398 BRCA1 domain RING BRCT coiled-coil aa positions",
                  "BRCA1 BRCT phosphopeptide binding pSXXF structure 2010 2011",
                  "BRCA1-BARD1 H2A K125 K127 K129 ubiquitination Witus Hu 2021",
                  "BRCA1-BARD1 promotes DNA end resection CtIP interaction 2017 2018"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_11",
              "type": "reasoning",
              "text": "**Planning direct UniProt search**\n\nI'll perform a direct UniProt search for the given protein and domain ranges to locate domain positions. If results are insufficient, I'll open UniProt manually to verify details."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9c5f29081a3a5bec80a20a06164",
              "type": "web_search",
              "query": "UniProt P38398 BRCA1 RING-type zinc finger 24-65 BRCT 1646-1863 coiled-coil 1364-1437",
              "action": {
                "type": "search",
                "query": "UniProt P38398 BRCA1 RING-type zinc finger 24-65 BRCT 1646-1863 coiled-coil 1364-1437",
                "queries": [
                  "UniProt P38398 BRCA1 RING-type zinc finger 24-65 BRCT 1646-1863 coiled-coil 1364-1437",
                  "BRCA1 coiled-coil domain residues 1364 1437 PALB2 interaction Sy 2009 2008",
                  "BRCA1 BRCT domain recognizes pSXXF motif Abraxas 2007 structure",
                  "BRCA1 185delAG reinitiation AUG128 Buisson 2006 translation reinitiation"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_13",
              "type": "reasoning",
              "text": "**Searching UniProt for domain data**\n\nPlanning to obtain domain positions from the authoritative UniProt source, focusing on UniProt entries filtered by domains."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9ca1ce481a3b3b54f60cb3b70af",
              "type": "web_search",
              "query": "site:uniprot.org BRCA1 P38398 domain RING BRCT coiled-coil positions",
              "action": {
                "type": "search",
                "query": "site:uniprot.org BRCA1 P38398 domain RING BRCT coiled-coil positions",
                "queries": [
                  "site:uniprot.org BRCA1 P38398 domain RING BRCT coiled-coil positions",
                  "BRCA1 Uniprot P38398 \"RING\" \"BRCT\" \"coiled-coil\"",
                  "BRCA1 BARD1 RING heterodimer nucleosome H2A K125 K127 K129 2021 Nat Struct Mol Biol Witus",
                  "BRCA1 reversion mutations PARP inhibitor resistance 2021 2023 ovarian breast"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_15",
              "type": "reasoning",
              "text": "**Opening Uniprot entry directly**\n\nI'm opening the specific Uniprot entry URL directly since the search didn't yield results, ensuring accurate access to the needed data."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9cf440c81a38e6126331c2079aa",
              "type": "web_search",
              "query": "https://www.uniprot.org/uniprotkb/P38398/entry",
              "action": {
                "type": "open_page",
                "url": "https://www.uniprot.org/uniprotkb/P38398/entry"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_17",
              "type": "reasoning",
              "text": "**Choosing Uniprot REST API**\n\nDecided to use the Uniprot REST API with open requests to fetch data in text or JSON format for fallback instead of JS-rendered content."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9d2226081a3b5ebbaeb99457dfc",
              "type": "web_search",
              "query": "https://rest.uniprot.org/uniprotkb/P38398.txt",
              "action": {
                "type": "open_page",
                "url": "https://rest.uniprot.org/uniprotkb/P38398.txt"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_19",
              "type": "reasoning",
              "text": "**Planning domain feature search**\n\nI'm preparing to use the find tool with a pattern like \"RING\" or \"BRCT\" on the Uniprot text to locate specific domain features efficiently."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9d4a8d081a3b2f60053c2e884c0",
              "type": "web_search",
              "query": "'RING' in https://rest.uniprot.org/uniprotkb/P38398.txt",
              "action": {
                "type": "find_in_page",
                "url": "https://rest.uniprot.org/uniprotkb/P38398.txt",
                "pattern": "RING"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_21",
              "type": "reasoning",
              "text": "**Adjusting file read start for features**\n\nThe file preview of 200 lines misses the features section, so I'll open the file further down, around line 800–1200, to locate the \"FT\" lines and relevant domain features."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9d895b881a3a6bc44274e16dca2",
              "type": "web_search",
              "query": "https://rest.uniprot.org/uniprotkb/P38398.txt",
              "action": {
                "type": "open_page",
                "url": "https://rest.uniprot.org/uniprotkb/P38398.txt"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_23",
              "type": "reasoning",
              "text": "**Switching to Uniprot JSON API**\n\nOpening the local file with line numbers is limited by a 200-line truncate, blocking feature inspection. I'll use the Uniprot REST JSON API instead to get full feature data and parse it within the tool."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9ddcfc481a396c7b9128bcc2547",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "open_page"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_25",
              "type": "reasoning",
              "text": "**Searching for JSON data URL**\n\nI'm searching for a JSON or TSV endpoint for the given UniProt ID to locate an allowed URL for opening and further data extraction."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9e0c0d481a3bcf215c2abffee01",
              "type": "web_search",
              "query": "rest.uniprot.org/uniprotkb/P38398?format=json",
              "action": {
                "type": "search",
                "query": "rest.uniprot.org/uniprotkb/P38398?format=json",
                "queries": [
                  "rest.uniprot.org/uniprotkb/P38398?format=json",
                  "Uniprot P38398 features tsv domain"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_27",
              "type": "reasoning",
              "text": "**Clarifying URL opening constraints**\n\nThe REST API JSON URL isn't directly from search results or user message, so opening it violates URL safety rules; the .txt URL was allowed likely because it matched a previous context. Next, I'll explore ways to retrieve allowed URLs from search results or user input to access the JSON data safely."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_28",
              "type": "reasoning",
              "text": "**Pivoting to primary literature for domain positions**\n\nSince opening new UniProt API URLs is restricted, I'll rely on primary studies to specify domain positions precisely, citing key papers for RING, BRCT, and coiled-coil regions. Next, I'll search specifically for primary sources on the BRCA1 coiled-coil domain in Sy et al. 2009/2010 to confirm exact residue ranges."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9f2fb2c81a3b87371e529a7ec44",
              "type": "web_search",
              "query": "BRCA1 coiled-coil 1367 1437 PALB2 binding Sy 2009 2010 paper",
              "action": {
                "type": "search",
                "query": "BRCA1 coiled-coil 1367 1437 PALB2 binding Sy 2009 2010 paper",
                "queries": [
                  "BRCA1 coiled-coil 1367 1437 PALB2 binding Sy 2009 2010 paper",
                  "BRCA1 PALB2 interaction coiled-coil residues 1364 1437 Cell 2009",
                  "BRCA1 PALB2 bridge BRCA2 2009 Nature 2009 2010",
                  "PALB2 bridges BRCA1 and BRCA2 coiled-coil domain residues BRCA1 1364 1437"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_30",
              "type": "reasoning",
              "text": "**Identifying primary sources for PALB2 mapping**\n\nPlanning to locate primary papers for PALB2 coiled-coil region mapping, focusing on Sy et al. 2009 to precisely define residues 1367-1437 and complement Zhang et al. 2009, ensuring technical accuracy beyond review citations."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9f9f02c81a38671cc56225b1c9f",
              "type": "web_search",
              "query": "Sy PALB2 BRCA1 coiled-coil 1364 1437 2009 BRCA1 interaction residues",
              "action": {
                "type": "search",
                "query": "Sy PALB2 BRCA1 coiled-coil 1364 1437 2009 BRCA1 interaction residues",
                "queries": [
                  "Sy PALB2 BRCA1 coiled-coil 1364 1437 2009 BRCA1 interaction residues",
                  "BRCA1 PALB2 coiled-coil interaction 1364 1437 Genes Dev 2009",
                  "BRCA1 PALB2 coiled-coil interaction 2010 paper residues 1367 1437"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_32",
              "type": "reasoning",
              "text": "**Identifying primary source for PALB2-BRCA1**\n\nI'm focusing on a primary PMC article, likely Xia et al. 2007, that details the BRCA1 coiled-coil region and residues 1364-1437 relevant for PALB2 interaction to confirm and cite accurately."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996ba000dec81a3a211c7a11782ef81",
              "type": "web_search",
              "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/",
              "action": {
                "type": "open_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_34",
              "type": "reasoning",
              "text": "**Searching page for residue references**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996ba00f8b481a3afbd837cd0397eef",
              "type": "web_search",
              "query": "'1364' in https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/",
              "action": {
                "type": "find_in_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/",
                "pattern": "1364"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_36",
              "type": "reasoning",
              "text": "**Specifying precise domain boundaries**\n\nDecided on precise BRCA1 domain ranges: RING domain at amino acids 1–100/110 supported by Brzovic 2001 NMR structure, coiled-coil at 1364–1437 from PNAS 2009, and BRCT domain at 1646–1859 per Williams 2001 Nat Struct Biol. These targeted citations support detailed domain and interaction mapping as requested."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_37",
              "type": "reasoning",
              "text": "**Planning precise functional domain citations**\n\nPreparing to cite primary sources linking truncated BRCA1 from 185delAG to loss of RING domain (aa 1–110) using Buisson 2006, with RING domain functions and E3 activity detailed via Brzovic 2001 and Witus 2021. Also gathering structural evidence for BRCT domain phospho-peptide binding from Clapperton 2004 NSMB to meet the requirement for primary structural citations."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996ba0f6df081a3977e819880ea6a98",
              "type": "web_search",
              "query": "BRCA1 BRCT BACH1 phosphopeptide structure 2004 PubMed 15133502",
              "action": {
                "type": "search",
                "query": "BRCA1 BRCT BACH1 phosphopeptide structure 2004 PubMed 15133502",
                "queries": [
                  "BRCA1 BRCT BACH1 phosphopeptide structure 2004 PubMed 15133502",
                  "BRCA1 BRCT CtIP structure phosphopeptide Varma 2005 PubMed 16101277",
                  "BRCA1 BRCT Abraxas complex 2016 Mol Cell PubMed 26778126",
                  "BRCA1 BARD1 RING UbcH5c interaction PNAS 2003 PubMed 12732733"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_39",
              "type": "reasoning",
              "text": "**Synthesizing key BRCA and PARPi literature**\n\nIdentified primary papers on BRCT domain phospho-recognition, BRCAness, and synthetic lethality with PARP inhibitors, prioritizing Bryant et al. 2005 and Farmer et al. 2005. Planning to include reversion mutations conferring PARPi resistance, highlighting classic and recent studies, including a 2024 Molecular Cancer paper on BRCA1 splice-site mutations causing exon 11 skipping as a novel resistance mechanism."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_40",
              "type": "reasoning",
              "text": "**Detailing reversion and compensatory mutations**\n\nPlanning to summarize secondary BRCA1/2 mutations restoring reading frame causing PARPi/platinum resistance, citing foundational 2008 studies and the 2024 Molecular Cancer paper on exon 11 skipping as compensatory. Also including compensatory loss-of-function mutations in 53BP1/Shieldin complex restoring homologous recombination, supported by primary research like Bouwman et al. 2010."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996ba20b9c481a398020808e1b10ca6",
              "type": "web_search",
              "query": "loss of 53BP1 rescues BRCA1 deficiency homologous recombination 2010 Nature",
              "action": {
                "type": "search",
                "query": "loss of 53BP1 rescues BRCA1 deficiency homologous recombination 2010 Nature",
                "queries": [
                  "loss of 53BP1 rescues BRCA1 deficiency homologous recombination 2010 Nature",
                  "Shieldin REV7 loss restores HR BRCA1 PARP inhibitor resistance 2017 Nature",
                  "BRCA1 reversion mutations platinum resistance ovarian cancer 2008 2014",
                  "secondary BRCA1 mutations restore open reading frame PARP inhibitor resistance ovarian breast"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_42",
              "type": "reasoning",
              "text": "**Identifying key citations**\n\nI found a 2008 study on secondary BRCA1 mutations related to platinum resistance to use as a primary reference, and noted that 2005 Nature papers cover PARP synthetic lethality; I'll search to include these appropriately."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996ba25016c81a3b08e858c354e6365",
              "type": "web_search",
              "query": "PARP inhibitor synthetic lethality BRCA2 2005 Nature Bryant 2005",
              "action": {
                "type": "search",
                "query": "PARP inhibitor synthetic lethality BRCA2 2005 Nature Bryant 2005",
                "queries": [
                  "PARP inhibitor synthetic lethality BRCA2 2005 Nature Bryant 2005",
                  "PARP inhibitors BRCA1 BRCA2 synthetic lethality 2005 Farmer Nature",
                  "PARP inhibitors selectively kill BRCA1 BRCA2 defective cells 2005 Science"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_44",
              "type": "reasoning",
              "text": "**Mapping core literature for synthetic lethality explanation**\n\nThe plan is to primarily cite Bryant 2005 for PARP inhibitor synthetic lethality, possibly supplemented by Farmer 2005, though we may rely on Bryant alone. To illustrate PARP1 trapping, a primary mechanistic paper like Murai 2012 is suitable. Recent key papers on BRCA1-BARD1 in DNA end resection and RNF168-BARD1 recruitment from 2024 and 2021 will also be incorporated, ensuring primary research supports the molecular details."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_45",
              "type": "reasoning",
              "text": "**Outlining detailed BRCA1 domain functions and repair axis**\n\nI'm structuring the mechanistic explanation to cover key BRCA1 domains—RING, coiled-coil, BRCT—with their precise positions and functions, including mutation effects like 185delAG truncation. The plan integrates primary studies on BRCA1-BARD1 complex recruitment, PALB2 bridging, BRCA2-RAD51 interactions, and recent papers on ubiquitin-mediated recruitment and resection. I'll also address BRCAness as an HR deficiency phenotype linked to PARP sensitivity and cover known compensatory/reversion mutations restoring HR, ensuring all key claims are tightly cited and organized into clear sections."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_08b7f638efd06faa016996ba535c4081a3961c03e77061538e",
              "type": "web_search",
              "query": "15133502 BRCA1 BRCT BACH1 phosphopeptide PubMed",
              "action": {
                "type": "search",
                "query": "15133502 BRCA1 BRCT BACH1 phosphopeptide PubMed",
                "queries": [
                  "15133502 BRCA1 BRCT BACH1 phosphopeptide PubMed",
                  "BRCA1 BRCT CtIP structure 16101277 PubMed"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_47",
              "type": "reasoning",
              "text": "**Summarizing key citations for BRCT and RING domains**\n\nI'm compiling foundational citations for BRCT pSXXF interactions, RING domain boundaries and activity, BARD1-E2 binding, nucleosomal H2A ubiquitination, recruitment mechanisms, and PARP inhibitor resistance, ensuring key structural and biochemical studies are properly referenced."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_48",
              "type": "reasoning",
              "text": "**Clarifying BRCA1 domains, HR disruption, and resistance mechanisms**\n\nI'm organizing detailed domain mappings for the 185delAG frameshift with citation-backed positions and effects on protein function, outlining the BRCA1-PALB2-BRCA2-RAD51 HR axis disruption and recruitment steps, defining BRCAness including related gene defects, and summarizing reversion and compensatory resistance mechanisms with precise source attributions."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_49",
              "type": "reasoning",
              "text": "**Finalizing resistance and domain impact citations**\n\nI'm outlining a clear bullet list of tumor-acquired resistance mutations restoring BRCA1 function with primary research citations, confirming BARD1's recognition of RNF168-ubiquitinated H2A via BUDR, emphasizing the loss of RING-mediated E3 ligase activity in 185delAG truncations, and structuring the final response with domain maps, HR disruption steps, and mechanism overviews fully backed by primary sources."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_50",
              "type": "agent_message",
              "text": "Below is a focused mechanistic analysis of the **BRCA1 c.68_69delAG (185delAG)** allele, emphasizing domain-level impact, HRR axis disruption, BRCA1–BARD1 E3 ligase behavior, BRCAness/PARP synthetic lethality, and documented compensatory or reversion mechanisms. I’ve prioritized **primary mechanistic studies** and recent work.\n\n**Domain-Level Consequences of 185delAG**\n- **Early truncation with translation reinitiation**: The frameshift introduces a premature stop near codon 39, and translation can reinitiate at a downstream AUG (~128), producing an N‑terminally truncated BRCA1. This removes the N‑terminal segment that contains the RING domain. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16941470/?utm_source=openai))  \n- **RING domain loss**: The RING domain is an N‑terminal (~1–110) zinc‑binding module that heterodimerizes with BARD1; losing this region abolishes the BRCA1–BARD1 RING–RING interface and its E3 ligase activity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11573085/?utm_source=openai))  \n- **Coiled‑coil region remains but cannot be productively used**: The BRCA1 coiled‑coil domain that binds PALB2 lies in residues ~1364–1437; it is intact in the reinitiated protein, but **recruitment and function are compromised** without the N‑terminal BRCA1–BARD1 module that anchors BRCA1 at damage sites. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/))  \n- **BRCT tandem domains remain**: The C‑terminal tandem BRCT domains (approx. 1651–1863) are intact in the reinitiated protein and still recognize phosphorylated pSXXF motifs (e.g., CtIP/BACH1/Abraxas), but their DNA‑damage recruitment context is disrupted because the upstream BRCA1–BARD1 axis is lost. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S002192581960058X?utm_source=openai))  \n\n**How Loss of Functional BRCA1 Impairs HRR (BRCA1–PALB2–BRCA2–RAD51 Axis)**\n1. **Damage-site recruitment**: RNF168‑dependent H2A ubiquitin marks promote BARD1‑mediated recruitment of BRCA1–PALB2 to DNA breaks; without BRCA1’s N‑terminal RING/BARD1 module, this recruitment is impaired. ([nature.com](https://www.nature.com/articles/s41467-021-25346-4?utm_source=openai))  \n2. **DNA end resection**: BRCA1–BARD1 works with CtIP/MRN and long‑range resection machinery (WRN/BLM–DNA2–RPA) to stimulate resection. Loss of BRCA1–BARD1 reduces productive resection and HR entry. ([nature.com](https://www.nature.com/articles/s41586-024-07909-9?utm_source=openai))  \n3. **PALB2 bridging**: BRCA1’s coiled‑coil region binds PALB2 (BRCA1 residues ~1364–1437), enabling PALB2 to bridge BRCA1 with BRCA2 and organize BRCA2/RAD51 loading at breaks. Disruption of BRCA1–PALB2 binding compromises HR. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/))  \n4. **BRCA2-mediated RAD51 loading**: BRCA2’s BRC repeats and C‑terminal RAD51‑binding region load and stabilize RAD51 filaments on RPA‑coated ssDNA; this step fails when BRCA1 cannot recruit PALB2/BRCA2. ([nature.com](https://www.nature.com/articles/s41467-023-36211-x?utm_source=openai))  \n5. **RAD51‑driven strand invasion**: BRCA1–BARD1 also directly enhances RAD51‑mediated homologous pairing and synaptic complex formation, a late HR step that is lost when BRCA1–BARD1 is absent. ([nature.com](https://www.nature.com/articles/nature24060?utm_source=openai))  \n\n**BRCA1–BARD1 E3 Ubiquitin Ligase Complex**\n- The BRCA1 RING domain binds BARD1 to form an active E3 ligase; the E2 enzyme UbcH5c binds **BRCA1’s** RING and is required for ligase activity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11573085/?utm_source=openai))  \n- Structural and biochemical studies show BRCA1–BARD1 ubiquitinates nucleosomal H2A specifically at K125/127/129, with BARD1 providing key nucleosome‑recognition surfaces. Loss of the BRCA1 RING abolishes this activity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33589814/?utm_source=openai))  \n\n**BRCAness and Synthetic Lethality with PARP Inhibition**\n- **BRCAness** is a functional state of **HR deficiency** that phenocopies BRCA1/2 loss, including defects in PALB2 or RAD51 paralogs; such tumors show HR impairment and PARP‑inhibitor sensitivity. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/))  \n- **Synthetic lethality (PARP inhibition + HR deficiency)**: PARP inhibitors cause lesions that convert into DSBs during replication; BRCA‑deficient cells cannot repair these DSBs by HR and die, establishing the synthetic lethal interaction. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15829966/?utm_source=openai))  \n\n**Documented Compensatory or Reversion Mechanisms**\n1. **BRCA1 reversion mutations**: Secondary BRCA1 mutations restoring the reading frame appear in platinum‑resistant ovarian tumors, re‑establishing BRCA1 protein expression and HR. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18413725/?utm_source=openai))  \n2. **Secondary splice‑site changes (exon 11 skipping)**: Acquired BRCA1 splice‑site mutations can increase Δ11/Δ11q isoforms and promote PARP‑inhibitor resistance in BRCA1 exon‑11 mutant tumors. ([link.springer.com](https://link.springer.com/article/10.1186/s12943-024-02048-1?utm_source=openai))  \n3. **Reversion in other HR genes**: Secondary mutations restoring RAD51C/D have been observed after PARP‑inhibitor treatment, consistent with regained HR and drug resistance. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28588062/?utm_source=openai))  \n4. **Compensatory pathway shifts**: Loss of 53BP1 (or its pathway) can partially restore HR in BRCA1‑deficient cells by allowing resection and PALB2‑dependent recruitment, reducing PARP‑inhibitor sensitivity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20362325/?utm_source=openai))  \n\nIf you want, I can extend this with a compact **protein‑domain schematic** that annotates all interaction partners (BARD1, CtIP, Abraxas, BRIP1, PALB2, BRCA2, RAD51) mapped onto residue ranges, or I can integrate these mechanisms into a patient‑facing or clinician‑facing decision summary."
            }
          }
        ],
        "item.started": [
          {
            "type": "item.started",
            "item": {
              "id": "item_1",
              "type": "command_execution",
              "command": "/bin/zsh -lc \"sed -n '1,200p' /Users/lingzhi/.codex/skills/web-search/SKILL.md\"",
              "aggregated_output": "",
              "exit_code": null,
              "status": "in_progress"
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9b3923c81a389c4ee36e9c0f462",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9b95a4081a3b7e543e77a7db09b",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9bda37481a3999e4238ffdd664a",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9c1604081a3877e29b962829187",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9c5f29081a3a5bec80a20a06164",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9ca1ce481a3b3b54f60cb3b70af",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9cf440c81a38e6126331c2079aa",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9d2226081a3b5ebbaeb99457dfc",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9d4a8d081a3b2f60053c2e884c0",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9d895b881a3a6bc44274e16dca2",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9ddcfc481a396c7b9128bcc2547",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9e0c0d481a3bcf215c2abffee01",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9f2fb2c81a3b87371e529a7ec44",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996b9f9f02c81a38671cc56225b1c9f",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996ba000dec81a3a211c7a11782ef81",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996ba00f8b481a3afbd837cd0397eef",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996ba0f6df081a3977e819880ea6a98",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996ba20b9c481a398020808e1b10ca6",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996ba25016c81a3b08e858c354e6365",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_08b7f638efd06faa016996ba535c4081a3961c03e77061538e",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          }
        ],
        "turn.completed": [
          {
            "type": "turn.completed",
            "usage": {
              "input_tokens": 106038,
              "cached_input_tokens": 17664,
              "output_tokens": 17160
            }
          }
        ]
      }
    },
    {
      "agent_name": "cancer-pathologist",
      "system_prompt": "You are an anatomic pathologist and cancer biologist specializing in hereditary breast and ovarian cancers. You have access to web search — USE IT to look up NCCN guidelines, SEER data, tumor classification systems, and recent pathology literature. Integrate the molecular findings from previous experts into a pathological risk profile.",
      "user_prompt": "Based on the genomics and molecular biology research provided, analyze:\n- What specific cancer types is this patient at elevated risk for? (breast, ovarian, pancreatic, others) — provide lifetime risk percentages from recent studies.\n- What are the expected histological subtypes? (triple-negative breast cancer, high-grade serous ovarian carcinoma, etc.) — explain why BRCA1 tumors show these patterns.\n- What molecular subtypes are expected (basal-like, etc.) and what are the immunohistochemical profiles (ER/PR/HER2 status)?\n- What is the typical age of onset and tumor grade?\n- How does the tumor microenvironment differ in BRCA1-mutant cancers? (TILs, PD-L1 expression, genomic instability scores)\n\nUse web search for the latest NCCN guidelines and epidemiological data.",
      "full_prompt_sent": "You are: You are an anatomic pathologist and cancer biologist specializing in hereditary breast and ovarian cancers. You have access to web search — USE IT to look up NCCN guidelines, SEER data, tumor classification systems, and recent pathology literature. Integrate the molecular findings from previous experts into a pathological risk profile.\n\nContext from previous work:\nBelow is a focused mechanistic analysis of the **BRCA1 c.68_69delAG (185delAG)** allele, emphasizing domain-level impact, HRR axis disruption, BRCA1–BARD1 E3 ligase behavior, BRCAness/PARP synthetic lethality, and documented compensatory or reversion mechanisms. I’ve prioritized **primary mechanistic studies** and recent work.\n\n**Domain-Level Consequences of 185delAG**\n- **Early truncation with translation reinitiation**: The frameshift introduces a premature stop near codon 39, and translation can reinitiate at a downstream AUG (~128), producing an N‑terminally truncated BRCA1. This removes the N‑terminal segment that contains the RING domain. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16941470/?utm_source=openai))  \n- **RING domain loss**: The RING domain is an N‑terminal (~1–110) zinc‑binding module that heterodimerizes with BARD1; losing this region abolishes the BRCA1–BARD1 RING–RING interface and its E3 ligase activity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11573085/?utm_source=openai))  \n- **Coiled‑coil region remains but cannot be productively used**: The BRCA1 coiled‑coil domain that binds PALB2 lies in residues ~1364–1437; it is intact in the reinitiated protein, but **recruitment and function are compromised** without the N‑terminal BRCA1–BARD1 module that anchors BRCA1 at damage sites. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/))  \n- **BRCT tandem domains remain**: The C‑terminal tandem BRCT domains (approx. 1651–1863) are intact in the reinitiated protein and still recognize phosphorylated pSXXF motifs (e.g., CtIP/BACH1/Abraxas), but their DNA‑damage recruitment context is disrupted because the upstream BRCA1–BARD1 axis is lost. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S002192581960058X?utm_source=openai))  \n\n**How Loss of Functional BRCA1 Impairs HRR (BRCA1–PALB2–BRCA2–RAD51 Axis)**\n1. **Damage-site recruitment**: RNF168‑dependent H2A ubiquitin marks promote BARD1‑mediated recruitment of BRCA1–PALB2 to DNA breaks; without BRCA1’s N‑terminal RING/BARD1 module, this recruitment is impaired. ([nature.com](https://www.nature.com/articles/s41467-021-25346-4?utm_source=openai))  \n2. **DNA end resection**: BRCA1–BARD1 works with CtIP/MRN and long‑range resection machinery (WRN/BLM–DNA2–RPA) to stimulate resection. Loss of BRCA1–BARD1 reduces productive resection and HR entry. ([nature.com](https://www.nature.com/articles/s41586-024-07909-9?utm_source=openai))  \n3. **PALB2 bridging**: BRCA1’s coiled‑coil region binds PALB2 (BRCA1 residues ~1364–1437), enabling PALB2 to bridge BRCA1 with BRCA2 and organize BRCA2/RAD51 loading at breaks. Disruption of BRCA1–PALB2 binding compromises HR. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/))  \n4. **BRCA2-mediated RAD51 loading**: BRCA2’s BRC repeats and C‑terminal RAD51‑binding region load and stabilize RAD51 filaments on RPA‑coated ssDNA; this step fails when BRCA1 cannot recruit PALB2/BRCA2. ([nature.com](https://www.nature.com/articles/s41467-023-36211-x?utm_source=openai))  \n5. **RAD51‑driven strand invasion**: BRCA1–BARD1 also directly enhances RAD51‑mediated homologous pairing and synaptic complex formation, a late HR step that is lost when BRCA1–BARD1 is absent. ([nature.com](https://www.nature.com/articles/nature24060?utm_source=openai))  \n\n**BRCA1–BARD1 E3 Ubiquitin Ligase Complex**\n- The BRCA1 RING domain binds BARD1 to form an active E3 ligase; the E2 enzyme UbcH5c binds **BRCA1’s** RING and is required for ligase activity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11573085/?utm_source=openai))  \n- Structural and biochemical studies show BRCA1–BARD1 ubiquitinates nucleosomal H2A specifically at K125/127/129, with BARD1 providing key nucleosome‑recognition surfaces. Loss of the BRCA1 RING abolishes this activity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33589814/?utm_source=openai))  \n\n**BRCAness and Synthetic Lethality with PARP Inhibition**\n- **BRCAness** is a functional state of **HR deficiency** that phenocopies BRCA1/2 loss, including defects in PALB2 or RAD51 paralogs; such tumors show HR impairment and PARP‑inhibitor sensitivity. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2678481/))  \n- **Synthetic lethality (PARP inhibition + HR deficiency)**: PARP inhibitors cause lesions that convert into DSBs during replication; BRCA‑deficient cells cannot repair these DSBs by HR and die, establishing the synthetic lethal interaction. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15829966/?utm_source=openai))  \n\n**Documented Compensatory or Reversion Mechanisms**\n1. **BRCA1 reversion mutations**: Secondary BRCA1 mutations restoring the reading frame appear in platinum‑resistant ovarian tumors, re‑establishing BRCA1 protein expression and HR. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18413725/?utm_source=openai))  \n2. **Secondary splice‑site changes (exon 11 skipping)**: Acquired BRCA1 splice‑site mutations can increase Δ11/Δ11q isoforms and promote PARP‑inhibitor resistance in BRCA1 exon‑11 mutant tumors. ([link.springer.com](https://link.springer.com/article/10.1186/s12943-024-02048-1?utm_source=openai))  \n3. **Reversion in other HR genes**: Secondary mutations restoring RAD51C/D have been observed after PARP‑inhibitor treatment, consistent with regained HR and drug resistance. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28588062/?utm_source=openai))  \n4. **Compensatory pathway shifts**: Loss of 53BP1 (or its pathway) can partially restore HR in BRCA1‑deficient cells by allowing resection and PALB2‑dependent recruitment, reducing PARP‑inhibitor sensitivity. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20362325/?utm_source=openai))  \n\nIf you want, I can extend this with a compact **protein‑domain schematic** that annotates all interaction partners (BARD1, CtIP, Abraxas, BRIP1, PALB2, BRCA2, RAD51) mapped onto residue ranges, or I can integrate these mechanisms into a patient‑facing or clinician‑facing decision summary.\n\nMain question:\nA 35-year-old woman of Ashkenazi Jewish descent, with a family history of breast cancer (mother diagnosed at 42, maternal aunt at 38), undergoes genetic testing and is found to carry a pathogenic BRCA1 c.68_69delAG (185delAG) founder mutation. She currently has no signs of cancer.\n\nWe need a comprehensive analysis covering:\n1. The molecular genetics of this specific mutation\n2. How the resulting protein defect disrupts DNA repair\n3. The cancer risk profile and expected tumor pathology\n4. Evidence-based prevention, surveillance, and treatment strategies\n\nYour specific assignment:\nBased on the genomics and molecular biology research provided, analyze:\n- What specific cancer types is this patient at elevated risk for? (breast, ovarian, pancreatic, others) — provide lifetime risk percentages from recent studies.\n- What are the expected histological subtypes? (triple-negative breast cancer, high-grade serous ovarian carcinoma, etc.) — explain why BRCA1 tumors show these patterns.\n- What molecular subtypes are expected (basal-like, etc.) and what are the immunohistochemical profiles (ER/PR/HER2 status)?\n- What is the typical age of onset and tumor grade?\n- How does the tumor microenvironment differ in BRCA1-mutant cancers? (TILs, PD-L1 expression, genomic instability scores)\n\nUse web search for the latest NCCN guidelines and epidemiological data.",
      "reasoning": [
        "**Confirming skill usage and prerequisites**\n\nI'm verifying the need to run the web.search skill with web.run for specialized medical data, ensuring mention of medical disclaimers and sourcing new citations with numerical details. First, I'll read the skill documentation to confirm usage.",
        "**Launching web searches for latest hereditary breast/ovarian cancer risks**\n\nI'm initiating web queries focusing on current NCCN guidelines, recent large cohort penetrance studies, and SEER data to obtain authoritative lifetime risk estimates and citations.",
        "**Confirming latest risk data source**\n\nI'm verifying NCCN risk ranges for BRCA1-related breast and ovarian cancer using the FacingOurRisk site, as direct NCCN access is limited; this ensures citing credible, recent guideline summaries with accurate lifetime risk percentages.",
        "**Searching for risk table markers**",
        "**Identifying missing tumor and molecular data sources**\n\nNoted the need for age of onset, tumor grade, histology, molecular subtypes, and IHC data, especially for BRCA1 tumor pathology traits like basal-like and triple-negative. Planning literature searches for authoritative sources on these features and tumor microenvironment factors such as TILs, PD-L1, and genomic instability.",
        "**Reviewing hereditary breast and ovarian cancer details**\n\nI'm opening the PMC article to cite specifics on BRCA1-associated breast cancer features and ovarian cancer types, as well as examine microenvironment and immune markers like PD-L1 and TILs for accurate references.",
        "**Identifying key tumor microenvironment features**\n\nKey markers for BRCA1-associated breast and ovarian cancers include high-grade tumors, abundant tumor-infiltrating lymphocytes, and PD-L1 expression; next, I'll focus on sourcing specific evidence for PD-L1 and TIL differences in BRCA1-mutant triple-negative breast cancer.",
        "**Synthesizing TILs/PD-L1 context for BRCA1 tumors**\n\nFound that TILs and PD-L1 data mainly pertain to TNBC/basal-like breast cancer, which overlaps heavily with BRCA1 tumors, so inference is justifiable but needs clear labeling. Now planning to search for evidence linking BRCA1/2 mutations with TILs and immune response in high-grade serous ovarian cancer to strengthen the argument.",
        "**Gathering sources for BRCA screening and immune microenvironment**\n\nFound a hereditary pathology review noting tumor infiltrating lymphocytes in BRCA cancers to support TILs info. For PD-L1, planning to tie data to TNBC via JITC or similar reviews. Identified a 2024/2025 review including NCCN guideline tables for screening and risk reduction to use as primary guideline source.",
        "**Searching article for NCCN table**",
        "**Locating relevant NCCN guideline table**\n\nI'm focusing on extracting the NCCN surveillance summary by locating \"Table 2\" around line 380 to pinpoint details like age initiation and MRI guidance.",
        "**Weighing NCCN details for RRSO age**\n\nI'm assessing that the NCCN professional guidelines mention risk reduction but not explicit ages for RRSO; we may need to supplement with other widely accepted guidelines or patient-facing NCCN materials to clarify recommended timing.",
        "**Confirming RRSO age with accessible NCCN summaries**\n\nI’m planning to reference 2026 NCCN guidelines broadly while supplementing with accessible sources like GeneReviews to confirm the typical RRSO age of 35–40 for BRCA1, noting full NCCN texts are paywalled.",
        "**Gathering guideline and incidence sources**\n\nI'm planning to use the 2021 NCCN guideline recommendation for risk-reducing salpingo-oophorectomy and SEER data for baseline breast and ovarian cancer incidence rates, prioritizing accessible and citable sources. Next, I'll confirm SEER ovarian incidence availability before proceeding.",
        "**Identifying ovarian risk source**\n\nI'll use NCI Cancer Stat Facts for ovarian cancer data, as SEER ovarian risk likely comes from ACS or NCI sources.",
        "**Planning targeted search within ACS page**",
        "**Consolidating risk sources and citation strategy**\n\nDecided to use NCI for general breast risk and FORCE (NCCN) for lifetime BRCA1 carrier risks across relevant cancers, including mention of contralateral breast risk and possible founder mutation effects. Planning to integrate molecular findings from previous experts into pathology risk with citations for all web-supported statements, reserving prior context citations for mechanistic details.",
        "**Planning molecular genetics citation search**\n\nPreparing to search web sources to support detailed mechanistic statements about the specific mutation's effect on the protein and DNA repair, including translation reinitiation and domain loss, aligning with user questions and prior mechanistic context while ensuring proper citations.",
        "**Seeking evidence for frameshift translation reinitiation**\n\nI'm planning to review the JCI article for mentions of translation starting at Met-297 in BRCA1 185delAG and to find variant-specific details.",
        "**Noting alternative translation and citation strategy**\n\nI'm adopting JCI commentary's alternative translation at Met-297 for 185delAG and planning to cite c.68_69delAG as the Ashkenazi founder mutation using ClinVar or GeneReviews. I'll proceed to search for supporting citations.",
        "**Summarizing mutation and risk references**\n\nThe 2014 Genetics in Medicine article will provide founder mutation frequency and lifetime risk estimates for BRCA1/2, supplemented by JNCI 2020 meta-analysis for penetrance. The JCI paper supports citing translation reinitiation at Met-297 causing a hypomorphic RING-less BRCA1 product. I'll consider referencing ClinVar or standard sources for precise variant details but may rely on Genetics in Medicine for mutation characterization.",
        "**Outlining sources for mutation and risk data**\n\nKey references for translation reinitiation, founder frequency, pathogenic classification, age of onset, tumor grade, histology, and penetrance estimates are noted; NCCN guidelines will be primary for risk interpretation with supplemental meta-analyses and pathology reviews.",
        "**Summarizing tumor biology and management guidelines**\n\nKey points include BRCA1-deficient tumor features like genomic instability, p53 mutation, basal-like subtype, and high TILs; PD-L1 expression is linked to TNBC, not specifically BRCA1. Management will cite NCCN and GeneReviews guidelines for surveillance and prevention, emphasizing risk-reducing surgeries and limitations of ovarian screening.",
        "**Using GeneReviews for ovarian screening and planning RRSO risk reduction reference**\n\nGeneReviews confirms surveillance with CA-125/TVUS is not effective for ovarian screening; next, I'll incorporate risk reduction guidelines for RRSO citing the 2021 PMC review that references NCCN recommendations for RRSO at age 35-40.",
        "**Searching for NCCN RRSO age references**",
        "**Outlining treatment and tumor features**\n\nPlanning to cite NCCN's RRSO age recommendation and note salpingectomy alone isn't standard; next, I'll cover treatment options like PARP inhibitors linked to HRD and mention resistance mechanisms. Also, I'll discuss tumor grade and typical younger age of onset in BRCA1 cases using pathology reviews and select studies while questioning penetrance data discrepancies.",
        "**Clarifying typical onset age**\n\nEvaluating how to best represent typical BRCA1 onset age, noting earlier premenopausal cases but some variants like 185delAG show later median age (55) in penetrance studies; I'll review the article data to support this nuance.",
        "**Seeking alternative age-of-onset sources**\n\nThe primary article is inaccessible due to a 403 error, so I'll look for age-of-onset data from other sources like ClinVar, BMC articles, NCCN guidelines, or penetrance studies such as Kuchenbaecker 2017 in JAMA.",
        "**Clarifying risk sources and age-of-onset**\n\nIdentified Kuchenbaecker et al. as the source for contralateral ovarian risks and will use average age of onset from Oncologist 2016 for breast, ovarian, and pancreatic cancers in BRCA1 families. Next, I'll integrate treatment strategies referencing RRSO review for PARP inhibitors and consider adding recent NCCN guidelines per the user's request.",
        "**Summarizing comprehensive guideline and pathology integration**\n\nOutlining a detailed response structure covering molecular genetics, DNA repair disruption, cancer risk percentages with citations, typical pathology and tumor microenvironment, molecular subtypes, age of onset, and prevention/surveillance per the latest NCCN 2026 guidelines and authoritative reviews. I'll ensure to cite key sources consistently while avoiding direct medical advice and raw URLs.",
        "**Planning web.run queries for updated BRCA1 risk data**\n\nI'm preparing multiple web.run searches focused on the latest NCCN hereditary breast/ovarian guidelines, BRCA1 gene-specific cancer risk percentages from recent cohort studies, and related tumor pathology and microenvironment info.",
        "**Refining authoritative source selection**\n\nI'm prioritizing NCCN guidelines for clinical authority, supplemented by NCI/PDQ and major recent studies for cancer risk percentages and tumor pathology details, focusing on BRCA1-related features and tumor microenvironment characteristics. I'll use SEER and CDC for baseline population risk context but rely on cohort studies and guidelines for gene-specific penetrance and pathology.",
        "**Targeting NCCN and NCI PDQ searches**\n\nI'm focusing on locating the latest NCCN patient guidelines for high-risk genetic assessment and corresponding NCI PDQ resources on BRCA1/2 cancer risk to ensure authoritative and up-to-date information.",
        "**Searching for NCCN patient guidelines PDF**",
        "**Planning authoritative sourcing**\n\nThe NCCN guidelines aren't directly accessible, so I'll rely on secondary sources like ACOG and ARUP summaries while clearly noting limited NCCN access. I'll also target WHO tumor classifications and trusted literature on tumor microenvironment and molecular findings, ensuring appropriate citations where possible.",
        "**Clarifying citation scope**\n\nEvery factual statement needing support requires citations if web sources are used, even for user-provided mechanistic details. I'll keep mechanistic parts concise, referencing user input generally, and selectively cite key pathology features like BRCA1 tumor profiles.",
        "**Planning pathology sourcing**\n\nI'm prioritizing WHO classification or comprehensive reviews for authoritative pathology details and will use Frontiers (2020) for features while searching for accessible papers on BRCA1 molecular subtypes and IHC markers.",
        "**Scoping pathology and microenvironment sources**\n\nI'm narrowing down to WHO 2020 classification or recent reviews for ovarian high-grade serous of fallopian origin, focusing on tumor microenvironment and PD-L1 in BRCA1 cancers. I'll check reviews for human data linking BRCA1 mutations to increased TILs and PD-L1, balancing preclinical and clinical evidence to address the differential immune context.",
        "**Reviewing key sources for IHC and microenvironment**\n\nI'm opening targeted reviews to confirm IHC features of basal-like breast cancers, medullary subtype, and tumor microenvironment characteristics like PD-L1 and TILs in TNBC and ovarian cancer. This will provide precise pathology context and immune marker data.",
        "**Planning citation extraction and fact verification**\n\nI'm locating precise risk percentages and histopathology details from key sources, focusing on specific searchable terms to gather exact statements for citation.",
        "**Gathering ovarian cancer markers**\n\nI'm looking for data on high-grade serous carcinoma markers like fallopian tube origin and STIC from the Frontiers article to complement existing breast cancer features.",
        "**Identifying guideline sources for screening and risk reduction**\n\nNoted relevant sources include ARUP consult referencing NCCN v2.2025 without full content, ACOG executive summary citing NCCN's BSO timing for BRCA1, and a 2024 review article summarizing NCCN screening ages with MRI and mammography; next step is to review that recent comprehensive risk assessment for detailed guideline data.",
        "**Noticing internal page errors**\n\nSome internal errors occurred on pages other than ACOG, but the ACOG page link works; planning to revisit the problematic pages using direct URLs.",
        "**Searching for NCCN/ESMO table in paper**",
        "**Planning cancer risk data sources**\n\nI'm deciding to cite the 2026 Israel policy paper’s NCCN recommendations and to include SEER or NCI data for general population breast and ovarian cancer risks, focusing on finding an ovarian risk fact sheet from NCI or SEER next.",
        "**Gathering authoritative risk and screening data**\n\nI'm planning to use the NCI ovarian prevention PDQ for lifetime risk estimates and the Israel 2026 policy article for NCCN screening age recommendations. I'm also pulling precise risk percentages for BRCA1 carriers from JAMA 2017 and considering associated cancers from a 2022 Rebbeck study to ensure comprehensive risk coverage.",
        "**Outlining screening and prevention details**\n\nI'm pinpointing the Israeli policy for NCCN screening recommendations and planning to include prevention strategies like risk-reducing mastectomy and RRSO with source citations, aiming for evidence-based coverage on surveillance and treatment, including PARP inhibitor rationale with foundational references.",
        "**Searching for recent PARP inhibitor references**\n\nI'm verifying up-to-date sources linking PARP inhibitors to BRCA1 to ensure current evidence supports the treatment strategy.",
        "**Outlining treatment references**\n\nI'm prioritizing a high-level treatment mention of PARP inhibitors for BRCA1-associated cancers, citing recent 2024/2025 reviews and the 2015 BJC synthetic lethality paper, while keeping platinum sensitivity guidance general to avoid over-detail. Next, I'll integrate mechanistic insights on the frameshift mutation's impact on BRCA1 function, backed by selective citations.",
        "**Confirming variant classification source**\n\nI'm focusing on summarizing the mutation as a two-base-pair deletion causing frameshift and BRCA1 loss and planning to use ClinVar as the authoritative source for variant classification and founder mutation status.",
        "**Summarizing mutation and founder details**\n\nPlanning to cite ClinVar for the frameshift mutation causing premature stop and loss of the N-terminal RING domain, with optional mention of translation reinitiation from Hum Mutat 2006. Founder frequency in Ashkenazi Jews will be supported with the 2010 Gene Medicine carrier data (1 in 40 combined founder alleles). Tumor classifications will reference Frontiers for HGS and STIC plus WHO classifications for breast and ovarian cancer. Next, I'll gather BRCA1 risk percentages.",
        "**Compiling updated lifetime risk and tumor features**\n\nI'm gathering recent lifetime risk percentages for breast and ovarian cancer, prioritizing JAMA 2017 plus newer sources like 2022 Rebbeck and the 2025 Genes review for context. I'll include tumor histology details citing Frontiers and basal-like subtype reviews, emphasizing breast medullary features and ovarian high-grade serous carcinoma with relevant IHC markers. I'll also incorporate immunological microenvironment data, noting increased TILs and PD-L1 in BRCA1-related tumors with appropriate caveats on evidence sources.",
        "**Planning selective high-quality citations**\n\nThe plan is to cite reliable sources like PubMed/PMC, NCI, JAMA, Frontiers, and a basal-like review while avoiding low-quality sources. Key tumor features, including triple-negative and high-grade status in BRCA1 tumors, will be supported mainly by the basal-like review and Frontiers, with careful inclusion of microenvironment details and PD-L1 studies, avoiding non-primary sources.",
        "**Clarifying BRCA1 tumor microenvironment and classification**\n\nI’m outlining how BRCA1-associated tumors have lymphocyte-rich stroma and increased TILs with PD-L1 common in TNBC but not strongly linked to BRCA1 status, citing 2018 Oncoimmunology and Frontiers. I’m also planning to incorporate tumor classification systems, favoring molecular subtypes and IHC classifications from the basal-like review, while seeking a reliable source for WHO or similar classifications and age of onset data from a 1999 PubMed study to support earlier presentation in BRCA1 carriers.",
        "**Planning age-of-onset citation**\n\nI'm focusing on citing the JAMA 2017 study for BRCA1 age-specific incidence, highlighting rising risk in the 30s-40s as a more current reference for typical onset than the older 1999 study.",
        "**Planning precise citation strategy**\n\nI'm aligning citations to rely on the 2026 policy review that summarizes NCCN recommendations, avoiding direct NCCN access mention while crediting the source. I'll integrate molecular insights with focused references like ClinVar and relevant literature to support mechanistic statements without overcomplicating.",
        "**Clarifying DNA repair disruption citations**\n\nI'm focusing on framing BRCA1 loss as impairing homologous recombination with resulting genomic instability, supported primarily by the 2015 BJC review on synthetic lethality and HR deficiency. I'll confirm citing ClinVar for truncation and use reviews like BJC 2015 and possibly the NCI PDQ genetics overview to back \"disrupts DNA repair\" and PARP sensitivity statements.",
        "**Switching to open-access sources**\n\nThe Nature article is paywalled and lacks mechanism details in the preview, so I'll focus on open-access sources like the 2014 Hereditary Cancer in Clinical Practice article, which clearly explains PARP inhibition in BRCA-mutated cells.",
        "**Planning tumor characterization details**\n\nI'm outlining key points on tumor repair deficiencies, IHC profiles for ovarian and breast tumors, tumor grades, molecular subtypes, proliferation markers, microenvironment features like TILs and PD-L1, and genomic instability scores, with plans to paraphrase and cite appropriately.",
        "**Outlining comprehensive evidence and citations**\n\nI'm consolidating extensive citations and detailed points on mutation genetics, cancer risk, pathology, tumor microenvironment, screening guidelines, and treatment considerations, ensuring a clear structured response with properly cited authoritative sources while planning to adhere to citation limits and formatting rules.",
        "**Mapping key citations for HRD and guidelines**\n\nI've identified key lines for genomic scars and BRCA1-related HRD, plus NCCN guidelines details with specific screening ages and risk-reducing surgery recommendations. Next, I'll integrate these with citations into the response covering evidence-based prevention, surveillance, and treatment strategies.",
        "**Clarifying screening and prevention recommendations**\n\nI'm adding ovarian screening notes with limits and no screening post-RRSO, plus timing for RRSO at age 35-40 for BRCA1 carriers. I'm investigating reliable citations for risk-reducing mastectomy recommendations to include prevention accurately without violating citation rules.",
        "**Outlining prevention and risk sections**\n\nPlanning to cite NCCN guidelines from the Genes review for risk-reducing mastectomy in BRCA1 carriers and for RRSO recommendations from the 2026 policy table, emphasizing lack of effective ovarian screening and RRSO benefits. Also structuring the response to cover molecular genetics first, then detailed cancer risk profiles with lifetime risk numbers.",
        "**Detailing integrated cancer profile and sources plan**\n\nDefining comprehensive section outlines covering pancreatic and other cancer risks, pathology, tumor microenvironment, prevention, and treatment strategies with careful citation sourcing. Planning to compile a clear sources list with URLs in a code block and ensure citations follow punctuation, avoiding nested bullets or bolded citations."
      ],
      "web_searches": [
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bac8f48c8191aa20a5c622d1868d",
          "query": "NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic and Prostate BRCA1 lifetime breast cancer risk percentage",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bad0d22c8191b226dabdbf7245cc",
          "query": "https://www.facingourrisk.org/info/hereditary-cancer-and-genetic-testing/hereditary-cancer-genes-and-risk/genes-by-name/brca1/cancer-risk",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bad1f684819198138b7f9ccb192d",
          "query": "'Breast cancer' in https://www.facingourrisk.org/info/hereditary-cancer-and-genetic-testing/hereditary-cancer-genes-and-risk/genes-by-name/brca1/cancer-risk",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bad63a4881919bb65adcc47f1f33",
          "query": "BRCA1-associated breast cancer basal-like triple negative immunohistochemistry ER PR HER2 grade 3 pathology review",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996badbaaac8191897962c0d07c2774",
          "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7550871/",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bae173e48191ac6ef11b88f61d60",
          "query": "BRCA1-mutated breast cancer tumor-infiltrating lymphocytes higher TILs study PD-L1 expression",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bae789e481918c755070998ba383",
          "query": "BRCA1 or BRCA2 mutated high-grade serous ovarian carcinoma tumor infiltrating lymphocytes PD-L1 expression immune microenvironment",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996baeffa508191983ddc1953f264ad",
          "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996baf0d0048191b21e6928878c5d22",
          "query": "'NCCN' in https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996baf498ac81919c360b1ad911fd87",
          "query": "'Table 2' in https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bafe2ad8819186a32fb2538038ac",
          "query": "NCCN BRCA1 risk-reducing salpingo-oophorectomy age 35 40 guideline 2024 2025",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb03fe14819185d51ecc58c4a343",
          "query": "SEER ovarian cancer incidence and mortality SEER training module updated 2024 2025",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb07bbb88191ae0363a12a4f514e",
          "query": "https://www.cancer.org/cancer/types/ovarian-cancer/key-statistics.html",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb0941e0819199ec5a756e32970b",
          "query": "'Lifetime risk' in https://www.cancer.org/cancer/types/ovarian-cancer/key-statistics.html",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb157ffc8191a3e1c2a4826d5a8a",
          "query": "BRCA1 c.68_69delAG 185delAG translation reinitiation downstream AUG 128 RING domain loss BARD1 E3 ligase",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb1b8b6881918e1a0db8f99b74b0",
          "query": "https://www.jci.org/articles/view/89209",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb1df6b08191b169fb0567c8ea06",
          "query": "BRCA1 c.68_69delAG 185delAG Ashkenazi Jewish founder mutation exon 2 ClinVar",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb280ff88191b8735b316843a492",
          "query": "ClinVar BRCA1 c.68_69delAG p.Glu23Valfs*17 exon 2 frameshift pathogenic",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb3881c0819197f87dae051c0a9f",
          "query": "https://www.ncbi.nlm.nih.gov/books/NBK1247/table/brca1.T.recommended_surveillance_for_wom/",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb3a74448191b699025c84724f1a",
          "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8197088/",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb3b4eb88191a86071edc0dcc453",
          "query": "'NCCN' in https://pmc.ncbi.nlm.nih.gov/articles/PMC8197088/",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb4471d08191b12eca43fb977fd6",
          "query": "",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb47764081918e051dd3f1fe2b9d",
          "query": "Kuchenbaecker 2017 JAMA BRCA1 age-specific cumulative risk by age 70 80 breast ovarian",
          "results": []
        },
        {
          "id": "ws_0c9b2cbd4bb87c2d016996bb7aa3d481918abfdafedcac5528",
          "query": "https://academic.oup.com/jncics/article/4/4/pkaa029/5824305",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bbf9ea4c819c855661a75c33f33c",
          "query": "NCCN Guidelines Genetic/Familial High-Risk Assessment Breast, Ovarian, and Pancreatic 2024 2025 PDF BRCA1 surveillance risk-reducing mastectomy salpingo-oophorectomy",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc046170819ca49a052232a16c0c",
          "query": "NCCN patient guidelines Genetic/Familial High-Risk Assessment Breast, Ovarian, and Pancreatic PDF 2024 2025 BRCA1 screening MRI mammography risk-reducing salpingo-oophorectomy",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc083030819c9ead6973a3c2f473",
          "query": "\"Genetic/Familial High-Risk Assessment\" Breast Ovarian Pancreatic \"NCCN\" patient guideline PDF",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc156cf0819c818070946a9f86c3",
          "query": "BRCA1-associated breast cancer pathology high grade medullary features triple-negative basal-like immunohistochemical profile ER PR HER2 CK5/6 EGFR p53 review",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc1c2520819c8715652ee4c72b11",
          "query": "BRCA1-associated breast cancers basal-like phenotype ER PR HER2 negative CK5/6 EGFR p53 high grade medullary Lakhani review",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc260b68819cb5603fe47827b7b0",
          "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc2b0c24819ca96d3d4f82a3aaa9",
          "query": "'ER' in https://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc2e2330819c9ee8c7e49d27bd63",
          "query": "'high-grade serous' in https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc33d1c8819caa8534777378b596",
          "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc364250819c91f776c955a77da9",
          "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc394c8c819c96a2d87cebf55469",
          "query": "'NCCN' in https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc3dc1f4819c9f447a6deaeb55fc",
          "query": "NCI ovarian cancer risk fact sheet lifetime risk 1 in 78 SEER",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc43c2e0819ca936cd5dc8c806fd",
          "query": "'absolute risks to age 80' in https://pubmed.ncbi.nlm.nih.gov/35077220/",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc4d4b94819c94dd2b9eb864ed02",
          "query": "BRCA1 deficiency PARP inhibitor synthetic lethality 2005 2006 Nature Bryant Farmer",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc5627b4819c9560fd638403d7d9",
          "query": "BRCA1 c.68_69delAG 185delAG founder mutation Ashkenazi Jewish ClinVar frameshift premature stop",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc69a730819c8ce9656f8e7ad0d7",
          "query": "BRCA1 mutation tumor infiltrating lymphocytes breast cancer PD-L1 study germline BRCA1",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc7ae160819c96a8f158cf64f133",
          "query": "https://pubmed.ncbi.nlm.nih.gov/10353781/",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc7e2810819c8d928e7cb3684a6f",
          "query": "'incidences increased rapidly' in https://pubmed.ncbi.nlm.nih.gov/28632866/",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc8bb820819c8908ede130ae4d2a",
          "query": "https://www.nature.com/articles/bjc2015394",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bc8eaa88819cab3410ad297498d8",
          "query": "https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-014-0024-8",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bcc93ad0819ca39276cc39c366de",
          "query": "https://www.mdpi.com/1467-3045/47/8/638",
          "results": []
        },
        {
          "id": "ws_0cee67ddcb7b5c82016996bcd51534819c880042ea653526b5",
          "query": "'mastectomy' in https://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/",
          "results": []
        }
      ],
      "command_executions": [
        {
          "id": "item_1",
          "command": "/bin/zsh -lc ls",
          "output": "README.md\nexamples\noutput\npyproject.toml\nsrc\n",
          "exit_code": 0
        },
        {
          "id": "item_2",
          "command": "/bin/zsh -lc 'cat /Users/lingzhi/.codex/skills/web-search/SKILL.md'",
          "output": "---\nname: web-search\ndescription: Search and browse the public web from Codex CLI (联网搜索/查网页/找资料/给链接/带出处). Use when you need up-to-date info or answers that must cite web sources.\n---\n\n# Web Search (联网搜索)\n\nThis skill provides a repeatable workflow to search the web, optionally fetch page text, and answer with sources.\n\n## Quick start\n\n- Search:\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --format md`\n- Search + fetch page text (for evidence):\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --fetch --format md`\n\n## Providers (auto)\n\nThe script picks the first available provider:\n\n- **Tavily**: set `TAVILY_API_KEY`\n- **Serper**: set `SERPER_API_KEY`\n- **Brave**: set `BRAVE_API_KEY` (or `BRAVE_SEARCH_API_KEY`)\n- **Fallback**: DuckDuckGo HTML scrape (best-effort; may break)\n\n## Workflow\n\n- Clarify what must be looked up and what must be cited.\n- Run the search script; pick 3–5 sources.\n- If a claim is important/controversial, re-run with `--fetch` and quote specific lines from sources.\n- In the final answer:\n  - Include a **Sources** list with URLs.\n  - Never invent citations; if evidence is missing, say so.\n\n## Notes\n\n- This skill uses network access. In restricted network/sandbox modes, request escalation before running the script.\n",
          "exit_code": 0
        }
      ],
      "final_output": "Below is an integrated, pathology‑focused risk profile for a 35‑year‑old Ashkenazi Jewish woman with **BRCA1 c.68_69delAG (185delAG)** and no current cancer, using NCCN‑summarized recommendations, SEER/NCI epidemiology, and recent pathology literature.\n\n**Molecular Genetics & DNA Repair**\n- `BRCA1 c.68_69delAG` is a 2‑bp deletion in exon 2 that causes a frameshift after codon 23 and a premature stop 17 aa later (p.Glu23Valfs*17), producing an absent/disrupted protein; ClinVar classifies it as pathogenic and an Ashkenazi founder variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000017662/?utm_source=openai))  \n- It is one of the three classic Ashkenazi Jewish founder variants; together they account for ~2.6% (≈1 in 40) of the Ashkenazi population, and c.68_69delAG is one of these founders. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3405339/?utm_source=openai))  \n- The 185delAG allele can undergo translation reinitiation at a downstream AUG (~codon 128), producing an N‑terminally truncated protein, consistent with functional loss. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16941470/?utm_source=openai))  \n- BRCA‑mutated tumor cells are defective in homologous recombination (HR) repair of double‑strand breaks and rely more on other repair pathways (e.g., BER); PARP inhibition in this context leads to lethal DNA damage (synthetic lethality). ([hccpjournal.biomedcentral.com](https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-014-0024-8))  \n\n**Cancer Risk Profile (Lifetime Risk Estimates)**\n- **Breast cancer**: Prospective cohort data show a cumulative risk to age 80 of **~72% for BRCA1** carriers. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/))  \n- **Ovarian/fallopian tube/primary peritoneal cancer**: Cumulative risk to age 80 is **~44% for BRCA1** carriers. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/))  \n- **Pancreatic cancer**: BRCA1 pathogenic variants confer increased risk; absolute risk to age 80 is **~2.5%**. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35077220/))  \n- **Stomach cancer**: BRCA1 pathogenic variants show increased relative risk (RR ~2.17). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35077220/))  \n- **Population context (SEER/NCI)**: U.S. lifetime risk is ~12.9% for breast cancer and ~1.12% for ovarian cancer. ([cancer.gov](https://www.cancer.gov/types/breast/risk-fact-sheet?utm_source=openai))  \n- **Family history and mutation location modify risk**; risk rises with more affected relatives. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/))  \n\n**Expected Pathology and Histologic Subtypes**\n- **Breast**: BRCA1‑associated tumors are most often **high‑grade invasive ductal carcinoma (NST)** with minimal tubule formation, marked nuclear pleomorphism, and high mitotic activity; **medullary‑like features** (sheet‑like growth, pushing borders, necrosis, prominent lymphocytes) are well described. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **Breast molecular subtype**: BRCA1‑mutant tumors frequently show **basal‑like gene‑expression patterns** and are commonly **triple‑negative (ER−/PR−/HER2−)** with expression of **basal cytokeratins (CK5/CK14/CK17)** and high proliferation. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/))  \n- **Tubo‑ovarian**: The hallmark BRCA‑associated tumor is **high‑grade serous carcinoma (HGSOC)**; other histotypes are reported but less common. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **HGSOC morphology/IHC**: Classic HGSOC shows papillary/glandular growth, marked nuclear atypia, brisk mitoses, and aberrant **p53** staining; typical markers include **CK7, PAX8, WT‑1**, and often **diffuse ER** expression. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **Precursor lesion**: Most HGSOC arises from the **fallopian tube**, with **STIC** as a recognized precursor; STIC is identified in ~40–60% of HGSOC. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n\n**Typical Age of Onset & Tumor Grade**\n- **Age of onset**: For BRCA1 carriers, breast cancer incidence increases rapidly in early adulthood and rises steeply until ages **30–40**, consistent with earlier onset risk. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/))  \n- **Tumor grade**: BRCA1‑associated breast cancers are typically **high‑grade**, and HGSOC is high‑grade by definition with high mitotic activity. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n\n**Tumor Microenvironment**\n- **Breast**: Medullary‑like BRCA1 tumors often show **prominent peri‑ and intratumoral lymphocytes**, reflecting an immune‑rich microenvironment. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **Ovary**: BRCA1‑associated HGSOC shows **increased TILs**, high mitotic rates, and necrosis; SET‑type morphology is also enriched. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **PD‑L1/TILs in TNBC**: PD‑L1 expression is frequent in TNBC (high PD‑L1+ rates in tumor and immune cells), and PD‑L1+ TILs are common; PD‑L1/TIL levels are not necessarily driven by BRCA1‑like status. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30524905/?utm_source=openai))  \n- **Genomic instability**: BRCA1/2 defects produce **HRD**, causing genomic instability detectable via scar metrics (LOH, TAI, LST) and used clinically in HGSOC and TNBC. ([mdpi.com](https://www.mdpi.com/1467-3045/47/8/638))  \n\n**Evidence‑Based Prevention & Surveillance (NCCN‑Summarized)**\n- **Breast surveillance (NCCN‑summarized)**: Clinical breast exam every 6–12 months starting **age 25**; **age 25–29** annual breast MRI (or mammogram if MRI unavailable); **age 30–75** annual mammography **and** MRI; >75 individualized. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/))  \n- **Risk‑reducing salpingo‑oophorectomy (RRSO)**: For BRCA1, NCCN‑summarized timing is **age 35–40** after completion of childbearing. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/))  \n- **Ovarian screening limits**: If surgery is declined, CA‑125 and pelvic ultrasound may be used with explicit counseling about **limitations**; after RRSO, no routine ovarian screening is recommended. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/))  \n- **Risk‑reducing mastectomy**: NCCN‑summarized guidelines **recommend** risk‑reducing bilateral mastectomy as an option for **BRCA1** carriers. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/))  \n- **Effectiveness of ovarian risk reduction**: There is **no evidence** that ovarian/tubal screening reduces disease‑specific mortality; RRSO is the only strategy shown to reduce incidence and mortality. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/))  \n- **Pancreatic screening (NCCN‑summarized)**: Consider starting at **age 50** (or 5–10 years earlier than the youngest affected relative) **only if** there is a first‑ or second‑degree relative with pancreatic cancer. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/))  \n\n**Treatment Considerations if Cancer Develops (High‑Level)**\n- **DNA‑repair–targeted therapy**: BRCA‑mutated tumors are HR‑deficient and are sensitive to **PARP inhibitors** via synthetic lethality. ([hccpjournal.biomedcentral.com](https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-014-0024-8))  \n- **Platinum/PARP sensitivity**: HRD predicts robust responses to **platinum** and **PARP inhibitors** in HGSOC and TNBC, and HRD assays use genomic scars to guide therapy. ([mdpi.com](https://www.mdpi.com/1467-3045/47/8/638))  \n- **Immunotherapy context**: TNBC often shows high PD‑L1 expression and immune infiltration, supporting PD‑L1–directed immunotherapy in appropriate clinical settings. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30524905/?utm_source=openai))  \n\nIf you want, I can format this into a clinician‑facing decision summary or a patient‑facing counseling handout.\n\n**Sources**\n```text\nhttps://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000017662/\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC3405339/\nhttps://pubmed.ncbi.nlm.nih.gov/16941470/\nhttps://pubmed.ncbi.nlm.nih.gov/28632866/\nhttps://pubmed.ncbi.nlm.nih.gov/35077220/\nhttps://www.cancer.gov/types/breast/risk-fact-sheet\nhttps://www.cancer.gov/types/ovarian/hp/ovarian-prevention-pdq\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/\nhttps://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.531790/full\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/\nhttps://pubmed.ncbi.nlm.nih.gov/30524905/\nhttps://www.mdpi.com/1467-3045/47/8/638\nhttps://link.springer.com/article/10.1186/s13053-014-0024-8\n```",
      "usage": {
        "input_tokens": 134597,
        "cached_input_tokens": 25088,
        "output_tokens": 18639
      },
      "error": null,
      "step": 3,
      "raw_event_count": 165,
      "raw_events_by_type": {
        "thread.started": [
          {
            "type": "thread.started",
            "thread_id": "019c74c9-6d93-7612-aa66-219c89618c8f"
          }
        ],
        "turn.started": [
          {
            "type": "turn.started"
          }
        ],
        "item.completed": [
          {
            "type": "item.completed",
            "item": {
              "id": "item_0",
              "type": "reasoning",
              "text": "**Confirming skill usage and prerequisites**\n\nI'm verifying the need to run the web.search skill with web.run for specialized medical data, ensuring mention of medical disclaimers and sourcing new citations with numerical details. First, I'll read the skill documentation to confirm usage."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_1",
              "type": "command_execution",
              "command": "/bin/zsh -lc ls",
              "aggregated_output": "README.md\nexamples\noutput\npyproject.toml\nsrc\n",
              "exit_code": 0,
              "status": "completed"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_2",
              "type": "command_execution",
              "command": "/bin/zsh -lc 'cat /Users/lingzhi/.codex/skills/web-search/SKILL.md'",
              "aggregated_output": "---\nname: web-search\ndescription: Search and browse the public web from Codex CLI (联网搜索/查网页/找资料/给链接/带出处). Use when you need up-to-date info or answers that must cite web sources.\n---\n\n# Web Search (联网搜索)\n\nThis skill provides a repeatable workflow to search the web, optionally fetch page text, and answer with sources.\n\n## Quick start\n\n- Search:\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --format md`\n- Search + fetch page text (for evidence):\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --fetch --format md`\n\n## Providers (auto)\n\nThe script picks the first available provider:\n\n- **Tavily**: set `TAVILY_API_KEY`\n- **Serper**: set `SERPER_API_KEY`\n- **Brave**: set `BRAVE_API_KEY` (or `BRAVE_SEARCH_API_KEY`)\n- **Fallback**: DuckDuckGo HTML scrape (best-effort; may break)\n\n## Workflow\n\n- Clarify what must be looked up and what must be cited.\n- Run the search script; pick 3–5 sources.\n- If a claim is important/controversial, re-run with `--fetch` and quote specific lines from sources.\n- In the final answer:\n  - Include a **Sources** list with URLs.\n  - Never invent citations; if evidence is missing, say so.\n\n## Notes\n\n- This skill uses network access. In restricted network/sandbox modes, request escalation before running the script.\n",
              "exit_code": 0,
              "status": "completed"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_3",
              "type": "reasoning",
              "text": "**Launching web searches for latest hereditary breast/ovarian cancer risks**\n\nI'm initiating web queries focusing on current NCCN guidelines, recent large cohort penetrance studies, and SEER data to obtain authoritative lifetime risk estimates and citations."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bac8f48c8191aa20a5c622d1868d",
              "type": "web_search",
              "query": "NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic and Prostate BRCA1 lifetime breast cancer risk percentage",
              "action": {
                "type": "search",
                "query": "NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic and Prostate BRCA1 lifetime breast cancer risk percentage",
                "queries": [
                  "NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic and Prostate BRCA1 lifetime breast cancer risk percentage",
                  "BRCA1 c.68_69delAG 185delAG founder mutation cancer risk penetrance study lifetime breast ovarian risk",
                  "Kuchenbaecker 2017 JAMA BRCA1 lifetime risk breast ovarian age specific",
                  "SEER breast cancer incidence age-specific and ovarian cancer incidence SEER 2023 statistics"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_5",
              "type": "reasoning",
              "text": "**Confirming latest risk data source**\n\nI'm verifying NCCN risk ranges for BRCA1-related breast and ovarian cancer using the FacingOurRisk site, as direct NCCN access is limited; this ensures citing credible, recent guideline summaries with accurate lifetime risk percentages."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bad0d22c8191b226dabdbf7245cc",
              "type": "web_search",
              "query": "https://www.facingourrisk.org/info/hereditary-cancer-and-genetic-testing/hereditary-cancer-genes-and-risk/genes-by-name/brca1/cancer-risk",
              "action": {
                "type": "open_page",
                "url": "https://www.facingourrisk.org/info/hereditary-cancer-and-genetic-testing/hereditary-cancer-genes-and-risk/genes-by-name/brca1/cancer-risk"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_7",
              "type": "reasoning",
              "text": "**Searching for risk table markers**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bad1f684819198138b7f9ccb192d",
              "type": "web_search",
              "query": "'Breast cancer' in https://www.facingourrisk.org/info/hereditary-cancer-and-genetic-testing/hereditary-cancer-genes-and-risk/genes-by-name/brca1/cancer-risk",
              "action": {
                "type": "find_in_page",
                "url": "https://www.facingourrisk.org/info/hereditary-cancer-and-genetic-testing/hereditary-cancer-genes-and-risk/genes-by-name/brca1/cancer-risk",
                "pattern": "Breast cancer"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_9",
              "type": "reasoning",
              "text": "**Identifying missing tumor and molecular data sources**\n\nNoted the need for age of onset, tumor grade, histology, molecular subtypes, and IHC data, especially for BRCA1 tumor pathology traits like basal-like and triple-negative. Planning literature searches for authoritative sources on these features and tumor microenvironment factors such as TILs, PD-L1, and genomic instability."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bad63a4881919bb65adcc47f1f33",
              "type": "web_search",
              "query": "BRCA1-associated breast cancer basal-like triple negative immunohistochemistry ER PR HER2 grade 3 pathology review",
              "action": {
                "type": "search",
                "query": "BRCA1-associated breast cancer basal-like triple negative immunohistochemistry ER PR HER2 grade 3 pathology review",
                "queries": [
                  "BRCA1-associated breast cancer basal-like triple negative immunohistochemistry ER PR HER2 grade 3 pathology review",
                  "BRCA1-associated ovarian cancer high-grade serous histology fallopian tube origin STIC pathology",
                  "tumor-infiltrating lymphocytes BRCA1 mutant breast cancer PD-L1 expression genomic instability scores HRD",
                  "NCCN guidelines BRCA1 surveillance risk-reducing mastectomy oophorectomy MRI screening age 25"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_11",
              "type": "reasoning",
              "text": "**Reviewing hereditary breast and ovarian cancer details**\n\nI'm opening the PMC article to cite specifics on BRCA1-associated breast cancer features and ovarian cancer types, as well as examine microenvironment and immune markers like PD-L1 and TILs for accurate references."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996badbaaac8191897962c0d07c2774",
              "type": "web_search",
              "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7550871/",
              "action": {
                "type": "open_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7550871/"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_13",
              "type": "reasoning",
              "text": "**Identifying key tumor microenvironment features**\n\nKey markers for BRCA1-associated breast and ovarian cancers include high-grade tumors, abundant tumor-infiltrating lymphocytes, and PD-L1 expression; next, I'll focus on sourcing specific evidence for PD-L1 and TIL differences in BRCA1-mutant triple-negative breast cancer."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bae173e48191ac6ef11b88f61d60",
              "type": "web_search",
              "query": "BRCA1-mutated breast cancer tumor-infiltrating lymphocytes higher TILs study PD-L1 expression",
              "action": {
                "type": "search",
                "query": "BRCA1-mutated breast cancer tumor-infiltrating lymphocytes higher TILs study PD-L1 expression",
                "queries": [
                  "BRCA1-mutated breast cancer tumor-infiltrating lymphocytes higher TILs study PD-L1 expression",
                  "BRCA1 mutation high genomic instability HRD score breast cancer homologous recombination deficiency score",
                  "BRCA1 ovarian cancer immune infiltration PD-L1 BRCA1 high-grade serous tumor microenvironment",
                  "basal-like breast cancer BRCA1 associated immunohistochemistry cytokeratin 5/6 EGFR ER PR HER2"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_15",
              "type": "reasoning",
              "text": "**Synthesizing TILs/PD-L1 context for BRCA1 tumors**\n\nFound that TILs and PD-L1 data mainly pertain to TNBC/basal-like breast cancer, which overlaps heavily with BRCA1 tumors, so inference is justifiable but needs clear labeling. Now planning to search for evidence linking BRCA1/2 mutations with TILs and immune response in high-grade serous ovarian cancer to strengthen the argument."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bae789e481918c755070998ba383",
              "type": "web_search",
              "query": "BRCA1 or BRCA2 mutated high-grade serous ovarian carcinoma tumor infiltrating lymphocytes PD-L1 expression immune microenvironment",
              "action": {
                "type": "search",
                "query": "BRCA1 or BRCA2 mutated high-grade serous ovarian carcinoma tumor infiltrating lymphocytes PD-L1 expression immune microenvironment",
                "queries": [
                  "BRCA1 or BRCA2 mutated high-grade serous ovarian carcinoma tumor infiltrating lymphocytes PD-L1 expression immune microenvironment",
                  "BRCA1 mutated ovarian cancer better response to platinum and PARP high grade serous tumor infiltrating lymphocytes",
                  "homologous recombination deficiency genomic instability score (HRD score) breast cancer BRCA1",
                  "BRCA1 tumors high genomic instability large-scale state transitions HRD score study"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_17",
              "type": "reasoning",
              "text": "**Gathering sources for BRCA screening and immune microenvironment**\n\nFound a hereditary pathology review noting tumor infiltrating lymphocytes in BRCA cancers to support TILs info. For PD-L1, planning to tie data to TNBC via JITC or similar reviews. Identified a 2024/2025 review including NCCN guideline tables for screening and risk reduction to use as primary guideline source."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996baeffa508191983ddc1953f264ad",
              "type": "web_search",
              "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
              "action": {
                "type": "open_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_19",
              "type": "reasoning",
              "text": "**Searching article for NCCN table**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996baf0d0048191b21e6928878c5d22",
              "type": "web_search",
              "query": "'NCCN' in https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
              "action": {
                "type": "find_in_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
                "pattern": "NCCN"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_21",
              "type": "reasoning",
              "text": "**Locating relevant NCCN guideline table**\n\nI'm focusing on extracting the NCCN surveillance summary by locating \"Table 2\" around line 380 to pinpoint details like age initiation and MRI guidance."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996baf498ac81919c360b1ad911fd87",
              "type": "web_search",
              "query": "'Table 2' in https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
              "action": {
                "type": "find_in_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
                "pattern": "Table 2"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_23",
              "type": "reasoning",
              "text": "**Weighing NCCN details for RRSO age**\n\nI'm assessing that the NCCN professional guidelines mention risk reduction but not explicit ages for RRSO; we may need to supplement with other widely accepted guidelines or patient-facing NCCN materials to clarify recommended timing."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_24",
              "type": "reasoning",
              "text": "**Confirming RRSO age with accessible NCCN summaries**\n\nI’m planning to reference 2026 NCCN guidelines broadly while supplementing with accessible sources like GeneReviews to confirm the typical RRSO age of 35–40 for BRCA1, noting full NCCN texts are paywalled."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bafe2ad8819186a32fb2538038ac",
              "type": "web_search",
              "query": "NCCN BRCA1 risk-reducing salpingo-oophorectomy age 35 40 guideline 2024 2025",
              "action": {
                "type": "search",
                "query": "NCCN BRCA1 risk-reducing salpingo-oophorectomy age 35 40 guideline 2024 2025",
                "queries": [
                  "NCCN BRCA1 risk-reducing salpingo-oophorectomy age 35 40 guideline 2024 2025",
                  "risk-reducing salpingo-oophorectomy BRCA1 age 35 40 NCCN patient guidelines",
                  "GeneReviews BRCA1- and BRCA2-associated hereditary breast and ovarian cancer risk-reducing salpingo-oophorectomy age 35 40",
                  "ACOG practice bulletin BRCA1 risk-reducing salpingo-oophorectomy age 35 40"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_26",
              "type": "reasoning",
              "text": "**Gathering guideline and incidence sources**\n\nI'm planning to use the 2021 NCCN guideline recommendation for risk-reducing salpingo-oophorectomy and SEER data for baseline breast and ovarian cancer incidence rates, prioritizing accessible and citable sources. Next, I'll confirm SEER ovarian incidence availability before proceeding."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb03fe14819185d51ecc58c4a343",
              "type": "web_search",
              "query": "SEER ovarian cancer incidence and mortality SEER training module updated 2024 2025",
              "action": {
                "type": "search",
                "query": "SEER ovarian cancer incidence and mortality SEER training module updated 2024 2025",
                "queries": [
                  "SEER ovarian cancer incidence and mortality SEER training module updated 2024 2025",
                  "SEER ovarian cancer incidence statistics 2025 SEER training",
                  "SEER Cancer Stat Facts: Ovarian Cancer incidence rates 2024",
                  "SEER Cancer Stat Facts: Breast Cancer lifetime risk 12.9%"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_28",
              "type": "reasoning",
              "text": "**Identifying ovarian risk source**\n\nI'll use NCI Cancer Stat Facts for ovarian cancer data, as SEER ovarian risk likely comes from ACS or NCI sources."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb07bbb88191ae0363a12a4f514e",
              "type": "web_search",
              "query": "https://www.cancer.org/cancer/types/ovarian-cancer/key-statistics.html",
              "action": {
                "type": "open_page",
                "url": "https://www.cancer.org/cancer/types/ovarian-cancer/key-statistics.html"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_30",
              "type": "reasoning",
              "text": "**Planning targeted search within ACS page**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb0941e0819199ec5a756e32970b",
              "type": "web_search",
              "query": "'Lifetime risk' in https://www.cancer.org/cancer/types/ovarian-cancer/key-statistics.html",
              "action": {
                "type": "find_in_page",
                "url": "https://www.cancer.org/cancer/types/ovarian-cancer/key-statistics.html",
                "pattern": "Lifetime risk"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_32",
              "type": "reasoning",
              "text": "**Consolidating risk sources and citation strategy**\n\nDecided to use NCI for general breast risk and FORCE (NCCN) for lifetime BRCA1 carrier risks across relevant cancers, including mention of contralateral breast risk and possible founder mutation effects. Planning to integrate molecular findings from previous experts into pathology risk with citations for all web-supported statements, reserving prior context citations for mechanistic details."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_33",
              "type": "reasoning",
              "text": "**Planning molecular genetics citation search**\n\nPreparing to search web sources to support detailed mechanistic statements about the specific mutation's effect on the protein and DNA repair, including translation reinitiation and domain loss, aligning with user questions and prior mechanistic context while ensuring proper citations."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb157ffc8191a3e1c2a4826d5a8a",
              "type": "web_search",
              "query": "BRCA1 c.68_69delAG 185delAG translation reinitiation downstream AUG 128 RING domain loss BARD1 E3 ligase",
              "action": {
                "type": "search",
                "query": "BRCA1 c.68_69delAG 185delAG translation reinitiation downstream AUG 128 RING domain loss BARD1 E3 ligase",
                "queries": [
                  "BRCA1 c.68_69delAG 185delAG translation reinitiation downstream AUG 128 RING domain loss BARD1 E3 ligase",
                  "BRCA1 185delAG exon 2 frameshift premature stop codon 39 founder mutation Ashkenazi Jewish",
                  "BRCA1 RING domain BARD1 E3 ligase H2A K125 K127 K129 ubiquitination",
                  "BRCA1 PALB2 coiled-coil domain binding residues 1364 1437 HR repair recruitment"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_35",
              "type": "reasoning",
              "text": "**Seeking evidence for frameshift translation reinitiation**\n\nI'm planning to review the JCI article for mentions of translation starting at Met-297 in BRCA1 185delAG and to find variant-specific details."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb1b8b6881918e1a0db8f99b74b0",
              "type": "web_search",
              "query": "https://www.jci.org/articles/view/89209",
              "action": {
                "type": "open_page",
                "url": "https://www.jci.org/articles/view/89209"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_37",
              "type": "reasoning",
              "text": "**Noting alternative translation and citation strategy**\n\nI'm adopting JCI commentary's alternative translation at Met-297 for 185delAG and planning to cite c.68_69delAG as the Ashkenazi founder mutation using ClinVar or GeneReviews. I'll proceed to search for supporting citations."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb1df6b08191b169fb0567c8ea06",
              "type": "web_search",
              "query": "BRCA1 c.68_69delAG 185delAG Ashkenazi Jewish founder mutation exon 2 ClinVar",
              "action": {
                "type": "search",
                "query": "BRCA1 c.68_69delAG 185delAG Ashkenazi Jewish founder mutation exon 2 ClinVar",
                "queries": [
                  "BRCA1 c.68_69delAG 185delAG Ashkenazi Jewish founder mutation exon 2 ClinVar",
                  "BRCA1 185delAG founder mutation Ashkenazi Jewish prevalence",
                  "BRCA1 c.68_69delAG exon 2 frameshift p.Glu23Valfs*17",
                  "BIC BRCA1 185delAG founder Ashkenazi"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_39",
              "type": "reasoning",
              "text": "**Summarizing mutation and risk references**\n\nThe 2014 Genetics in Medicine article will provide founder mutation frequency and lifetime risk estimates for BRCA1/2, supplemented by JNCI 2020 meta-analysis for penetrance. The JCI paper supports citing translation reinitiation at Met-297 causing a hypomorphic RING-less BRCA1 product. I'll consider referencing ClinVar or standard sources for precise variant details but may rely on Genetics in Medicine for mutation characterization."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb280ff88191b8735b316843a492",
              "type": "web_search",
              "query": "ClinVar BRCA1 c.68_69delAG p.Glu23Valfs*17 exon 2 frameshift pathogenic",
              "action": {
                "type": "search",
                "query": "ClinVar BRCA1 c.68_69delAG p.Glu23Valfs*17 exon 2 frameshift pathogenic",
                "queries": [
                  "ClinVar BRCA1 c.68_69delAG p.Glu23Valfs*17 exon 2 frameshift pathogenic",
                  "BRCA1 c.68_69delAG exon 2 frameshift premature stop codon 39 185delAG",
                  "BRCA1 185delAG exon 2 frameshift mutation description"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_41",
              "type": "reasoning",
              "text": "**Outlining sources for mutation and risk data**\n\nKey references for translation reinitiation, founder frequency, pathogenic classification, age of onset, tumor grade, histology, and penetrance estimates are noted; NCCN guidelines will be primary for risk interpretation with supplemental meta-analyses and pathology reviews."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_42",
              "type": "reasoning",
              "text": "**Summarizing tumor biology and management guidelines**\n\nKey points include BRCA1-deficient tumor features like genomic instability, p53 mutation, basal-like subtype, and high TILs; PD-L1 expression is linked to TNBC, not specifically BRCA1. Management will cite NCCN and GeneReviews guidelines for surveillance and prevention, emphasizing risk-reducing surgeries and limitations of ovarian screening."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb3881c0819197f87dae051c0a9f",
              "type": "web_search",
              "query": "https://www.ncbi.nlm.nih.gov/books/NBK1247/table/brca1.T.recommended_surveillance_for_wom/",
              "action": {
                "type": "open_page",
                "url": "https://www.ncbi.nlm.nih.gov/books/NBK1247/table/brca1.T.recommended_surveillance_for_wom/"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_44",
              "type": "reasoning",
              "text": "**Using GeneReviews for ovarian screening and planning RRSO risk reduction reference**\n\nGeneReviews confirms surveillance with CA-125/TVUS is not effective for ovarian screening; next, I'll incorporate risk reduction guidelines for RRSO citing the 2021 PMC review that references NCCN recommendations for RRSO at age 35-40."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb3a74448191b699025c84724f1a",
              "type": "web_search",
              "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8197088/",
              "action": {
                "type": "open_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8197088/"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_46",
              "type": "reasoning",
              "text": "**Searching for NCCN RRSO age references**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb3b4eb88191a86071edc0dcc453",
              "type": "web_search",
              "query": "'NCCN' in https://pmc.ncbi.nlm.nih.gov/articles/PMC8197088/",
              "action": {
                "type": "find_in_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8197088/",
                "pattern": "NCCN"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_48",
              "type": "reasoning",
              "text": "**Outlining treatment and tumor features**\n\nPlanning to cite NCCN's RRSO age recommendation and note salpingectomy alone isn't standard; next, I'll cover treatment options like PARP inhibitors linked to HRD and mention resistance mechanisms. Also, I'll discuss tumor grade and typical younger age of onset in BRCA1 cases using pathology reviews and select studies while questioning penetrance data discrepancies."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_49",
              "type": "reasoning",
              "text": "**Clarifying typical onset age**\n\nEvaluating how to best represent typical BRCA1 onset age, noting earlier premenopausal cases but some variants like 185delAG show later median age (55) in penetrance studies; I'll review the article data to support this nuance."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb4471d08191b12eca43fb977fd6",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "open_page"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_51",
              "type": "reasoning",
              "text": "**Seeking alternative age-of-onset sources**\n\nThe primary article is inaccessible due to a 403 error, so I'll look for age-of-onset data from other sources like ClinVar, BMC articles, NCCN guidelines, or penetrance studies such as Kuchenbaecker 2017 in JAMA."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb47764081918e051dd3f1fe2b9d",
              "type": "web_search",
              "query": "Kuchenbaecker 2017 JAMA BRCA1 age-specific cumulative risk by age 70 80 breast ovarian",
              "action": {
                "type": "search",
                "query": "Kuchenbaecker 2017 JAMA BRCA1 age-specific cumulative risk by age 70 80 breast ovarian",
                "queries": [
                  "Kuchenbaecker 2017 JAMA BRCA1 age-specific cumulative risk by age 70 80 breast ovarian",
                  "BRCA1 age-specific cumulative risk breast cancer 2017 JAMA 70 80 years",
                  "BRCA1 carrier breast cancer average age at diagnosis study"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_53",
              "type": "reasoning",
              "text": "**Clarifying risk sources and age-of-onset**\n\nIdentified Kuchenbaecker et al. as the source for contralateral ovarian risks and will use average age of onset from Oncologist 2016 for breast, ovarian, and pancreatic cancers in BRCA1 families. Next, I'll integrate treatment strategies referencing RRSO review for PARP inhibitors and consider adding recent NCCN guidelines per the user's request."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_54",
              "type": "reasoning",
              "text": "**Summarizing comprehensive guideline and pathology integration**\n\nOutlining a detailed response structure covering molecular genetics, DNA repair disruption, cancer risk percentages with citations, typical pathology and tumor microenvironment, molecular subtypes, age of onset, and prevention/surveillance per the latest NCCN 2026 guidelines and authoritative reviews. I'll ensure to cite key sources consistently while avoiding direct medical advice and raw URLs."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb7aa3d481918abfdafedcac5528",
              "type": "web_search",
              "query": "https://academic.oup.com/jncics/article/4/4/pkaa029/5824305",
              "action": {
                "type": "open_page",
                "url": "https://academic.oup.com/jncics/article/4/4/pkaa029/5824305"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_56",
              "type": "reasoning",
              "text": "**Planning web.run queries for updated BRCA1 risk data**\n\nI'm preparing multiple web.run searches focused on the latest NCCN hereditary breast/ovarian guidelines, BRCA1 gene-specific cancer risk percentages from recent cohort studies, and related tumor pathology and microenvironment info."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bbf9ea4c819c855661a75c33f33c",
              "type": "web_search",
              "query": "NCCN Guidelines Genetic/Familial High-Risk Assessment Breast, Ovarian, and Pancreatic 2024 2025 PDF BRCA1 surveillance risk-reducing mastectomy salpingo-oophorectomy",
              "action": {
                "type": "search",
                "query": "NCCN Guidelines Genetic/Familial High-Risk Assessment Breast, Ovarian, and Pancreatic 2024 2025 PDF BRCA1 surveillance risk-reducing mastectomy salpingo-oophorectomy",
                "queries": [
                  "NCCN Guidelines Genetic/Familial High-Risk Assessment Breast, Ovarian, and Pancreatic 2024 2025 PDF BRCA1 surveillance risk-reducing mastectomy salpingo-oophorectomy",
                  "BRCA1 c.68_69delAG 185delAG founder mutation breast ovarian cancer lifetime risk percentage study 2023 2024",
                  "BRCA1 mutation lifetime risk breast ovarian cancer by age 70 80 prospective cohort Kuchenbaecker 2017 JAMA 2020 2021 update",
                  "BRCA1-associated breast cancer basal-like triple-negative histology grade tumor infiltrating lymphocytes PD-L1 high-grade serous ovarian carcinoma pathology"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_58",
              "type": "reasoning",
              "text": "**Refining authoritative source selection**\n\nI'm prioritizing NCCN guidelines for clinical authority, supplemented by NCI/PDQ and major recent studies for cancer risk percentages and tumor pathology details, focusing on BRCA1-related features and tumor microenvironment characteristics. I'll use SEER and CDC for baseline population risk context but rely on cohort studies and guidelines for gene-specific penetrance and pathology."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_59",
              "type": "reasoning",
              "text": "**Targeting NCCN and NCI PDQ searches**\n\nI'm focusing on locating the latest NCCN patient guidelines for high-risk genetic assessment and corresponding NCI PDQ resources on BRCA1/2 cancer risk to ensure authoritative and up-to-date information."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc046170819ca49a052232a16c0c",
              "type": "web_search",
              "query": "NCCN patient guidelines Genetic/Familial High-Risk Assessment Breast, Ovarian, and Pancreatic PDF 2024 2025 BRCA1 screening MRI mammography risk-reducing salpingo-oophorectomy",
              "action": {
                "type": "search",
                "query": "NCCN patient guidelines Genetic/Familial High-Risk Assessment Breast, Ovarian, and Pancreatic PDF 2024 2025 BRCA1 screening MRI mammography risk-reducing salpingo-oophorectomy",
                "queries": [
                  "NCCN patient guidelines Genetic/Familial High-Risk Assessment Breast, Ovarian, and Pancreatic PDF 2024 2025 BRCA1 screening MRI mammography risk-reducing salpingo-oophorectomy",
                  "NCI PDQ BRCA1 cancer risks breast ovarian pancreatic risk percentages",
                  "Kuchenbaecker 2017 JAMA risks of breast ovarian cancer BRCA1 BRCA2 cumulative risk to age 70 80",
                  "BRCA1-associated breast cancer triple-negative basal-like immunohistochemistry ER PR HER2 pathology high grade medullary features review"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_61",
              "type": "reasoning",
              "text": "**Searching for NCCN patient guidelines PDF**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc083030819c9ead6973a3c2f473",
              "type": "web_search",
              "query": "\"Genetic/Familial High-Risk Assessment\" Breast Ovarian Pancreatic \"NCCN\" patient guideline PDF",
              "action": {
                "type": "search",
                "query": "\"Genetic/Familial High-Risk Assessment\" Breast Ovarian Pancreatic \"NCCN\" patient guideline PDF",
                "queries": [
                  "\"Genetic/Familial High-Risk Assessment\" Breast Ovarian Pancreatic \"NCCN\" patient guideline PDF",
                  "NCCN patient guidelines hereditary breast ovarian cancer BRCA1 MRI age 25 30 salpingo-oophorectomy 35 40",
                  "NCCN Clinical Practice Guidelines in Oncology Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic 2024 2025 NCCN.org PDF",
                  "NCCN patient guideline BRCA1 risk-reducing salpingo-oophorectomy timing 35-40"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_63",
              "type": "reasoning",
              "text": "**Planning authoritative sourcing**\n\nThe NCCN guidelines aren't directly accessible, so I'll rely on secondary sources like ACOG and ARUP summaries while clearly noting limited NCCN access. I'll also target WHO tumor classifications and trusted literature on tumor microenvironment and molecular findings, ensuring appropriate citations where possible."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_64",
              "type": "reasoning",
              "text": "**Clarifying citation scope**\n\nEvery factual statement needing support requires citations if web sources are used, even for user-provided mechanistic details. I'll keep mechanistic parts concise, referencing user input generally, and selectively cite key pathology features like BRCA1 tumor profiles."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc156cf0819c818070946a9f86c3",
              "type": "web_search",
              "query": "BRCA1-associated breast cancer pathology high grade medullary features triple-negative basal-like immunohistochemical profile ER PR HER2 CK5/6 EGFR p53 review",
              "action": {
                "type": "search",
                "query": "BRCA1-associated breast cancer pathology high grade medullary features triple-negative basal-like immunohistochemical profile ER PR HER2 CK5/6 EGFR p53 review",
                "queries": [
                  "BRCA1-associated breast cancer pathology high grade medullary features triple-negative basal-like immunohistochemical profile ER PR HER2 CK5/6 EGFR p53 review",
                  "BRCA1 tumors tumor-infiltrating lymphocytes PD-L1 expression triple-negative breast cancer BRCA1 germline study",
                  "BRCA1 ovarian cancer high-grade serous fallopian tube origin STIC WHO classification 2020 2023",
                  "SEER lifetime risk breast cancer ovarian cancer women in United States SEER 2024 2025"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_66",
              "type": "reasoning",
              "text": "**Planning pathology sourcing**\n\nI'm prioritizing WHO classification or comprehensive reviews for authoritative pathology details and will use Frontiers (2020) for features while searching for accessible papers on BRCA1 molecular subtypes and IHC markers."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc1c2520819c8715652ee4c72b11",
              "type": "web_search",
              "query": "BRCA1-associated breast cancers basal-like phenotype ER PR HER2 negative CK5/6 EGFR p53 high grade medullary Lakhani review",
              "action": {
                "type": "search",
                "query": "BRCA1-associated breast cancers basal-like phenotype ER PR HER2 negative CK5/6 EGFR p53 high grade medullary Lakhani review",
                "queries": [
                  "BRCA1-associated breast cancers basal-like phenotype ER PR HER2 negative CK5/6 EGFR p53 high grade medullary Lakhani review",
                  "BRCA1 mutation breast cancer histopathology high grade medullary features lymphocytic infiltrate review",
                  "BRCA1 germline mutation triple negative breast cancer proportion basal-like subtype study",
                  "WHO classification breast tumors basal-like triple-negative immunohistochemistry CK5/6 EGFR"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_68",
              "type": "reasoning",
              "text": "**Scoping pathology and microenvironment sources**\n\nI'm narrowing down to WHO 2020 classification or recent reviews for ovarian high-grade serous of fallopian origin, focusing on tumor microenvironment and PD-L1 in BRCA1 cancers. I'll check reviews for human data linking BRCA1 mutations to increased TILs and PD-L1, balancing preclinical and clinical evidence to address the differential immune context."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_69",
              "type": "reasoning",
              "text": "**Reviewing key sources for IHC and microenvironment**\n\nI'm opening targeted reviews to confirm IHC features of basal-like breast cancers, medullary subtype, and tumor microenvironment characteristics like PD-L1 and TILs in TNBC and ovarian cancer. This will provide precise pathology context and immune marker data."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc260b68819cb5603fe47827b7b0",
              "type": "web_search",
              "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/",
              "action": {
                "type": "open_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_71",
              "type": "reasoning",
              "text": "**Planning citation extraction and fact verification**\n\nI'm locating precise risk percentages and histopathology details from key sources, focusing on specific searchable terms to gather exact statements for citation."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc2b0c24819ca96d3d4f82a3aaa9",
              "type": "web_search",
              "query": "'ER' in https://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/",
              "action": {
                "type": "find_in_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/",
                "pattern": "ER"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_73",
              "type": "reasoning",
              "text": "**Gathering ovarian cancer markers**\n\nI'm looking for data on high-grade serous carcinoma markers like fallopian tube origin and STIC from the Frontiers article to complement existing breast cancer features."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc2e2330819c9ee8c7e49d27bd63",
              "type": "web_search",
              "query": "'high-grade serous' in https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full",
              "action": {
                "type": "find_in_page",
                "url": "https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full",
                "pattern": "high-grade serous"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_75",
              "type": "reasoning",
              "text": "**Identifying guideline sources for screening and risk reduction**\n\nNoted relevant sources include ARUP consult referencing NCCN v2.2025 without full content, ACOG executive summary citing NCCN's BSO timing for BRCA1, and a 2024 review article summarizing NCCN screening ages with MRI and mammography; next step is to review that recent comprehensive risk assessment for detailed guideline data."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc33d1c8819caa8534777378b596",
              "type": "web_search",
              "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/",
              "action": {
                "type": "open_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_77",
              "type": "reasoning",
              "text": "**Noticing internal page errors**\n\nSome internal errors occurred on pages other than ACOG, but the ACOG page link works; planning to revisit the problematic pages using direct URLs."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc364250819c91f776c955a77da9",
              "type": "web_search",
              "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
              "action": {
                "type": "open_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_79",
              "type": "reasoning",
              "text": "**Searching for NCCN/ESMO table in paper**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc394c8c819c96a2d87cebf55469",
              "type": "web_search",
              "query": "'NCCN' in https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
              "action": {
                "type": "find_in_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/",
                "pattern": "NCCN"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_81",
              "type": "reasoning",
              "text": "**Planning cancer risk data sources**\n\nI'm deciding to cite the 2026 Israel policy paper’s NCCN recommendations and to include SEER or NCI data for general population breast and ovarian cancer risks, focusing on finding an ovarian risk fact sheet from NCI or SEER next."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc3dc1f4819c9f447a6deaeb55fc",
              "type": "web_search",
              "query": "NCI ovarian cancer risk fact sheet lifetime risk 1 in 78 SEER",
              "action": {
                "type": "search",
                "query": "NCI ovarian cancer risk fact sheet lifetime risk 1 in 78 SEER",
                "queries": [
                  "NCI ovarian cancer risk fact sheet lifetime risk 1 in 78 SEER",
                  "SEER lifetime risk ovarian cancer women United States risk fact sheet",
                  "NCI ovarian cancer risk 1.2 percent lifetime risk SEER",
                  "NCI ovarian cancer statistics lifetime risk 1 in 78"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_83",
              "type": "reasoning",
              "text": "**Gathering authoritative risk and screening data**\n\nI'm planning to use the NCI ovarian prevention PDQ for lifetime risk estimates and the Israel 2026 policy article for NCCN screening age recommendations. I'm also pulling precise risk percentages for BRCA1 carriers from JAMA 2017 and considering associated cancers from a 2022 Rebbeck study to ensure comprehensive risk coverage."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc43c2e0819ca936cd5dc8c806fd",
              "type": "web_search",
              "query": "'absolute risks to age 80' in https://pubmed.ncbi.nlm.nih.gov/35077220/",
              "action": {
                "type": "find_in_page",
                "url": "https://pubmed.ncbi.nlm.nih.gov/35077220/",
                "pattern": "absolute risks to age 80"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_85",
              "type": "reasoning",
              "text": "**Outlining screening and prevention details**\n\nI'm pinpointing the Israeli policy for NCCN screening recommendations and planning to include prevention strategies like risk-reducing mastectomy and RRSO with source citations, aiming for evidence-based coverage on surveillance and treatment, including PARP inhibitor rationale with foundational references."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_86",
              "type": "reasoning",
              "text": "**Searching for recent PARP inhibitor references**\n\nI'm verifying up-to-date sources linking PARP inhibitors to BRCA1 to ensure current evidence supports the treatment strategy."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc4d4b94819c94dd2b9eb864ed02",
              "type": "web_search",
              "query": "BRCA1 deficiency PARP inhibitor synthetic lethality 2005 2006 Nature Bryant Farmer",
              "action": {
                "type": "search",
                "query": "BRCA1 deficiency PARP inhibitor synthetic lethality 2005 2006 Nature Bryant Farmer",
                "queries": [
                  "BRCA1 deficiency PARP inhibitor synthetic lethality 2005 2006 Nature Bryant Farmer",
                  "PARP inhibitors BRCA1-associated breast ovarian cancer mechanism synthetic lethality review",
                  "NCCN BRCA1 breast cancer treatment PARP inhibitor olaparib adjuvant guideline 2024 2025",
                  "platinum sensitivity BRCA1-mutated ovarian cancer homologous recombination deficiency review"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_88",
              "type": "reasoning",
              "text": "**Outlining treatment references**\n\nI'm prioritizing a high-level treatment mention of PARP inhibitors for BRCA1-associated cancers, citing recent 2024/2025 reviews and the 2015 BJC synthetic lethality paper, while keeping platinum sensitivity guidance general to avoid over-detail. Next, I'll integrate mechanistic insights on the frameshift mutation's impact on BRCA1 function, backed by selective citations."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_89",
              "type": "reasoning",
              "text": "**Confirming variant classification source**\n\nI'm focusing on summarizing the mutation as a two-base-pair deletion causing frameshift and BRCA1 loss and planning to use ClinVar as the authoritative source for variant classification and founder mutation status."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc5627b4819c9560fd638403d7d9",
              "type": "web_search",
              "query": "BRCA1 c.68_69delAG 185delAG founder mutation Ashkenazi Jewish ClinVar frameshift premature stop",
              "action": {
                "type": "search",
                "query": "BRCA1 c.68_69delAG 185delAG founder mutation Ashkenazi Jewish ClinVar frameshift premature stop",
                "queries": [
                  "BRCA1 c.68_69delAG 185delAG founder mutation Ashkenazi Jewish ClinVar frameshift premature stop",
                  "BRCA1 185delAG Ashkenazi founder mutation frameshift truncating pathogenic variant",
                  "BRCA1 c.68_69delAG p.Glu23Valfs*17 ClinVar",
                  "BRCA1 c.68_69delAG founder mutation prevalence Ashkenazi Jewish 1 in 40"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_91",
              "type": "reasoning",
              "text": "**Summarizing mutation and founder details**\n\nPlanning to cite ClinVar for the frameshift mutation causing premature stop and loss of the N-terminal RING domain, with optional mention of translation reinitiation from Hum Mutat 2006. Founder frequency in Ashkenazi Jews will be supported with the 2010 Gene Medicine carrier data (1 in 40 combined founder alleles). Tumor classifications will reference Frontiers for HGS and STIC plus WHO classifications for breast and ovarian cancer. Next, I'll gather BRCA1 risk percentages."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_92",
              "type": "reasoning",
              "text": "**Compiling updated lifetime risk and tumor features**\n\nI'm gathering recent lifetime risk percentages for breast and ovarian cancer, prioritizing JAMA 2017 plus newer sources like 2022 Rebbeck and the 2025 Genes review for context. I'll include tumor histology details citing Frontiers and basal-like subtype reviews, emphasizing breast medullary features and ovarian high-grade serous carcinoma with relevant IHC markers. I'll also incorporate immunological microenvironment data, noting increased TILs and PD-L1 in BRCA1-related tumors with appropriate caveats on evidence sources."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc69a730819c8ce9656f8e7ad0d7",
              "type": "web_search",
              "query": "BRCA1 mutation tumor infiltrating lymphocytes breast cancer PD-L1 study germline BRCA1",
              "action": {
                "type": "search",
                "query": "BRCA1 mutation tumor infiltrating lymphocytes breast cancer PD-L1 study germline BRCA1",
                "queries": [
                  "BRCA1 mutation tumor infiltrating lymphocytes breast cancer PD-L1 study germline BRCA1",
                  "BRCA1-associated breast cancer lymphocytic infiltrate medullary features TILs",
                  "BRCA1 high-grade serous ovarian carcinoma increased tumor infiltrating lymphocytes study",
                  "BRCA1-mutated breast cancer PD-L1 expression study"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_94",
              "type": "reasoning",
              "text": "**Planning selective high-quality citations**\n\nThe plan is to cite reliable sources like PubMed/PMC, NCI, JAMA, Frontiers, and a basal-like review while avoiding low-quality sources. Key tumor features, including triple-negative and high-grade status in BRCA1 tumors, will be supported mainly by the basal-like review and Frontiers, with careful inclusion of microenvironment details and PD-L1 studies, avoiding non-primary sources."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_95",
              "type": "reasoning",
              "text": "**Clarifying BRCA1 tumor microenvironment and classification**\n\nI’m outlining how BRCA1-associated tumors have lymphocyte-rich stroma and increased TILs with PD-L1 common in TNBC but not strongly linked to BRCA1 status, citing 2018 Oncoimmunology and Frontiers. I’m also planning to incorporate tumor classification systems, favoring molecular subtypes and IHC classifications from the basal-like review, while seeking a reliable source for WHO or similar classifications and age of onset data from a 1999 PubMed study to support earlier presentation in BRCA1 carriers."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc7ae160819c96a8f158cf64f133",
              "type": "web_search",
              "query": "https://pubmed.ncbi.nlm.nih.gov/10353781/",
              "action": {
                "type": "open_page",
                "url": "https://pubmed.ncbi.nlm.nih.gov/10353781/"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_97",
              "type": "reasoning",
              "text": "**Planning age-of-onset citation**\n\nI'm focusing on citing the JAMA 2017 study for BRCA1 age-specific incidence, highlighting rising risk in the 30s-40s as a more current reference for typical onset than the older 1999 study."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc7e2810819c8d928e7cb3684a6f",
              "type": "web_search",
              "query": "'incidences increased rapidly' in https://pubmed.ncbi.nlm.nih.gov/28632866/",
              "action": {
                "type": "find_in_page",
                "url": "https://pubmed.ncbi.nlm.nih.gov/28632866/",
                "pattern": "incidences increased rapidly"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_99",
              "type": "reasoning",
              "text": "**Planning precise citation strategy**\n\nI'm aligning citations to rely on the 2026 policy review that summarizes NCCN recommendations, avoiding direct NCCN access mention while crediting the source. I'll integrate molecular insights with focused references like ClinVar and relevant literature to support mechanistic statements without overcomplicating."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_100",
              "type": "reasoning",
              "text": "**Clarifying DNA repair disruption citations**\n\nI'm focusing on framing BRCA1 loss as impairing homologous recombination with resulting genomic instability, supported primarily by the 2015 BJC review on synthetic lethality and HR deficiency. I'll confirm citing ClinVar for truncation and use reviews like BJC 2015 and possibly the NCI PDQ genetics overview to back \"disrupts DNA repair\" and PARP sensitivity statements."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc8bb820819c8908ede130ae4d2a",
              "type": "web_search",
              "query": "https://www.nature.com/articles/bjc2015394",
              "action": {
                "type": "open_page",
                "url": "https://www.nature.com/articles/bjc2015394"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_102",
              "type": "reasoning",
              "text": "**Switching to open-access sources**\n\nThe Nature article is paywalled and lacks mechanism details in the preview, so I'll focus on open-access sources like the 2014 Hereditary Cancer in Clinical Practice article, which clearly explains PARP inhibition in BRCA-mutated cells."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc8eaa88819cab3410ad297498d8",
              "type": "web_search",
              "query": "https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-014-0024-8",
              "action": {
                "type": "open_page",
                "url": "https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-014-0024-8"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_104",
              "type": "reasoning",
              "text": "**Planning tumor characterization details**\n\nI'm outlining key points on tumor repair deficiencies, IHC profiles for ovarian and breast tumors, tumor grades, molecular subtypes, proliferation markers, microenvironment features like TILs and PD-L1, and genomic instability scores, with plans to paraphrase and cite appropriately."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_105",
              "type": "reasoning",
              "text": "**Outlining comprehensive evidence and citations**\n\nI'm consolidating extensive citations and detailed points on mutation genetics, cancer risk, pathology, tumor microenvironment, screening guidelines, and treatment considerations, ensuring a clear structured response with properly cited authoritative sources while planning to adhere to citation limits and formatting rules."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bcc93ad0819ca39276cc39c366de",
              "type": "web_search",
              "query": "https://www.mdpi.com/1467-3045/47/8/638",
              "action": {
                "type": "open_page",
                "url": "https://www.mdpi.com/1467-3045/47/8/638"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_107",
              "type": "reasoning",
              "text": "**Mapping key citations for HRD and guidelines**\n\nI've identified key lines for genomic scars and BRCA1-related HRD, plus NCCN guidelines details with specific screening ages and risk-reducing surgery recommendations. Next, I'll integrate these with citations into the response covering evidence-based prevention, surveillance, and treatment strategies."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_108",
              "type": "reasoning",
              "text": "**Clarifying screening and prevention recommendations**\n\nI'm adding ovarian screening notes with limits and no screening post-RRSO, plus timing for RRSO at age 35-40 for BRCA1 carriers. I'm investigating reliable citations for risk-reducing mastectomy recommendations to include prevention accurately without violating citation rules."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bcd51534819c880042ea653526b5",
              "type": "web_search",
              "query": "'mastectomy' in https://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/",
              "action": {
                "type": "find_in_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/",
                "pattern": "mastectomy"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_110",
              "type": "reasoning",
              "text": "**Outlining prevention and risk sections**\n\nPlanning to cite NCCN guidelines from the Genes review for risk-reducing mastectomy in BRCA1 carriers and for RRSO recommendations from the 2026 policy table, emphasizing lack of effective ovarian screening and RRSO benefits. Also structuring the response to cover molecular genetics first, then detailed cancer risk profiles with lifetime risk numbers."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_111",
              "type": "reasoning",
              "text": "**Detailing integrated cancer profile and sources plan**\n\nDefining comprehensive section outlines covering pancreatic and other cancer risks, pathology, tumor microenvironment, prevention, and treatment strategies with careful citation sourcing. Planning to compile a clear sources list with URLs in a code block and ensure citations follow punctuation, avoiding nested bullets or bolded citations."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_112",
              "type": "agent_message",
              "text": "Below is an integrated, pathology‑focused risk profile for a 35‑year‑old Ashkenazi Jewish woman with **BRCA1 c.68_69delAG (185delAG)** and no current cancer, using NCCN‑summarized recommendations, SEER/NCI epidemiology, and recent pathology literature.\n\n**Molecular Genetics & DNA Repair**\n- `BRCA1 c.68_69delAG` is a 2‑bp deletion in exon 2 that causes a frameshift after codon 23 and a premature stop 17 aa later (p.Glu23Valfs*17), producing an absent/disrupted protein; ClinVar classifies it as pathogenic and an Ashkenazi founder variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000017662/?utm_source=openai))  \n- It is one of the three classic Ashkenazi Jewish founder variants; together they account for ~2.6% (≈1 in 40) of the Ashkenazi population, and c.68_69delAG is one of these founders. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3405339/?utm_source=openai))  \n- The 185delAG allele can undergo translation reinitiation at a downstream AUG (~codon 128), producing an N‑terminally truncated protein, consistent with functional loss. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16941470/?utm_source=openai))  \n- BRCA‑mutated tumor cells are defective in homologous recombination (HR) repair of double‑strand breaks and rely more on other repair pathways (e.g., BER); PARP inhibition in this context leads to lethal DNA damage (synthetic lethality). ([hccpjournal.biomedcentral.com](https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-014-0024-8))  \n\n**Cancer Risk Profile (Lifetime Risk Estimates)**\n- **Breast cancer**: Prospective cohort data show a cumulative risk to age 80 of **~72% for BRCA1** carriers. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/))  \n- **Ovarian/fallopian tube/primary peritoneal cancer**: Cumulative risk to age 80 is **~44% for BRCA1** carriers. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/))  \n- **Pancreatic cancer**: BRCA1 pathogenic variants confer increased risk; absolute risk to age 80 is **~2.5%**. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35077220/))  \n- **Stomach cancer**: BRCA1 pathogenic variants show increased relative risk (RR ~2.17). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35077220/))  \n- **Population context (SEER/NCI)**: U.S. lifetime risk is ~12.9% for breast cancer and ~1.12% for ovarian cancer. ([cancer.gov](https://www.cancer.gov/types/breast/risk-fact-sheet?utm_source=openai))  \n- **Family history and mutation location modify risk**; risk rises with more affected relatives. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/))  \n\n**Expected Pathology and Histologic Subtypes**\n- **Breast**: BRCA1‑associated tumors are most often **high‑grade invasive ductal carcinoma (NST)** with minimal tubule formation, marked nuclear pleomorphism, and high mitotic activity; **medullary‑like features** (sheet‑like growth, pushing borders, necrosis, prominent lymphocytes) are well described. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **Breast molecular subtype**: BRCA1‑mutant tumors frequently show **basal‑like gene‑expression patterns** and are commonly **triple‑negative (ER−/PR−/HER2−)** with expression of **basal cytokeratins (CK5/CK14/CK17)** and high proliferation. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/))  \n- **Tubo‑ovarian**: The hallmark BRCA‑associated tumor is **high‑grade serous carcinoma (HGSOC)**; other histotypes are reported but less common. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **HGSOC morphology/IHC**: Classic HGSOC shows papillary/glandular growth, marked nuclear atypia, brisk mitoses, and aberrant **p53** staining; typical markers include **CK7, PAX8, WT‑1**, and often **diffuse ER** expression. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **Precursor lesion**: Most HGSOC arises from the **fallopian tube**, with **STIC** as a recognized precursor; STIC is identified in ~40–60% of HGSOC. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n\n**Typical Age of Onset & Tumor Grade**\n- **Age of onset**: For BRCA1 carriers, breast cancer incidence increases rapidly in early adulthood and rises steeply until ages **30–40**, consistent with earlier onset risk. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/))  \n- **Tumor grade**: BRCA1‑associated breast cancers are typically **high‑grade**, and HGSOC is high‑grade by definition with high mitotic activity. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n\n**Tumor Microenvironment**\n- **Breast**: Medullary‑like BRCA1 tumors often show **prominent peri‑ and intratumoral lymphocytes**, reflecting an immune‑rich microenvironment. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **Ovary**: BRCA1‑associated HGSOC shows **increased TILs**, high mitotic rates, and necrosis; SET‑type morphology is also enriched. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **PD‑L1/TILs in TNBC**: PD‑L1 expression is frequent in TNBC (high PD‑L1+ rates in tumor and immune cells), and PD‑L1+ TILs are common; PD‑L1/TIL levels are not necessarily driven by BRCA1‑like status. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30524905/?utm_source=openai))  \n- **Genomic instability**: BRCA1/2 defects produce **HRD**, causing genomic instability detectable via scar metrics (LOH, TAI, LST) and used clinically in HGSOC and TNBC. ([mdpi.com](https://www.mdpi.com/1467-3045/47/8/638))  \n\n**Evidence‑Based Prevention & Surveillance (NCCN‑Summarized)**\n- **Breast surveillance (NCCN‑summarized)**: Clinical breast exam every 6–12 months starting **age 25**; **age 25–29** annual breast MRI (or mammogram if MRI unavailable); **age 30–75** annual mammography **and** MRI; >75 individualized. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/))  \n- **Risk‑reducing salpingo‑oophorectomy (RRSO)**: For BRCA1, NCCN‑summarized timing is **age 35–40** after completion of childbearing. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/))  \n- **Ovarian screening limits**: If surgery is declined, CA‑125 and pelvic ultrasound may be used with explicit counseling about **limitations**; after RRSO, no routine ovarian screening is recommended. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/))  \n- **Risk‑reducing mastectomy**: NCCN‑summarized guidelines **recommend** risk‑reducing bilateral mastectomy as an option for **BRCA1** carriers. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/))  \n- **Effectiveness of ovarian risk reduction**: There is **no evidence** that ovarian/tubal screening reduces disease‑specific mortality; RRSO is the only strategy shown to reduce incidence and mortality. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/))  \n- **Pancreatic screening (NCCN‑summarized)**: Consider starting at **age 50** (or 5–10 years earlier than the youngest affected relative) **only if** there is a first‑ or second‑degree relative with pancreatic cancer. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/))  \n\n**Treatment Considerations if Cancer Develops (High‑Level)**\n- **DNA‑repair–targeted therapy**: BRCA‑mutated tumors are HR‑deficient and are sensitive to **PARP inhibitors** via synthetic lethality. ([hccpjournal.biomedcentral.com](https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-014-0024-8))  \n- **Platinum/PARP sensitivity**: HRD predicts robust responses to **platinum** and **PARP inhibitors** in HGSOC and TNBC, and HRD assays use genomic scars to guide therapy. ([mdpi.com](https://www.mdpi.com/1467-3045/47/8/638))  \n- **Immunotherapy context**: TNBC often shows high PD‑L1 expression and immune infiltration, supporting PD‑L1–directed immunotherapy in appropriate clinical settings. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30524905/?utm_source=openai))  \n\nIf you want, I can format this into a clinician‑facing decision summary or a patient‑facing counseling handout.\n\n**Sources**\n```text\nhttps://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000017662/\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC3405339/\nhttps://pubmed.ncbi.nlm.nih.gov/16941470/\nhttps://pubmed.ncbi.nlm.nih.gov/28632866/\nhttps://pubmed.ncbi.nlm.nih.gov/35077220/\nhttps://www.cancer.gov/types/breast/risk-fact-sheet\nhttps://www.cancer.gov/types/ovarian/hp/ovarian-prevention-pdq\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/\nhttps://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.531790/full\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/\nhttps://pubmed.ncbi.nlm.nih.gov/30524905/\nhttps://www.mdpi.com/1467-3045/47/8/638\nhttps://link.springer.com/article/10.1186/s13053-014-0024-8\n```"
            }
          }
        ],
        "item.started": [
          {
            "type": "item.started",
            "item": {
              "id": "item_1",
              "type": "command_execution",
              "command": "/bin/zsh -lc ls",
              "aggregated_output": "",
              "exit_code": null,
              "status": "in_progress"
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "item_2",
              "type": "command_execution",
              "command": "/bin/zsh -lc 'cat /Users/lingzhi/.codex/skills/web-search/SKILL.md'",
              "aggregated_output": "",
              "exit_code": null,
              "status": "in_progress"
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bac8f48c8191aa20a5c622d1868d",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bad0d22c8191b226dabdbf7245cc",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bad1f684819198138b7f9ccb192d",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bad63a4881919bb65adcc47f1f33",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996badbaaac8191897962c0d07c2774",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bae173e48191ac6ef11b88f61d60",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bae789e481918c755070998ba383",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996baeffa508191983ddc1953f264ad",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996baf0d0048191b21e6928878c5d22",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996baf498ac81919c360b1ad911fd87",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bafe2ad8819186a32fb2538038ac",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb03fe14819185d51ecc58c4a343",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb07bbb88191ae0363a12a4f514e",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb0941e0819199ec5a756e32970b",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb157ffc8191a3e1c2a4826d5a8a",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb1b8b6881918e1a0db8f99b74b0",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb1df6b08191b169fb0567c8ea06",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb280ff88191b8735b316843a492",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb3881c0819197f87dae051c0a9f",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb3a74448191b699025c84724f1a",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb3b4eb88191a86071edc0dcc453",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb4471d08191b12eca43fb977fd6",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb47764081918e051dd3f1fe2b9d",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0c9b2cbd4bb87c2d016996bb7aa3d481918abfdafedcac5528",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bbf9ea4c819c855661a75c33f33c",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc046170819ca49a052232a16c0c",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc083030819c9ead6973a3c2f473",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc156cf0819c818070946a9f86c3",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc1c2520819c8715652ee4c72b11",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc260b68819cb5603fe47827b7b0",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc2b0c24819ca96d3d4f82a3aaa9",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc2e2330819c9ee8c7e49d27bd63",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc33d1c8819caa8534777378b596",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc364250819c91f776c955a77da9",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc394c8c819c96a2d87cebf55469",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc3dc1f4819c9f447a6deaeb55fc",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc43c2e0819ca936cd5dc8c806fd",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc4d4b94819c94dd2b9eb864ed02",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc5627b4819c9560fd638403d7d9",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc69a730819c8ce9656f8e7ad0d7",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc7ae160819c96a8f158cf64f133",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc7e2810819c8d928e7cb3684a6f",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc8bb820819c8908ede130ae4d2a",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bc8eaa88819cab3410ad297498d8",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bcc93ad0819ca39276cc39c366de",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0cee67ddcb7b5c82016996bcd51534819c880042ea653526b5",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          }
        ],
        "error": [
          {
            "type": "error",
            "message": "Reconnecting... 1/5 (stream disconnected before completion: Transport error: network error: error decoding response body)"
          }
        ],
        "turn.completed": [
          {
            "type": "turn.completed",
            "usage": {
              "input_tokens": 134597,
              "cached_input_tokens": 25088,
              "output_tokens": 18639
            }
          }
        ]
      }
    },
    {
      "agent_name": "clinical-oncologist",
      "system_prompt": "You are a clinical oncologist specializing in hereditary cancer management and precision oncology. You have access to web search — USE IT to look up the latest NCCN guidelines (2024-2025), FDA-approved therapies, ongoing clinical trials, and evidence-based risk reduction strategies. Synthesize all prior research into actionable clinical recommendations.",
      "user_prompt": "Based on ALL the research from previous domain experts, provide comprehensive clinical recommendations for this 35-year-old BRCA1 185delAG carrier:\n\nRISK REDUCTION:\n- Prophylactic bilateral mastectomy: risk reduction percentage, optimal timing\n- Prophylactic bilateral salpingo-oophorectomy (BSO): recommended age, risk reduction\n- Chemoprevention options (tamoxifen, olaparib prevention trials)\n\nSURVEILLANCE:\n- Breast MRI and mammography schedule per latest NCCN guidelines\n- Ovarian cancer screening limitations and recommendations\n- Any emerging screening modalities (liquid biopsy, ctDNA)\n\nTREATMENT (if cancer develops):\n- PARP inhibitors: which ones are FDA-approved, clinical trial evidence (OlympiAD, EMBRACA, etc.)\n- Platinum-based chemotherapy rationale and response rates\n- Immunotherapy potential (checkpoint inhibitors given high TILs/PD-L1)\n- Emerging therapies: antibody-drug conjugates, combination approaches\n\nFAMILY IMPLICATIONS:\n- Cascade genetic testing recommendations for relatives\n- Reproductive considerations (PGT-M)\n\nUse web search for the most current guidelines and clinical trial data.",
      "full_prompt_sent": "You are: You are a clinical oncologist specializing in hereditary cancer management and precision oncology. You have access to web search — USE IT to look up the latest NCCN guidelines (2024-2025), FDA-approved therapies, ongoing clinical trials, and evidence-based risk reduction strategies. Synthesize all prior research into actionable clinical recommendations.\n\nContext from previous work:\nBelow is an integrated, pathology‑focused risk profile for a 35‑year‑old Ashkenazi Jewish woman with **BRCA1 c.68_69delAG (185delAG)** and no current cancer, using NCCN‑summarized recommendations, SEER/NCI epidemiology, and recent pathology literature.\n\n**Molecular Genetics & DNA Repair**\n- `BRCA1 c.68_69delAG` is a 2‑bp deletion in exon 2 that causes a frameshift after codon 23 and a premature stop 17 aa later (p.Glu23Valfs*17), producing an absent/disrupted protein; ClinVar classifies it as pathogenic and an Ashkenazi founder variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000017662/?utm_source=openai))  \n- It is one of the three classic Ashkenazi Jewish founder variants; together they account for ~2.6% (≈1 in 40) of the Ashkenazi population, and c.68_69delAG is one of these founders. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3405339/?utm_source=openai))  \n- The 185delAG allele can undergo translation reinitiation at a downstream AUG (~codon 128), producing an N‑terminally truncated protein, consistent with functional loss. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16941470/?utm_source=openai))  \n- BRCA‑mutated tumor cells are defective in homologous recombination (HR) repair of double‑strand breaks and rely more on other repair pathways (e.g., BER); PARP inhibition in this context leads to lethal DNA damage (synthetic lethality). ([hccpjournal.biomedcentral.com](https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-014-0024-8))  \n\n**Cancer Risk Profile (Lifetime Risk Estimates)**\n- **Breast cancer**: Prospective cohort data show a cumulative risk to age 80 of **~72% for BRCA1** carriers. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/))  \n- **Ovarian/fallopian tube/primary peritoneal cancer**: Cumulative risk to age 80 is **~44% for BRCA1** carriers. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/))  \n- **Pancreatic cancer**: BRCA1 pathogenic variants confer increased risk; absolute risk to age 80 is **~2.5%**. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35077220/))  \n- **Stomach cancer**: BRCA1 pathogenic variants show increased relative risk (RR ~2.17). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35077220/))  \n- **Population context (SEER/NCI)**: U.S. lifetime risk is ~12.9% for breast cancer and ~1.12% for ovarian cancer. ([cancer.gov](https://www.cancer.gov/types/breast/risk-fact-sheet?utm_source=openai))  \n- **Family history and mutation location modify risk**; risk rises with more affected relatives. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/))  \n\n**Expected Pathology and Histologic Subtypes**\n- **Breast**: BRCA1‑associated tumors are most often **high‑grade invasive ductal carcinoma (NST)** with minimal tubule formation, marked nuclear pleomorphism, and high mitotic activity; **medullary‑like features** (sheet‑like growth, pushing borders, necrosis, prominent lymphocytes) are well described. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **Breast molecular subtype**: BRCA1‑mutant tumors frequently show **basal‑like gene‑expression patterns** and are commonly **triple‑negative (ER−/PR−/HER2−)** with expression of **basal cytokeratins (CK5/CK14/CK17)** and high proliferation. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/))  \n- **Tubo‑ovarian**: The hallmark BRCA‑associated tumor is **high‑grade serous carcinoma (HGSOC)**; other histotypes are reported but less common. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **HGSOC morphology/IHC**: Classic HGSOC shows papillary/glandular growth, marked nuclear atypia, brisk mitoses, and aberrant **p53** staining; typical markers include **CK7, PAX8, WT‑1**, and often **diffuse ER** expression. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **Precursor lesion**: Most HGSOC arises from the **fallopian tube**, with **STIC** as a recognized precursor; STIC is identified in ~40–60% of HGSOC. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n\n**Typical Age of Onset & Tumor Grade**\n- **Age of onset**: For BRCA1 carriers, breast cancer incidence increases rapidly in early adulthood and rises steeply until ages **30–40**, consistent with earlier onset risk. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/))  \n- **Tumor grade**: BRCA1‑associated breast cancers are typically **high‑grade**, and HGSOC is high‑grade by definition with high mitotic activity. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n\n**Tumor Microenvironment**\n- **Breast**: Medullary‑like BRCA1 tumors often show **prominent peri‑ and intratumoral lymphocytes**, reflecting an immune‑rich microenvironment. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **Ovary**: BRCA1‑associated HGSOC shows **increased TILs**, high mitotic rates, and necrosis; SET‑type morphology is also enriched. ([frontiersin.org](https://www.frontiersin.org/articles/10.3389/fonc.2020.531790/full))  \n- **PD‑L1/TILs in TNBC**: PD‑L1 expression is frequent in TNBC (high PD‑L1+ rates in tumor and immune cells), and PD‑L1+ TILs are common; PD‑L1/TIL levels are not necessarily driven by BRCA1‑like status. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30524905/?utm_source=openai))  \n- **Genomic instability**: BRCA1/2 defects produce **HRD**, causing genomic instability detectable via scar metrics (LOH, TAI, LST) and used clinically in HGSOC and TNBC. ([mdpi.com](https://www.mdpi.com/1467-3045/47/8/638))  \n\n**Evidence‑Based Prevention & Surveillance (NCCN‑Summarized)**\n- **Breast surveillance (NCCN‑summarized)**: Clinical breast exam every 6–12 months starting **age 25**; **age 25–29** annual breast MRI (or mammogram if MRI unavailable); **age 30–75** annual mammography **and** MRI; >75 individualized. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/))  \n- **Risk‑reducing salpingo‑oophorectomy (RRSO)**: For BRCA1, NCCN‑summarized timing is **age 35–40** after completion of childbearing. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/))  \n- **Ovarian screening limits**: If surgery is declined, CA‑125 and pelvic ultrasound may be used with explicit counseling about **limitations**; after RRSO, no routine ovarian screening is recommended. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/))  \n- **Risk‑reducing mastectomy**: NCCN‑summarized guidelines **recommend** risk‑reducing bilateral mastectomy as an option for **BRCA1** carriers. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/))  \n- **Effectiveness of ovarian risk reduction**: There is **no evidence** that ovarian/tubal screening reduces disease‑specific mortality; RRSO is the only strategy shown to reduce incidence and mortality. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/))  \n- **Pancreatic screening (NCCN‑summarized)**: Consider starting at **age 50** (or 5–10 years earlier than the youngest affected relative) **only if** there is a first‑ or second‑degree relative with pancreatic cancer. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/))  \n\n**Treatment Considerations if Cancer Develops (High‑Level)**\n- **DNA‑repair–targeted therapy**: BRCA‑mutated tumors are HR‑deficient and are sensitive to **PARP inhibitors** via synthetic lethality. ([hccpjournal.biomedcentral.com](https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-014-0024-8))  \n- **Platinum/PARP sensitivity**: HRD predicts robust responses to **platinum** and **PARP inhibitors** in HGSOC and TNBC, and HRD assays use genomic scars to guide therapy. ([mdpi.com](https://www.mdpi.com/1467-3045/47/8/638))  \n- **Immunotherapy context**: TNBC often shows high PD‑L1 expression and immune infiltration, supporting PD‑L1–directed immunotherapy in appropriate clinical settings. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30524905/?utm_source=openai))  \n\nIf you want, I can format this into a clinician‑facing decision summary or a patient‑facing counseling handout.\n\n**Sources**\n```text\nhttps://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000017662/\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC3405339/\nhttps://pubmed.ncbi.nlm.nih.gov/16941470/\nhttps://pubmed.ncbi.nlm.nih.gov/28632866/\nhttps://pubmed.ncbi.nlm.nih.gov/35077220/\nhttps://www.cancer.gov/types/breast/risk-fact-sheet\nhttps://www.cancer.gov/types/ovarian/hp/ovarian-prevention-pdq\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/\nhttps://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.531790/full\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12857140/\nhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11764557/\nhttps://pubmed.ncbi.nlm.nih.gov/30524905/\nhttps://www.mdpi.com/1467-3045/47/8/638\nhttps://link.springer.com/article/10.1186/s13053-014-0024-8\n```\n\nMain question:\nA 35-year-old woman of Ashkenazi Jewish descent, with a family history of breast cancer (mother diagnosed at 42, maternal aunt at 38), undergoes genetic testing and is found to carry a pathogenic BRCA1 c.68_69delAG (185delAG) founder mutation. She currently has no signs of cancer.\n\nWe need a comprehensive analysis covering:\n1. The molecular genetics of this specific mutation\n2. How the resulting protein defect disrupts DNA repair\n3. The cancer risk profile and expected tumor pathology\n4. Evidence-based prevention, surveillance, and treatment strategies\n\nYour specific assignment:\nBased on ALL the research from previous domain experts, provide comprehensive clinical recommendations for this 35-year-old BRCA1 185delAG carrier:\n\nRISK REDUCTION:\n- Prophylactic bilateral mastectomy: risk reduction percentage, optimal timing\n- Prophylactic bilateral salpingo-oophorectomy (BSO): recommended age, risk reduction\n- Chemoprevention options (tamoxifen, olaparib prevention trials)\n\nSURVEILLANCE:\n- Breast MRI and mammography schedule per latest NCCN guidelines\n- Ovarian cancer screening limitations and recommendations\n- Any emerging screening modalities (liquid biopsy, ctDNA)\n\nTREATMENT (if cancer develops):\n- PARP inhibitors: which ones are FDA-approved, clinical trial evidence (OlympiAD, EMBRACA, etc.)\n- Platinum-based chemotherapy rationale and response rates\n- Immunotherapy potential (checkpoint inhibitors given high TILs/PD-L1)\n- Emerging therapies: antibody-drug conjugates, combination approaches\n\nFAMILY IMPLICATIONS:\n- Cascade genetic testing recommendations for relatives\n- Reproductive considerations (PGT-M)\n\nUse web search for the most current guidelines and clinical trial data.",
      "reasoning": [
        "**Preparing to integrate web search skill**\n\nI'm retrieving the web skill file to enable use of the web-search capability via web.run and open commands for fulfilling the user's web search request.",
        "**Identifying skill file path**",
        "**Aligning search approach with skill and restrictions**\n\nPlanning to use the web-search skill as instructed but execute actual searches via web.run to comply with network restrictions; focusing on authoritative, freely accessible sources like NCCN patient guidelines, FDA labels, and clinical trials data to compile medical recommendations with citations and disclaimers.",
        "**Detailing comprehensive search strategy for latest guidelines**\n\nOutlining focused web.run queries to retrieve 2024-2025 NCCN patient guidelines and authoritative data on risk reduction, surveillance, treatments, and emerging therapies, emphasizing high-quality sources like ACOG, NCI PDQ, FDA labels, and clinicaltrials.gov for updated citations and clinical recommendations.",
        "**Expanding queries for guideline and data coverage**\n\nI identified missing NCCN patient guidelines and risk-reducing mastectomy percentages, so I'll run additional web searches covering NCCN patient guidelines, NCI BRCA facts, and FDA PARP inhibitor labels to fill these gaps.",
        "**Identifying missing NCCN patient guidelines**\n\nFound NCCN 2024 screening guidelines summary but not BRCA-specific schedule in patient guidelines; planning to search again for those and the mastectomy risk-reduction stats from NCI.",
        "**Defining trusted sources**\n\nI'm focusing on authoritative medical sources like NCI, ACS, ACOG, StatPearls, and peer-reviewed journals while excluding droracle, verywell, and allure. I'll prioritize NCCN patient guidelines by searching directly on nccn.org.",
        "**Gathering NCCN-related risk management sources**\n\nI'm planning to source NCCN 2024-2025 guideline summaries indirectly via peer-reviewed references like the ACOG 2023 executive summary that cites NCCN, noting NCCN guidelines require login; next, I'll confirm RRSO timing and risk-reducing mastectomy effectiveness with NCI and ACOG materials to ensure accurate risk reduction data.",
        "**Identifying mastectomy risk reduction data**\n\nThe fact sheet lacks mastectomy percentages, so I'll source updated risk reduction figures from ACOG, Mayo Clinic, NCI PDQ, and recent meta-analyses to provide an accurate, current range.",
        "**Summarizing risk reduction sources**\n\nI've identified key sources for risk reduction percentages including PROSE (2004) for overall risk reduction and 2009/2022 meta analyses plus ACOG 2023 for RRSO effects. I'll cover ovarian cancer risk reductions, mortality ranges, and note investigational status of early salpingectomy with delayed oophorectomy, citing NCI fact sheets and relevant trials, and include chemoprevention notes on tamoxifen and OCP use.",
        "**Searching PARP inhibitor prevention trials**\n\nI'm investigating clinical trials for olaparib or other PARP inhibitors in breast cancer prevention for BRCA carriers to clarify if any prevention trials exist beyond approved adjuvant uses.",
        "**Summarizing PARP inhibitor and immunotherapy approvals**\n\nNo established PARP inhibitor prevention trials were found; adjuvant olaparib is approved for early-stage high-risk breast cancer (OlympiA), not prevention. Next, I'll gather current FDA labels and approval details for olaparib, talazoparib, niraparib, and rucaparib, along with key immunotherapy approvals like pembrolizumab for breast and ovarian cancers.",
        "**Detailing ADC and immunotherapy approvals**\n\nI'm outlining key ADC approvals like sacituzumab govitecan for metastatic TNBC and HR+ breast cancer, trastuzumab deruxtecan for HER2-low breast cancer, and mirvetuximab soravtansine for platinum-resistant ovarian cancer. Next, I'll verify current FDA approvals and label specifics using official press releases and manufacturer documents to confirm indications and recent withdrawals for PARP inhibitors and immunotherapies.",
        "**Noting FDA approvals and planning search for others**\n\nI confirmed FDA approvals for olaparib adjuvant, talazoparib, and olaparib metastatic from the FDA D.I.S.C.O dataset and will now search for additional approvals like pembrolizumab.",
        "**Identifying relevant drug approvals**\n\nNoted that T-DXd is FDA-approved for 2025 and may be relevant for HER2-low cases in the patient context, while pembrolizumab approvals still need confirming with further searches.",
        "**Outlining immunotherapy and PARP inhibitor coverage**\n\nPlanning to include pembrolizumab plus chemo for early TNBC and PD-L1+ metastatic cases with FDA citations, then cover PARP inhibitors for ovarian and other cancers by verifying recent FDA approvals and potential withdrawals.",
        "**Refining search for olaparib first-line maintenance approval**",
        "**Clarifying PARP inhibitor indications**\n\nI'm prioritizing FDA and NCI sources, emphasizing rucaparib's maintenance and adjuvant approvals while avoiding uncertain late-line treatment claims, and planning to cite key approvals like olaparib with bevacizumab (PAOLA-1) and olaparib maintenance in pancreatic cancer (POLO).",
        "**Outlining clinical trial and pathology citations**\n\nPlanning to cover key trials for PARP inhibitors and platinum chemo sensitivity, citing FDA approvals and NCI fact sheets for high-level evidence; also considering citing recent pathology sources with potential web fetching to ensure updated references.",
        "**Committing to web.run for citation verification**\n\nDecided to use web.run to confirm and cite online sources for pathology details, focusing on high-level BRCA-associated cancer features and initiating searches for key articles like Frontiers in Oncology 2020 and the PMC basal-like study.",
        "**Including molecular genetics citation**\n\nPlanning to cite ClinVar for the molecular genetics of BRCA1 c.68_69delAG by searching and referencing its ClinVar page.",
        "**Locating BRCA1 breast/ovarian cancer risk data**\n\nI'm targeting lifetime risk estimates for breast and ovarian cancer in BRCA1 mutation carriers to age 80, focusing on the 2017 JAMA meta-analysis cited as PMID 28632866 for authoritative data.",
        "**Planning citations for risk and family history**\n\nI'm aligning risk data from JAMA and 2024 Cancer for pancreatic risk and considering citing NCI breast/ovarian risk sheets for baseline population risk. Next, I'll incorporate family history impact on screening timing and plan to cite NCI and GeneReviews or ACOG for cascade testing and inheritance details.",
        "**Planning guideline search for PGT-M**\n\nConsidering citing ASRM or ESHRE guidelines on PGT-M in reproductive contexts for hereditary cancer, aiming to support recommendations with committee opinions. Next step is to locate relevant guidelines to reference.",
        "**Summarizing screening and risk reduction guidance**\n\nThe ASRM opinion supports PGT-M including hereditary breast/ovarian cancer as adult-onset serious condition and highlights risk reduction via RRSO per ACOG and NCCN. I'll ensure surveillance schedules align with NCCN guidelines and address emerging screening like ctDNA tests, noting lack of FDA approval and current non-recommendation from authoritative sources.",
        "**Outlining comprehensive clinical analysis**\n\nI'm preparing detailed narrative sections on molecular genetics, risk, pathology, risk reduction, surveillance, treatment, and family for BRCA1 risk reduction, citing ongoing trials and using current sources dated up to February 19, 2026, while noting limitations around NCCN guideline access.",
        "**Detailing risk reduction and screening recommendations**\n\nI'm specifying recommended RRSO timing, prophylactic mastectomy considerations, investigational alternatives, and surveillance per NCCN guidelines citing Journal of Breast Imaging, while outlining ovarian and pancreatic screening nuances and evidence with supporting citations.",
        "**Identifying alternative screening guideline sources**\n\nARUP's page lacks detailed guidance, and NCCN specifics aren't accessible; I'll rely on the J Breast Imaging table for genetic risk-based NCCN screening guidelines and ACOG 2023 for RRSO timing. For pancreatic screening age thresholds, I'll search alternative sources like JNCCN or hereditary pancreatic screening reviews referencing NCCN guidance.",
        "**Integrating selective clinical trials**\n\nPlanning to mention key ongoing or relevant clinical trials tailored to this patient's BRCA1 context, like early salpingectomy (NCT04294927) and PARP-related therapies, while noting limited pancreatic screening given current age and family history. The approach includes highlighting trial categories with specific examples to balance relevance and clarity.",
        "**Verifying trial recruitment status**\n\nPlanning to confirm the active recruitment status of key clinical trials for BRCA1 prevention and treatment, including NCT04294927, to ensure accurate mention of ongoing trials for the user.",
        "**Clarifying clinical trial references**\n\nDeciding to describe ongoing trials on ClinicalTrials.gov cautiously without relying on unclear status, citing them as active studies with NCT numbers, and avoiding raw URLs in responses while preparing to include proper citations. Planning a clear, clinician-focused intro noting guideline updates and source types.",
        "**Outlining detailed content sections**\n\nDrafting comprehensive sections covering genetics, cancer risk, risk reduction, surveillance, treatment options, and family implications, with extensive citations planned for mutation specifics, guideline-based interventions, and emerging therapies while avoiding direct medical advice.",
        "**Planning treatment summary with trial mentions**\n\nI'm preparing a treatment summary that includes FDA approval for mirvetuximab, highlights ongoing clinical trials for both prevention and therapy, and references key examples like the PARTNER trial (noted as recent) and active trials such as NCT04294927, while advising readers to check clinicaltrials.gov for the latest on PARP combination studies.",
        "**Preparing comprehensive clinical summary**\n\nI'm consolidating a detailed clinical summary with molecular genetics, risk profiles, NCCN-based surveillance, FDA-approved treatments, actionable prevention and surveillance plans, family implications, and citations reflecting 2024–2025 guidelines and trials, while addressing paywalled NCCN sources and emphasizing proper citation placement without direct URLs."
      ],
      "web_searches": [
        {
          "id": "ws_07b69152b71a72a5016996bd4348f481a1afa4c2213f19fe05",
          "query": "NCCN Guidelines for Patients Genetic/Familial High-Risk Assessment Breast Ovarian Pancreatic 2024 PDF BRCA1 screening MRI mammography age 25 30 risk-reducing salpingo-oophorectomy 35-40",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd463ae081a181ef89ff5bac4b80",
          "query": "NCCN Guidelines for Patients Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic 2024 pdf BRCA1 MRI mammography screening age 25 30",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd4a589c81a1841d587367b449f7",
          "query": "NCCN Guidelines for Patients Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic 2025 pdf \"BRCA1\" \"risk-reducing\"",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd5031d481a1a24796f499ba1471",
          "query": "site:nccn.org \"Guidelines for Patients\" \"Genetic/Familial High-Risk Assessment\" Breast Ovarian Pancreatic PDF 2024",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd577c6881a18ad4f139712ad16b",
          "query": "https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd5bf32c81a188762661ecea8b2f",
          "query": "risk-reducing mastectomy BRCA1 risk reduction 90% 95% systematic review 2020 2021 2022",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd64884481a186602cd476172af3",
          "query": "olaparib prevention trial BRCA carriers breast cancer prevention clinical trial",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd767c7081a18a544a691ccd191f",
          "query": "FDA approval olaparib Lynparza adjuvant treatment germline BRCA HER2-negative high-risk early breast cancer OlympiA FDA press release",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd79892481a1b963cbe2ec7db6e4",
          "query": "FDA approval pembrolizumab KEYNOTE-522 high-risk early-stage triple-negative breast cancer neoadjuvant adjuvant",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd7e276081a188338aee11c42053",
          "query": "FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer KEYNOTE-522 March 2022 FDA",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd83aebc81a1bb4de0bd31f14992",
          "query": "FDA approves olaparib maintenance treatment first-line BRCA-mutated ovarian cancer SOLO-1 FDA press release",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd872c5881a185bb491ac04cea77",
          "query": "FDA approves olaparib maintenance first-line ovarian cancer BRCA 2018 SOLO-1 FDA press release",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd8ff6ec81a1930b22faa3bba0f6",
          "query": "FDA approves olaparib maintenance metastatic pancreatic cancer germline BRCA POLO trial FDA 2019",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd92b1b481a1bc6b6e434715fe2b",
          "query": "FDA approves olaparib maintenance pancreatic cancer germline BRCA metastatic POLO trial 2019 FDA press release",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bd9cfed881a18f29eccd4927918a",
          "query": "BRCA1-associated breast cancer high grade basal-like triple-negative medullary-like features Frontiers in Oncology 2020 531790",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bda191b881a1b93f5ffc8c7fe5a1",
          "query": "BRCA1 c.68_69delAG 185delAG ClinVar pathogenic founder Ashkenazi Jewish",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bda67c6c81a193e34aeb564758c9",
          "query": "prospective cohort BRCA1 lifetime risk age 80 72% 44% 2017 JAMA 28632866",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bdafac6881a19346ed667aef84c5",
          "query": "BRCA1 inherited autosomal dominant 50% chance of passing to children GeneReviews BRCA1 BRCA2",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bdb4e87081a18b04ecd977d72797",
          "query": "ASRM committee opinion preimplantation genetic testing for monogenic disorders 2023 BRCA PGT-M",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bdbaf78c81a18e53e50c143ae4a0",
          "query": "multi-cancer early detection blood test not FDA approved for screening statement American Cancer Society 2024",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bdcdb09481a1a3fd229c907ca184",
          "query": "https://arupconsult.com/reference/nccn-geneticfamilial-high-risk-assessment-breast-ovarian-pancreatic-prostate-v22025",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bdd043fc81a18ba573a4f9046699",
          "query": "NCCN pancreatic screening BRCA1 age 50 or 10 years earlier high-risk EUS MRCP guideline",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bddadecc81a1a5d6e25ae037ffcc",
          "query": "https://clinicaltrials.gov/study/NCT04294927",
          "results": []
        },
        {
          "id": "ws_07b69152b71a72a5016996bdf5a36881a19bb58869356792f7",
          "query": "FDA approves mirvetuximab soravtansine Elahere FRalpha high platinum-resistant ovarian cancer 2024 full approval",
          "results": []
        }
      ],
      "command_executions": [
        {
          "id": "item_1",
          "command": "/bin/zsh -lc ls",
          "output": "README.md\nexamples\noutput\npyproject.toml\nsrc\n",
          "exit_code": 0
        },
        {
          "id": "item_3",
          "command": "/bin/zsh -lc \"sed -n '1,200p' /Users/lingzhi/.codex/skills/web-search/SKILL.md\"",
          "output": "---\nname: web-search\ndescription: Search and browse the public web from Codex CLI (联网搜索/查网页/找资料/给链接/带出处). Use when you need up-to-date info or answers that must cite web sources.\n---\n\n# Web Search (联网搜索)\n\nThis skill provides a repeatable workflow to search the web, optionally fetch page text, and answer with sources.\n\n## Quick start\n\n- Search:\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --format md`\n- Search + fetch page text (for evidence):\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --fetch --format md`\n\n## Providers (auto)\n\nThe script picks the first available provider:\n\n- **Tavily**: set `TAVILY_API_KEY`\n- **Serper**: set `SERPER_API_KEY`\n- **Brave**: set `BRAVE_API_KEY` (or `BRAVE_SEARCH_API_KEY`)\n- **Fallback**: DuckDuckGo HTML scrape (best-effort; may break)\n\n## Workflow\n\n- Clarify what must be looked up and what must be cited.\n- Run the search script; pick 3–5 sources.\n- If a claim is important/controversial, re-run with `--fetch` and quote specific lines from sources.\n- In the final answer:\n  - Include a **Sources** list with URLs.\n  - Never invent citations; if evidence is missing, say so.\n\n## Notes\n\n- This skill uses network access. In restricted network/sandbox modes, request escalation before running the script.\n",
          "exit_code": 0
        }
      ],
      "final_output": "**Scope And Sources (As Of Feb 19, 2026)**  \nNCCN professional guidelines are paywalled; the most current publicly citable NCCN‑based content I can reference is from 2024–2025 secondary sources (e.g., peer‑reviewed summaries and ACOG’s evidence review that quotes NCCN BRCA management). I also used FDA, NCI, ACS, and clinicaltrials.gov for approvals and trials. ([academic.oup.com](https://academic.oup.com/jbi/article/7/6/636/8378424?searchresult=1&utm_source=openai))  \n\n**1. Molecular Genetics And DNA Repair**  \n`BRCA1 c.68_69delAG (185delAG)` causes a frameshift (p.Glu23Valfs*17) and premature stop, leading to loss of BRCA1 protein function; ClinVar classifies it as pathogenic and a common Ashkenazi founder variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV000034761/?utm_source=openai))  \nBRCA1 is central to homologous recombination (HR) DNA repair. Loss of function causes HR deficiency, making tumors more sensitive to DNA‑damaging agents (e.g., platinum) and PARP inhibitors. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \n\n**2. Cancer Risk Profile And Expected Pathology**  \nLifetime risks to age 80: breast cancer ~72% and ovarian/fallopian/peritoneal cancer ~44% for BRCA1 carriers; risk increases with family history (which is present here). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))  \nPancreatic cancer lifetime risk is ~2.2% for BRCA1 carriers (age 40–80). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39611336/?utm_source=openai))  \nBRCA1‑associated breast tumors are frequently high‑grade, basal‑like and triple‑negative with basal cytokeratin expression; medullary‑like features are enriched. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/?utm_source=openai))  \nBRCA1‑associated tubo‑ovarian cancers are predominantly high‑grade serous carcinoma; STIC in the fallopian tube is a recognized precursor and is found in ~40–60% of HGSOC. ([frontiersin.org](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.531790/full?utm_source=openai))  \n\n**3. Risk Reduction Recommendations (Actionable)**  \n**Risk‑reducing bilateral mastectomy**  \nRisk reduction is ~90–95% in BRCA1/2 carriers (not zero); strongest risk‑reduction option for breast cancer. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/14981104/?utm_source=openai))  \nGiven age 35 and early‑onset family history, this is reasonable to discuss now with reconstruction and quality‑of‑life counseling. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/14981104/?utm_source=openai))  \n\n**Risk‑reducing salpingo‑oophorectomy (RRSO)**  \nNCCN‑quoted guidance recommends RRSO for BRCA1 between ages 35–40 after completion of childbearing. ([journals.lww.com](https://journals.lww.com/greenjournal/fulltext/2023/07000/executive_summary_of_the_ovarian_cancer_evidence.22.aspx?utm_source=openai))  \nRRSO reduces ovarian/fallopian tube cancer risk by ~80% and lowers ovarian‑cancer mortality; it also lowers breast‑cancer risk (HR ~0.63 for BRCA1 in meta‑analysis). ([academic.oup.com](https://academic.oup.com/jnci/article/101/2/69/1208825?utm_source=openai))  \n\n**If deferring RRSO**  \nEarly salpingectomy with delayed oophorectomy is investigational; a clinical trials example is TUBectomy with delayed oophorectomy (NCT04294927). ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04294927?utm_source=openai))  \n\n**Chemoprevention**  \nTamoxifen/raloxifene are FDA‑approved for breast‑risk reduction in high‑risk women, but benefit in BRCA1 carriers is uncertain; tamoxifen may help contralateral risk and ER‑positive disease (more evident in BRCA2). ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \nNo PARP inhibitor is FDA‑approved for primary prevention in unaffected BRCA carriers; PARP use is in treatment/maintenance settings. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer?utm_source=openai))  \n\n**Ovarian risk reduction with OCPs**  \nOral contraceptives are associated with ~50% lower ovarian cancer risk even in BRCA carriers, with potential tradeoffs to discuss. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \n\n**4. Surveillance (NCCN‑Based Where Publicly Citable)**  \n**Breast**  \nNCCN‑based guidance for BRCA1: breast awareness from 18; clinical breast exam every 6–12 months from 25; annual MRI at 25–29; add annual mammography starting 30. Alternating MRI and mammography every 6 months is commonly used. ([academic.oup.com](https://academic.oup.com/jbi/article/7/6/636/8378424?searchresult=1&utm_source=openai))  \n\n**Ovarian**  \nCA‑125 and transvaginal ultrasound have not shown mortality benefit and have significant false‑positive harms; if RRSO is deferred, screening can be offered only with explicit counseling about limitations. ([uspreventiveservicestaskforce.org](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/ovarian-cancer-screening?utm_source=openai))  \n\n**Pancreatic**  \nCAPS consensus: BRCA1 carriers with at least one first‑degree relative with pancreatic cancer should start surveillance at age 50 or 10 years earlier than the youngest affected relative, using MRI/MRCP and/or EUS. Without that family history, routine pancreatic screening is not recommended. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/?utm_source=openai))  \n\n**Emerging screening (ctDNA / MCD tests)**  \nMulti‑cancer early detection blood tests are not FDA‑approved and are not recommended for routine screening; they do not replace standard imaging‑based screening. ([cancer.org](https://www.cancer.org/cancer/screening/multi-cancer-early-detection-tests.html?utm_source=openai))  \n\n**5. Treatment If Cancer Develops (FDA‑Approved Options + Key Evidence)**  \n\n**Breast (HER2‑negative, gBRCA)**  \nAdjuvant olaparib for high‑risk early‑stage HER2‑negative gBRCA breast cancer after (neo)adjuvant chemotherapy and local therapy (OlympiA) is FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer?utm_source=openai))  \nMetastatic HER2‑negative gBRCA breast cancer: olaparib (OlympiAD) and talazoparib (EMBRACA) are FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer?utm_source=openai))  \nPlatinum‑based chemotherapy is rational given HR‑deficiency. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \n\n**Immunotherapy**  \nPembrolizumab is FDA‑approved with chemotherapy for high‑risk early‑stage TNBC (neoadjuvant + adjuvant) and for PD‑L1‑positive metastatic TNBC. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer?utm_source=openai))  \nAtezolizumab’s TNBC indication was withdrawn in the U.S. ([roche.com](https://www.roche.com/media/releases/med-cor-2021-08-27?utm_source=openai))  \n\n**Antibody‑Drug Conjugates (ADCs)**  \nSacituzumab govitecan is FDA‑approved for metastatic TNBC after ≥2 prior lines (at least one in metastatic setting). ([gilead.com](https://www.gilead.com/news/news-details/2021/fda-approves-trodelvy-the-first-treatment-for-metastatic-triple-negative-breast-cancer-shown-to-improve-progression-free-survival-and-overall-survival?utm_source=openai))  \nTrastuzumab deruxtecan (Enhertu) is FDA‑approved for HR‑positive, HER2‑low/ultralow metastatic breast cancer after prior endocrine therapy; applicable if a future tumor is HER2‑low. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2?utm_source=openai))  \n\n**Ovarian/Fallopian/Peritoneal**  \nPARP maintenance after response to platinum: olaparib (recurrent maintenance), niraparib (first‑line maintenance), olaparib + bevacizumab for HRD‑positive, and rucaparib maintenance are FDA‑approved in relevant settings. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer?utm_source=openai))  \nFRα‑positive, platinum‑resistant disease: mirvetuximab soravtansine (Elahere) is FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian?utm_source=openai))  \n\n**Pancreatic**  \nOlaparib is FDA‑approved as maintenance after ≥16 weeks of platinum for gBRCA metastatic pancreatic cancer (POLO). ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-gbrcam-metastatic-pancreatic-adenocarcinoma?utm_source=openai))  \n\n**6. Family Implications**  \nInheritance is autosomal dominant: each child has a 50% chance of inheriting the BRCA1 variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/sites/books/NBK1247/?utm_source=openai))  \nCascade testing is recommended, starting with first‑degree relatives; genetic counselors can assist communication and testing strategy. ([cdc.gov](https://www.cdc.gov/cascade-testing/index.html?utm_source=openai))  \nReproductive options: PGT‑M is an accepted option for hereditary breast/ovarian cancer syndrome; it is optional and should be offered non‑directively with counseling. ([asrm.org](https://www.asrm.org/practice-guidance/practice-committee-documents/indications-and-management-of-preimplantation-genetic-testing-for-monogenic-conditions-a-committee-opinion-2023/?utm_source=openai))  \n\n---\n\n**Suggested Clinical Plan For This 35‑Year‑Old BRCA1 Carrier**  \n1. Continue annual breast MRI and annual mammography now; consider alternating every 6 months; clinical breast exam every 6–12 months. ([academic.oup.com](https://academic.oup.com/jbi/article/7/6/636/8378424?searchresult=1&utm_source=openai))  \n2. Discuss risk‑reducing bilateral mastectomy (90–95% risk reduction) and reconstruction timing. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/14981104/?utm_source=openai))  \n3. If childbearing is complete, proceed with RRSO between ages 35–40; if not, discuss fertility goals, timing, and investigational salpingectomy‑with‑delayed‑oophorectomy trials. ([journals.lww.com](https://journals.lww.com/greenjournal/fulltext/2023/07000/executive_summary_of_the_ovarian_cancer_evidence.22.aspx?utm_source=openai))  \n4. Review chemoprevention: tamoxifen/raloxifene have uncertain benefit in BRCA1 and are not a substitute for surgery; oral contraceptives can reduce ovarian cancer risk with known tradeoffs. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \n5. Pancreatic screening only if a first‑degree relative has pancreatic cancer; otherwise, routine screening is not advised. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/?utm_source=openai))  \n6. Implement cascade testing for first‑degree relatives and offer genetic counseling; discuss PGT‑M if family planning is desired. ([cdc.gov](https://www.cdc.gov/cascade-testing/index.html?utm_source=openai))  \n\nIf you want, I can convert this into a clinician‑facing one‑page decision summary or a patient‑facing counseling handout tailored to her reproductive plans and risk‑tolerance profile.",
      "usage": {
        "input_tokens": 136990,
        "cached_input_tokens": 33664,
        "output_tokens": 19330
      },
      "error": null,
      "step": 4,
      "raw_event_count": 90,
      "raw_events_by_type": {
        "thread.started": [
          {
            "type": "thread.started",
            "thread_id": "019c74d2-bfb1-7722-8aab-7d5d5899dfb1"
          }
        ],
        "turn.started": [
          {
            "type": "turn.started"
          }
        ],
        "item.completed": [
          {
            "type": "item.completed",
            "item": {
              "id": "item_0",
              "type": "reasoning",
              "text": "**Preparing to integrate web search skill**\n\nI'm retrieving the web skill file to enable use of the web-search capability via web.run and open commands for fulfilling the user's web search request."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_1",
              "type": "command_execution",
              "command": "/bin/zsh -lc ls",
              "aggregated_output": "README.md\nexamples\noutput\npyproject.toml\nsrc\n",
              "exit_code": 0,
              "status": "completed"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_2",
              "type": "reasoning",
              "text": "**Identifying skill file path**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_3",
              "type": "command_execution",
              "command": "/bin/zsh -lc \"sed -n '1,200p' /Users/lingzhi/.codex/skills/web-search/SKILL.md\"",
              "aggregated_output": "---\nname: web-search\ndescription: Search and browse the public web from Codex CLI (联网搜索/查网页/找资料/给链接/带出处). Use when you need up-to-date info or answers that must cite web sources.\n---\n\n# Web Search (联网搜索)\n\nThis skill provides a repeatable workflow to search the web, optionally fetch page text, and answer with sources.\n\n## Quick start\n\n- Search:\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --format md`\n- Search + fetch page text (for evidence):\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --fetch --format md`\n\n## Providers (auto)\n\nThe script picks the first available provider:\n\n- **Tavily**: set `TAVILY_API_KEY`\n- **Serper**: set `SERPER_API_KEY`\n- **Brave**: set `BRAVE_API_KEY` (or `BRAVE_SEARCH_API_KEY`)\n- **Fallback**: DuckDuckGo HTML scrape (best-effort; may break)\n\n## Workflow\n\n- Clarify what must be looked up and what must be cited.\n- Run the search script; pick 3–5 sources.\n- If a claim is important/controversial, re-run with `--fetch` and quote specific lines from sources.\n- In the final answer:\n  - Include a **Sources** list with URLs.\n  - Never invent citations; if evidence is missing, say so.\n\n## Notes\n\n- This skill uses network access. In restricted network/sandbox modes, request escalation before running the script.\n",
              "exit_code": 0,
              "status": "completed"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_4",
              "type": "reasoning",
              "text": "**Aligning search approach with skill and restrictions**\n\nPlanning to use the web-search skill as instructed but execute actual searches via web.run to comply with network restrictions; focusing on authoritative, freely accessible sources like NCCN patient guidelines, FDA labels, and clinical trials data to compile medical recommendations with citations and disclaimers."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_5",
              "type": "reasoning",
              "text": "**Detailing comprehensive search strategy for latest guidelines**\n\nOutlining focused web.run queries to retrieve 2024-2025 NCCN patient guidelines and authoritative data on risk reduction, surveillance, treatments, and emerging therapies, emphasizing high-quality sources like ACOG, NCI PDQ, FDA labels, and clinicaltrials.gov for updated citations and clinical recommendations."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd4348f481a1afa4c2213f19fe05",
              "type": "web_search",
              "query": "NCCN Guidelines for Patients Genetic/Familial High-Risk Assessment Breast Ovarian Pancreatic 2024 PDF BRCA1 screening MRI mammography age 25 30 risk-reducing salpingo-oophorectomy 35-40",
              "action": {
                "type": "search",
                "query": "NCCN Guidelines for Patients Genetic/Familial High-Risk Assessment Breast Ovarian Pancreatic 2024 PDF BRCA1 screening MRI mammography age 25 30 risk-reducing salpingo-oophorectomy 35-40",
                "queries": [
                  "NCCN Guidelines for Patients Genetic/Familial High-Risk Assessment Breast Ovarian Pancreatic 2024 PDF BRCA1 screening MRI mammography age 25 30 risk-reducing salpingo-oophorectomy 35-40",
                  "risk-reducing bilateral mastectomy BRCA1 risk reduction percentage 90 95 NCI fact sheet",
                  "risk-reducing salpingo-oophorectomy BRCA1 ovarian cancer risk reduction percentage mortality meta-analysis",
                  "NCI PDQ BRCA1 ovarian cancer screening CA-125 transvaginal ultrasound not proven to reduce mortality high-risk"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_7",
              "type": "reasoning",
              "text": "**Expanding queries for guideline and data coverage**\n\nI identified missing NCCN patient guidelines and risk-reducing mastectomy percentages, so I'll run additional web searches covering NCCN patient guidelines, NCI BRCA facts, and FDA PARP inhibitor labels to fill these gaps."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd463ae081a181ef89ff5bac4b80",
              "type": "web_search",
              "query": "NCCN Guidelines for Patients Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic 2024 pdf BRCA1 MRI mammography screening age 25 30",
              "action": {
                "type": "search",
                "query": "NCCN Guidelines for Patients Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic 2024 pdf BRCA1 MRI mammography screening age 25 30",
                "queries": [
                  "NCCN Guidelines for Patients Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic 2024 pdf BRCA1 MRI mammography screening age 25 30",
                  "NCCN Guidelines for Patients Breast Cancer Screening and Diagnosis 2024 MRI mammography BRCA1 annual",
                  "NCI BRCA gene mutations cancer risk management risk-reducing mastectomy 90 95 percent",
                  "ACOG practice bulletin hereditary breast ovarian cancer risk-reducing mastectomy percentage"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_9",
              "type": "reasoning",
              "text": "**Identifying missing NCCN patient guidelines**\n\nFound NCCN 2024 screening guidelines summary but not BRCA-specific schedule in patient guidelines; planning to search again for those and the mastectomy risk-reduction stats from NCI."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd4a589c81a1841d587367b449f7",
              "type": "web_search",
              "query": "NCCN Guidelines for Patients Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic 2025 pdf \"BRCA1\" \"risk-reducing\"",
              "action": {
                "type": "search",
                "query": "NCCN Guidelines for Patients Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic 2025 pdf \"BRCA1\" \"risk-reducing\"",
                "queries": [
                  "NCCN Guidelines for Patients Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic 2025 pdf \"BRCA1\" \"risk-reducing\"",
                  "NCCN patient guidelines BRCA1 breast screening MRI mammogram age 25 30 2024 PDF",
                  "NCI fact sheet risk-reducing mastectomy reduces breast cancer risk by 90 to 95 percent BRCA",
                  "NCI BRCA gene changes: Cancer risk and genetic testing fact sheet risk-reducing mastectomy 90 95"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_11",
              "type": "reasoning",
              "text": "**Defining trusted sources**\n\nI'm focusing on authoritative medical sources like NCI, ACS, ACOG, StatPearls, and peer-reviewed journals while excluding droracle, verywell, and allure. I'll prioritize NCCN patient guidelines by searching directly on nccn.org."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd5031d481a1a24796f499ba1471",
              "type": "web_search",
              "query": "site:nccn.org \"Guidelines for Patients\" \"Genetic/Familial High-Risk Assessment\" Breast Ovarian Pancreatic PDF 2024",
              "action": {
                "type": "search",
                "query": "site:nccn.org \"Guidelines for Patients\" \"Genetic/Familial High-Risk Assessment\" Breast Ovarian Pancreatic PDF 2024",
                "queries": [
                  "site:nccn.org \"Guidelines for Patients\" \"Genetic/Familial High-Risk Assessment\" Breast Ovarian Pancreatic PDF 2024",
                  "site:nccn.org \"Genetic/Familial High-Risk Assessment\" patient guidelines BRCA1 PDF",
                  "NCCN patient guidelines BRCA1 breast screening MRI 2024 \"Guidelines for Patients\" PDF",
                  "\"Genetic/Familial High-Risk Assessment\" PDF NCCN patients 2025"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_13",
              "type": "reasoning",
              "text": "**Gathering NCCN-related risk management sources**\n\nI'm planning to source NCCN 2024-2025 guideline summaries indirectly via peer-reviewed references like the ACOG 2023 executive summary that cites NCCN, noting NCCN guidelines require login; next, I'll confirm RRSO timing and risk-reducing mastectomy effectiveness with NCI and ACOG materials to ensure accurate risk reduction data."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd577c6881a18ad4f139712ad16b",
              "type": "web_search",
              "query": "https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet",
              "action": {
                "type": "open_page",
                "url": "https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_15",
              "type": "reasoning",
              "text": "**Identifying mastectomy risk reduction data**\n\nThe fact sheet lacks mastectomy percentages, so I'll source updated risk reduction figures from ACOG, Mayo Clinic, NCI PDQ, and recent meta-analyses to provide an accurate, current range."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd5bf32c81a188762661ecea8b2f",
              "type": "web_search",
              "query": "risk-reducing mastectomy BRCA1 risk reduction 90% 95% systematic review 2020 2021 2022",
              "action": {
                "type": "search",
                "query": "risk-reducing mastectomy BRCA1 risk reduction 90% 95% systematic review 2020 2021 2022",
                "queries": [
                  "risk-reducing mastectomy BRCA1 risk reduction 90% 95% systematic review 2020 2021 2022",
                  "bilateral prophylactic mastectomy BRCA1 reduces breast cancer risk percentage 90 95 study",
                  "society of surgical oncology risk-reducing mastectomy BRCA1 90%",
                  "NCI PDQ prophylactic mastectomy BRCA carriers risk reduction 95%"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_17",
              "type": "reasoning",
              "text": "**Summarizing risk reduction sources**\n\nI've identified key sources for risk reduction percentages including PROSE (2004) for overall risk reduction and 2009/2022 meta analyses plus ACOG 2023 for RRSO effects. I'll cover ovarian cancer risk reductions, mortality ranges, and note investigational status of early salpingectomy with delayed oophorectomy, citing NCI fact sheets and relevant trials, and include chemoprevention notes on tamoxifen and OCP use."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_18",
              "type": "reasoning",
              "text": "**Searching PARP inhibitor prevention trials**\n\nI'm investigating clinical trials for olaparib or other PARP inhibitors in breast cancer prevention for BRCA carriers to clarify if any prevention trials exist beyond approved adjuvant uses."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd64884481a186602cd476172af3",
              "type": "web_search",
              "query": "olaparib prevention trial BRCA carriers breast cancer prevention clinical trial",
              "action": {
                "type": "search",
                "query": "olaparib prevention trial BRCA carriers breast cancer prevention clinical trial",
                "queries": [
                  "olaparib prevention trial BRCA carriers breast cancer prevention clinical trial",
                  "PARP inhibitor prevention trial BRCA1 carriers cancer prevention NCT",
                  "WISP TUBA trial early salpingectomy delayed oophorectomy BRCA1 trial",
                  "clinicaltrials.gov salpingectomy delayed oophorectomy BRCA1 risk reducing"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_20",
              "type": "reasoning",
              "text": "**Summarizing PARP inhibitor and immunotherapy approvals**\n\nNo established PARP inhibitor prevention trials were found; adjuvant olaparib is approved for early-stage high-risk breast cancer (OlympiA), not prevention. Next, I'll gather current FDA labels and approval details for olaparib, talazoparib, niraparib, and rucaparib, along with key immunotherapy approvals like pembrolizumab for breast and ovarian cancers."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_21",
              "type": "reasoning",
              "text": "**Detailing ADC and immunotherapy approvals**\n\nI'm outlining key ADC approvals like sacituzumab govitecan for metastatic TNBC and HR+ breast cancer, trastuzumab deruxtecan for HER2-low breast cancer, and mirvetuximab soravtansine for platinum-resistant ovarian cancer. Next, I'll verify current FDA approvals and label specifics using official press releases and manufacturer documents to confirm indications and recent withdrawals for PARP inhibitors and immunotherapies."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd767c7081a18a544a691ccd191f",
              "type": "web_search",
              "query": "FDA approval olaparib Lynparza adjuvant treatment germline BRCA HER2-negative high-risk early breast cancer OlympiA FDA press release",
              "action": {
                "type": "search",
                "query": "FDA approval olaparib Lynparza adjuvant treatment germline BRCA HER2-negative high-risk early breast cancer OlympiA FDA press release",
                "queries": [
                  "FDA approval olaparib Lynparza adjuvant treatment germline BRCA HER2-negative high-risk early breast cancer OlympiA FDA press release",
                  "FDA approval olaparib germline BRCA HER2-negative metastatic breast cancer OlympiAD FDA press release",
                  "FDA approval talazoparib Talzenna germline BRCA HER2-negative metastatic breast cancer EMBRACA FDA",
                  "FDA approval pembrolizumab early-stage triple-negative breast cancer KEYNOTE-522 FDA"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_23",
              "type": "reasoning",
              "text": "**Noting FDA approvals and planning search for others**\n\nI confirmed FDA approvals for olaparib adjuvant, talazoparib, and olaparib metastatic from the FDA D.I.S.C.O dataset and will now search for additional approvals like pembrolizumab."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd79892481a1b963cbe2ec7db6e4",
              "type": "web_search",
              "query": "FDA approval pembrolizumab KEYNOTE-522 high-risk early-stage triple-negative breast cancer neoadjuvant adjuvant",
              "action": {
                "type": "search",
                "query": "FDA approval pembrolizumab KEYNOTE-522 high-risk early-stage triple-negative breast cancer neoadjuvant adjuvant",
                "queries": [
                  "FDA approval pembrolizumab KEYNOTE-522 high-risk early-stage triple-negative breast cancer neoadjuvant adjuvant",
                  "FDA approval pembrolizumab PD-L1 positive metastatic triple-negative breast cancer KEYNOTE-355",
                  "FDA approval sacituzumab govitecan triple-negative breast cancer 2021 2022 FDA",
                  "FDA approval trastuzumab deruxtecan HER2-low breast cancer FDA 2022"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_25",
              "type": "reasoning",
              "text": "**Identifying relevant drug approvals**\n\nNoted that T-DXd is FDA-approved for 2025 and may be relevant for HER2-low cases in the patient context, while pembrolizumab approvals still need confirming with further searches."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd7e276081a188338aee11c42053",
              "type": "web_search",
              "query": "FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer KEYNOTE-522 March 2022 FDA",
              "action": {
                "type": "search",
                "query": "FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer KEYNOTE-522 March 2022 FDA",
                "queries": [
                  "FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer KEYNOTE-522 March 2022 FDA",
                  "FDA approves pembrolizumab for PD-L1 positive metastatic triple-negative breast cancer KEYNOTE-355 November 2020 FDA",
                  "FDA approves pembrolizumab neoadjuvant and adjuvant for TNBC Keytruda 2021 2022",
                  "FDA approval atezolizumab triple-negative breast cancer withdrawn 2021"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_27",
              "type": "reasoning",
              "text": "**Outlining immunotherapy and PARP inhibitor coverage**\n\nPlanning to include pembrolizumab plus chemo for early TNBC and PD-L1+ metastatic cases with FDA citations, then cover PARP inhibitors for ovarian and other cancers by verifying recent FDA approvals and potential withdrawals."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd83aebc81a1bb4de0bd31f14992",
              "type": "web_search",
              "query": "FDA approves olaparib maintenance treatment first-line BRCA-mutated ovarian cancer SOLO-1 FDA press release",
              "action": {
                "type": "search",
                "query": "FDA approves olaparib maintenance treatment first-line BRCA-mutated ovarian cancer SOLO-1 FDA press release",
                "queries": [
                  "FDA approves olaparib maintenance treatment first-line BRCA-mutated ovarian cancer SOLO-1 FDA press release",
                  "FDA approves niraparib maintenance first-line ovarian cancer PRIMA FDA press release",
                  "FDA approves rucaparib maintenance recurrent ovarian cancer ARIEL3 FDA press release",
                  "FDA rucaparib withdrawal treatment indication ovarian cancer 2022 2023"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_29",
              "type": "reasoning",
              "text": "**Refining search for olaparib first-line maintenance approval**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd872c5881a185bb491ac04cea77",
              "type": "web_search",
              "query": "FDA approves olaparib maintenance first-line ovarian cancer BRCA 2018 SOLO-1 FDA press release",
              "action": {
                "type": "search",
                "query": "FDA approves olaparib maintenance first-line ovarian cancer BRCA 2018 SOLO-1 FDA press release",
                "queries": [
                  "FDA approves olaparib maintenance first-line ovarian cancer BRCA 2018 SOLO-1 FDA press release",
                  "FDA approves olaparib maintenance recurrent ovarian cancer BRCA SOLO-2 FDA press release",
                  "FDA approves rucaparib maintenance treatment recurrent ovarian cancer ARIEL3 FDA press release",
                  "FDA approves rucaparib maintenance ovarian cancer 2018"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_31",
              "type": "reasoning",
              "text": "**Clarifying PARP inhibitor indications**\n\nI'm prioritizing FDA and NCI sources, emphasizing rucaparib's maintenance and adjuvant approvals while avoiding uncertain late-line treatment claims, and planning to cite key approvals like olaparib with bevacizumab (PAOLA-1) and olaparib maintenance in pancreatic cancer (POLO)."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd8ff6ec81a1930b22faa3bba0f6",
              "type": "web_search",
              "query": "FDA approves olaparib maintenance metastatic pancreatic cancer germline BRCA POLO trial FDA 2019",
              "action": {
                "type": "search",
                "query": "FDA approves olaparib maintenance metastatic pancreatic cancer germline BRCA POLO trial FDA 2019",
                "queries": [
                  "FDA approves olaparib maintenance metastatic pancreatic cancer germline BRCA POLO trial FDA 2019",
                  "POLO trial olaparib maintenance pancreatic cancer FDA approval 2019",
                  "FDA approves olaparib for metastatic castration-resistant prostate cancer BRCA 2020",
                  "FDA approves talazoparib enzalutamide metastatic prostate cancer 2023"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd92b1b481a1bc6b6e434715fe2b",
              "type": "web_search",
              "query": "FDA approves olaparib maintenance pancreatic cancer germline BRCA metastatic POLO trial 2019 FDA press release",
              "action": {
                "type": "search",
                "query": "FDA approves olaparib maintenance pancreatic cancer germline BRCA metastatic POLO trial 2019 FDA press release",
                "queries": [
                  "FDA approves olaparib maintenance pancreatic cancer germline BRCA metastatic POLO trial 2019 FDA press release",
                  "FDA approves olaparib for metastatic pancreatic cancer germline BRCA mutation POLO trial January 2019 FDA",
                  "POLO trial olaparib metastatic pancreatic cancer maintenance FDA approval 2019 fda.gov",
                  "NCI olaparib pancreatic cancer maintenance POLO trial FDA approval 2019"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_34",
              "type": "reasoning",
              "text": "**Outlining clinical trial and pathology citations**\n\nPlanning to cover key trials for PARP inhibitors and platinum chemo sensitivity, citing FDA approvals and NCI fact sheets for high-level evidence; also considering citing recent pathology sources with potential web fetching to ensure updated references."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_35",
              "type": "reasoning",
              "text": "**Committing to web.run for citation verification**\n\nDecided to use web.run to confirm and cite online sources for pathology details, focusing on high-level BRCA-associated cancer features and initiating searches for key articles like Frontiers in Oncology 2020 and the PMC basal-like study."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd9cfed881a18f29eccd4927918a",
              "type": "web_search",
              "query": "BRCA1-associated breast cancer high grade basal-like triple-negative medullary-like features Frontiers in Oncology 2020 531790",
              "action": {
                "type": "search",
                "query": "BRCA1-associated breast cancer high grade basal-like triple-negative medullary-like features Frontiers in Oncology 2020 531790",
                "queries": [
                  "BRCA1-associated breast cancer high grade basal-like triple-negative medullary-like features Frontiers in Oncology 2020 531790",
                  "BRCA1 tumors basal-like CK5 CK14 triple-negative review 2018 PMC6117459",
                  "high-grade serous carcinoma BRCA1 STIC precursor fallopian tube Frontiers in Oncology 2020 531790",
                  "STIC precursor lesion fallopian tube high-grade serous carcinoma BRCA1 review"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_37",
              "type": "reasoning",
              "text": "**Including molecular genetics citation**\n\nPlanning to cite ClinVar for the molecular genetics of BRCA1 c.68_69delAG by searching and referencing its ClinVar page."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bda191b881a1b93f5ffc8c7fe5a1",
              "type": "web_search",
              "query": "BRCA1 c.68_69delAG 185delAG ClinVar pathogenic founder Ashkenazi Jewish",
              "action": {
                "type": "search",
                "query": "BRCA1 c.68_69delAG 185delAG ClinVar pathogenic founder Ashkenazi Jewish",
                "queries": [
                  "BRCA1 c.68_69delAG 185delAG ClinVar pathogenic founder Ashkenazi Jewish",
                  "BRCA1 c.68_69delAG p.Glu23Valfs*17 frameshift exon 2 ClinVar",
                  "BRCA1 185delAG founder mutation Ashkenazi frequency 1 in 40",
                  "BRCA1 185delAG translation reinitiation codon 128 truncated protein"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_39",
              "type": "reasoning",
              "text": "**Locating BRCA1 breast/ovarian cancer risk data**\n\nI'm targeting lifetime risk estimates for breast and ovarian cancer in BRCA1 mutation carriers to age 80, focusing on the 2017 JAMA meta-analysis cited as PMID 28632866 for authoritative data."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bda67c6c81a193e34aeb564758c9",
              "type": "web_search",
              "query": "prospective cohort BRCA1 lifetime risk age 80 72% 44% 2017 JAMA 28632866",
              "action": {
                "type": "search",
                "query": "prospective cohort BRCA1 lifetime risk age 80 72% 44% 2017 JAMA 28632866",
                "queries": [
                  "prospective cohort BRCA1 lifetime risk age 80 72% 44% 2017 JAMA 28632866",
                  "BRCA1 lifetime risk breast cancer 72% ovarian 44% prospective cohort 2017 study",
                  "penetrance BRCA1 ovarian breast cancer risk age 80 study 2017",
                  "BRCA1 lifetime risk pancreatic cancer meta-analysis 2022 2021 2.5% age 80"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_41",
              "type": "reasoning",
              "text": "**Planning citations for risk and family history**\n\nI'm aligning risk data from JAMA and 2024 Cancer for pancreatic risk and considering citing NCI breast/ovarian risk sheets for baseline population risk. Next, I'll incorporate family history impact on screening timing and plan to cite NCI and GeneReviews or ACOG for cascade testing and inheritance details."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bdafac6881a19346ed667aef84c5",
              "type": "web_search",
              "query": "BRCA1 inherited autosomal dominant 50% chance of passing to children GeneReviews BRCA1 BRCA2",
              "action": {
                "type": "search",
                "query": "BRCA1 inherited autosomal dominant 50% chance of passing to children GeneReviews BRCA1 BRCA2",
                "queries": [
                  "BRCA1 inherited autosomal dominant 50% chance of passing to children GeneReviews BRCA1 BRCA2",
                  "BRCA1 autosomal dominant inheritance 50% risk to first-degree relatives GeneReviews",
                  "cascade testing first-degree relatives BRCA1 recommendation genetic counseling",
                  "ASCO guideline germline testing cascade testing relatives BRCA"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_43",
              "type": "reasoning",
              "text": "**Planning guideline search for PGT-M**\n\nConsidering citing ASRM or ESHRE guidelines on PGT-M in reproductive contexts for hereditary cancer, aiming to support recommendations with committee opinions. Next step is to locate relevant guidelines to reference."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bdb4e87081a18b04ecd977d72797",
              "type": "web_search",
              "query": "ASRM committee opinion preimplantation genetic testing for monogenic disorders 2023 BRCA PGT-M",
              "action": {
                "type": "search",
                "query": "ASRM committee opinion preimplantation genetic testing for monogenic disorders 2023 BRCA PGT-M",
                "queries": [
                  "ASRM committee opinion preimplantation genetic testing for monogenic disorders 2023 BRCA PGT-M",
                  "PGT-M hereditary cancer BRCA guideline ESHRE 2020",
                  "preimplantation genetic testing BRCA1 BRCA2 ethics ASRM 2023",
                  "ACOG committee opinion preimplantation genetic testing monogenic disorders"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_45",
              "type": "reasoning",
              "text": "**Summarizing screening and risk reduction guidance**\n\nThe ASRM opinion supports PGT-M including hereditary breast/ovarian cancer as adult-onset serious condition and highlights risk reduction via RRSO per ACOG and NCCN. I'll ensure surveillance schedules align with NCCN guidelines and address emerging screening like ctDNA tests, noting lack of FDA approval and current non-recommendation from authoritative sources."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bdbaf78c81a18e53e50c143ae4a0",
              "type": "web_search",
              "query": "multi-cancer early detection blood test not FDA approved for screening statement American Cancer Society 2024",
              "action": {
                "type": "search",
                "query": "multi-cancer early detection blood test not FDA approved for screening statement American Cancer Society 2024",
                "queries": [
                  "multi-cancer early detection blood test not FDA approved for screening statement American Cancer Society 2024",
                  "ASCO statement liquid biopsy for cancer screening not recommended outside clinical trials",
                  "NCI statement liquid biopsy ctDNA screening not recommended outside research",
                  "FDA warning multi-cancer early detection tests not approved for screening"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_47",
              "type": "reasoning",
              "text": "**Outlining comprehensive clinical analysis**\n\nI'm preparing detailed narrative sections on molecular genetics, risk, pathology, risk reduction, surveillance, treatment, and family for BRCA1 risk reduction, citing ongoing trials and using current sources dated up to February 19, 2026, while noting limitations around NCCN guideline access."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_48",
              "type": "reasoning",
              "text": "**Detailing risk reduction and screening recommendations**\n\nI'm specifying recommended RRSO timing, prophylactic mastectomy considerations, investigational alternatives, and surveillance per NCCN guidelines citing Journal of Breast Imaging, while outlining ovarian and pancreatic screening nuances and evidence with supporting citations."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bdcdb09481a1a3fd229c907ca184",
              "type": "web_search",
              "query": "https://arupconsult.com/reference/nccn-geneticfamilial-high-risk-assessment-breast-ovarian-pancreatic-prostate-v22025",
              "action": {
                "type": "open_page",
                "url": "https://arupconsult.com/reference/nccn-geneticfamilial-high-risk-assessment-breast-ovarian-pancreatic-prostate-v22025"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_50",
              "type": "reasoning",
              "text": "**Identifying alternative screening guideline sources**\n\nARUP's page lacks detailed guidance, and NCCN specifics aren't accessible; I'll rely on the J Breast Imaging table for genetic risk-based NCCN screening guidelines and ACOG 2023 for RRSO timing. For pancreatic screening age thresholds, I'll search alternative sources like JNCCN or hereditary pancreatic screening reviews referencing NCCN guidance."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bdd043fc81a18ba573a4f9046699",
              "type": "web_search",
              "query": "NCCN pancreatic screening BRCA1 age 50 or 10 years earlier high-risk EUS MRCP guideline",
              "action": {
                "type": "search",
                "query": "NCCN pancreatic screening BRCA1 age 50 or 10 years earlier high-risk EUS MRCP guideline",
                "queries": [
                  "NCCN pancreatic screening BRCA1 age 50 or 10 years earlier high-risk EUS MRCP guideline",
                  "BRCA1 pancreatic cancer screening EUS MRCP age 50 NCCN 2024",
                  "pancreatic screening BRCA1 first-degree relative 50 years EUS MRCP guideline",
                  "International Cancer of the Pancreas Screening (CAPS) consortium BRCA1 screening age 50"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_52",
              "type": "reasoning",
              "text": "**Integrating selective clinical trials**\n\nPlanning to mention key ongoing or relevant clinical trials tailored to this patient's BRCA1 context, like early salpingectomy (NCT04294927) and PARP-related therapies, while noting limited pancreatic screening given current age and family history. The approach includes highlighting trial categories with specific examples to balance relevance and clarity."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_53",
              "type": "reasoning",
              "text": "**Verifying trial recruitment status**\n\nPlanning to confirm the active recruitment status of key clinical trials for BRCA1 prevention and treatment, including NCT04294927, to ensure accurate mention of ongoing trials for the user."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bddadecc81a1a5d6e25ae037ffcc",
              "type": "web_search",
              "query": "https://clinicaltrials.gov/study/NCT04294927",
              "action": {
                "type": "open_page",
                "url": "https://clinicaltrials.gov/study/NCT04294927"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_55",
              "type": "reasoning",
              "text": "**Clarifying clinical trial references**\n\nDeciding to describe ongoing trials on ClinicalTrials.gov cautiously without relying on unclear status, citing them as active studies with NCT numbers, and avoiding raw URLs in responses while preparing to include proper citations. Planning a clear, clinician-focused intro noting guideline updates and source types."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_56",
              "type": "reasoning",
              "text": "**Outlining detailed content sections**\n\nDrafting comprehensive sections covering genetics, cancer risk, risk reduction, surveillance, treatment options, and family implications, with extensive citations planned for mutation specifics, guideline-based interventions, and emerging therapies while avoiding direct medical advice."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_07b69152b71a72a5016996bdf5a36881a19bb58869356792f7",
              "type": "web_search",
              "query": "FDA approves mirvetuximab soravtansine Elahere FRalpha high platinum-resistant ovarian cancer 2024 full approval",
              "action": {
                "type": "search",
                "query": "FDA approves mirvetuximab soravtansine Elahere FRalpha high platinum-resistant ovarian cancer 2024 full approval",
                "queries": [
                  "FDA approves mirvetuximab soravtansine Elahere FRalpha high platinum-resistant ovarian cancer 2024 full approval",
                  "FDA approval mirvetuximab soravtansine Elahere ovarian 2022 2024",
                  "FDA approves sacituzumab govitecan triple-negative breast cancer FDA press release",
                  "FDA approval sacituzumab govitecan HR-positive HER2-negative breast cancer 2023"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_58",
              "type": "reasoning",
              "text": "**Planning treatment summary with trial mentions**\n\nI'm preparing a treatment summary that includes FDA approval for mirvetuximab, highlights ongoing clinical trials for both prevention and therapy, and references key examples like the PARTNER trial (noted as recent) and active trials such as NCT04294927, while advising readers to check clinicaltrials.gov for the latest on PARP combination studies."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_59",
              "type": "reasoning",
              "text": "**Preparing comprehensive clinical summary**\n\nI'm consolidating a detailed clinical summary with molecular genetics, risk profiles, NCCN-based surveillance, FDA-approved treatments, actionable prevention and surveillance plans, family implications, and citations reflecting 2024–2025 guidelines and trials, while addressing paywalled NCCN sources and emphasizing proper citation placement without direct URLs."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_60",
              "type": "agent_message",
              "text": "**Scope And Sources (As Of Feb 19, 2026)**  \nNCCN professional guidelines are paywalled; the most current publicly citable NCCN‑based content I can reference is from 2024–2025 secondary sources (e.g., peer‑reviewed summaries and ACOG’s evidence review that quotes NCCN BRCA management). I also used FDA, NCI, ACS, and clinicaltrials.gov for approvals and trials. ([academic.oup.com](https://academic.oup.com/jbi/article/7/6/636/8378424?searchresult=1&utm_source=openai))  \n\n**1. Molecular Genetics And DNA Repair**  \n`BRCA1 c.68_69delAG (185delAG)` causes a frameshift (p.Glu23Valfs*17) and premature stop, leading to loss of BRCA1 protein function; ClinVar classifies it as pathogenic and a common Ashkenazi founder variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV000034761/?utm_source=openai))  \nBRCA1 is central to homologous recombination (HR) DNA repair. Loss of function causes HR deficiency, making tumors more sensitive to DNA‑damaging agents (e.g., platinum) and PARP inhibitors. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \n\n**2. Cancer Risk Profile And Expected Pathology**  \nLifetime risks to age 80: breast cancer ~72% and ovarian/fallopian/peritoneal cancer ~44% for BRCA1 carriers; risk increases with family history (which is present here). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))  \nPancreatic cancer lifetime risk is ~2.2% for BRCA1 carriers (age 40–80). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39611336/?utm_source=openai))  \nBRCA1‑associated breast tumors are frequently high‑grade, basal‑like and triple‑negative with basal cytokeratin expression; medullary‑like features are enriched. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/?utm_source=openai))  \nBRCA1‑associated tubo‑ovarian cancers are predominantly high‑grade serous carcinoma; STIC in the fallopian tube is a recognized precursor and is found in ~40–60% of HGSOC. ([frontiersin.org](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.531790/full?utm_source=openai))  \n\n**3. Risk Reduction Recommendations (Actionable)**  \n**Risk‑reducing bilateral mastectomy**  \nRisk reduction is ~90–95% in BRCA1/2 carriers (not zero); strongest risk‑reduction option for breast cancer. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/14981104/?utm_source=openai))  \nGiven age 35 and early‑onset family history, this is reasonable to discuss now with reconstruction and quality‑of‑life counseling. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/14981104/?utm_source=openai))  \n\n**Risk‑reducing salpingo‑oophorectomy (RRSO)**  \nNCCN‑quoted guidance recommends RRSO for BRCA1 between ages 35–40 after completion of childbearing. ([journals.lww.com](https://journals.lww.com/greenjournal/fulltext/2023/07000/executive_summary_of_the_ovarian_cancer_evidence.22.aspx?utm_source=openai))  \nRRSO reduces ovarian/fallopian tube cancer risk by ~80% and lowers ovarian‑cancer mortality; it also lowers breast‑cancer risk (HR ~0.63 for BRCA1 in meta‑analysis). ([academic.oup.com](https://academic.oup.com/jnci/article/101/2/69/1208825?utm_source=openai))  \n\n**If deferring RRSO**  \nEarly salpingectomy with delayed oophorectomy is investigational; a clinical trials example is TUBectomy with delayed oophorectomy (NCT04294927). ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04294927?utm_source=openai))  \n\n**Chemoprevention**  \nTamoxifen/raloxifene are FDA‑approved for breast‑risk reduction in high‑risk women, but benefit in BRCA1 carriers is uncertain; tamoxifen may help contralateral risk and ER‑positive disease (more evident in BRCA2). ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \nNo PARP inhibitor is FDA‑approved for primary prevention in unaffected BRCA carriers; PARP use is in treatment/maintenance settings. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer?utm_source=openai))  \n\n**Ovarian risk reduction with OCPs**  \nOral contraceptives are associated with ~50% lower ovarian cancer risk even in BRCA carriers, with potential tradeoffs to discuss. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \n\n**4. Surveillance (NCCN‑Based Where Publicly Citable)**  \n**Breast**  \nNCCN‑based guidance for BRCA1: breast awareness from 18; clinical breast exam every 6–12 months from 25; annual MRI at 25–29; add annual mammography starting 30. Alternating MRI and mammography every 6 months is commonly used. ([academic.oup.com](https://academic.oup.com/jbi/article/7/6/636/8378424?searchresult=1&utm_source=openai))  \n\n**Ovarian**  \nCA‑125 and transvaginal ultrasound have not shown mortality benefit and have significant false‑positive harms; if RRSO is deferred, screening can be offered only with explicit counseling about limitations. ([uspreventiveservicestaskforce.org](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/ovarian-cancer-screening?utm_source=openai))  \n\n**Pancreatic**  \nCAPS consensus: BRCA1 carriers with at least one first‑degree relative with pancreatic cancer should start surveillance at age 50 or 10 years earlier than the youngest affected relative, using MRI/MRCP and/or EUS. Without that family history, routine pancreatic screening is not recommended. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/?utm_source=openai))  \n\n**Emerging screening (ctDNA / MCD tests)**  \nMulti‑cancer early detection blood tests are not FDA‑approved and are not recommended for routine screening; they do not replace standard imaging‑based screening. ([cancer.org](https://www.cancer.org/cancer/screening/multi-cancer-early-detection-tests.html?utm_source=openai))  \n\n**5. Treatment If Cancer Develops (FDA‑Approved Options + Key Evidence)**  \n\n**Breast (HER2‑negative, gBRCA)**  \nAdjuvant olaparib for high‑risk early‑stage HER2‑negative gBRCA breast cancer after (neo)adjuvant chemotherapy and local therapy (OlympiA) is FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer?utm_source=openai))  \nMetastatic HER2‑negative gBRCA breast cancer: olaparib (OlympiAD) and talazoparib (EMBRACA) are FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer?utm_source=openai))  \nPlatinum‑based chemotherapy is rational given HR‑deficiency. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \n\n**Immunotherapy**  \nPembrolizumab is FDA‑approved with chemotherapy for high‑risk early‑stage TNBC (neoadjuvant + adjuvant) and for PD‑L1‑positive metastatic TNBC. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer?utm_source=openai))  \nAtezolizumab’s TNBC indication was withdrawn in the U.S. ([roche.com](https://www.roche.com/media/releases/med-cor-2021-08-27?utm_source=openai))  \n\n**Antibody‑Drug Conjugates (ADCs)**  \nSacituzumab govitecan is FDA‑approved for metastatic TNBC after ≥2 prior lines (at least one in metastatic setting). ([gilead.com](https://www.gilead.com/news/news-details/2021/fda-approves-trodelvy-the-first-treatment-for-metastatic-triple-negative-breast-cancer-shown-to-improve-progression-free-survival-and-overall-survival?utm_source=openai))  \nTrastuzumab deruxtecan (Enhertu) is FDA‑approved for HR‑positive, HER2‑low/ultralow metastatic breast cancer after prior endocrine therapy; applicable if a future tumor is HER2‑low. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2?utm_source=openai))  \n\n**Ovarian/Fallopian/Peritoneal**  \nPARP maintenance after response to platinum: olaparib (recurrent maintenance), niraparib (first‑line maintenance), olaparib + bevacizumab for HRD‑positive, and rucaparib maintenance are FDA‑approved in relevant settings. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer?utm_source=openai))  \nFRα‑positive, platinum‑resistant disease: mirvetuximab soravtansine (Elahere) is FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian?utm_source=openai))  \n\n**Pancreatic**  \nOlaparib is FDA‑approved as maintenance after ≥16 weeks of platinum for gBRCA metastatic pancreatic cancer (POLO). ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-gbrcam-metastatic-pancreatic-adenocarcinoma?utm_source=openai))  \n\n**6. Family Implications**  \nInheritance is autosomal dominant: each child has a 50% chance of inheriting the BRCA1 variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/sites/books/NBK1247/?utm_source=openai))  \nCascade testing is recommended, starting with first‑degree relatives; genetic counselors can assist communication and testing strategy. ([cdc.gov](https://www.cdc.gov/cascade-testing/index.html?utm_source=openai))  \nReproductive options: PGT‑M is an accepted option for hereditary breast/ovarian cancer syndrome; it is optional and should be offered non‑directively with counseling. ([asrm.org](https://www.asrm.org/practice-guidance/practice-committee-documents/indications-and-management-of-preimplantation-genetic-testing-for-monogenic-conditions-a-committee-opinion-2023/?utm_source=openai))  \n\n---\n\n**Suggested Clinical Plan For This 35‑Year‑Old BRCA1 Carrier**  \n1. Continue annual breast MRI and annual mammography now; consider alternating every 6 months; clinical breast exam every 6–12 months. ([academic.oup.com](https://academic.oup.com/jbi/article/7/6/636/8378424?searchresult=1&utm_source=openai))  \n2. Discuss risk‑reducing bilateral mastectomy (90–95% risk reduction) and reconstruction timing. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/14981104/?utm_source=openai))  \n3. If childbearing is complete, proceed with RRSO between ages 35–40; if not, discuss fertility goals, timing, and investigational salpingectomy‑with‑delayed‑oophorectomy trials. ([journals.lww.com](https://journals.lww.com/greenjournal/fulltext/2023/07000/executive_summary_of_the_ovarian_cancer_evidence.22.aspx?utm_source=openai))  \n4. Review chemoprevention: tamoxifen/raloxifene have uncertain benefit in BRCA1 and are not a substitute for surgery; oral contraceptives can reduce ovarian cancer risk with known tradeoffs. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \n5. Pancreatic screening only if a first‑degree relative has pancreatic cancer; otherwise, routine screening is not advised. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/?utm_source=openai))  \n6. Implement cascade testing for first‑degree relatives and offer genetic counseling; discuss PGT‑M if family planning is desired. ([cdc.gov](https://www.cdc.gov/cascade-testing/index.html?utm_source=openai))  \n\nIf you want, I can convert this into a clinician‑facing one‑page decision summary or a patient‑facing counseling handout tailored to her reproductive plans and risk‑tolerance profile."
            }
          }
        ],
        "item.started": [
          {
            "type": "item.started",
            "item": {
              "id": "item_1",
              "type": "command_execution",
              "command": "/bin/zsh -lc ls",
              "aggregated_output": "",
              "exit_code": null,
              "status": "in_progress"
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "item_3",
              "type": "command_execution",
              "command": "/bin/zsh -lc \"sed -n '1,200p' /Users/lingzhi/.codex/skills/web-search/SKILL.md\"",
              "aggregated_output": "",
              "exit_code": null,
              "status": "in_progress"
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd4348f481a1afa4c2213f19fe05",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd463ae081a181ef89ff5bac4b80",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd4a589c81a1841d587367b449f7",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd5031d481a1a24796f499ba1471",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd577c6881a18ad4f139712ad16b",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd5bf32c81a188762661ecea8b2f",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd64884481a186602cd476172af3",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd767c7081a18a544a691ccd191f",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd79892481a1b963cbe2ec7db6e4",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd7e276081a188338aee11c42053",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd83aebc81a1bb4de0bd31f14992",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd872c5881a185bb491ac04cea77",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd8ff6ec81a1930b22faa3bba0f6",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd92b1b481a1bc6b6e434715fe2b",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bd9cfed881a18f29eccd4927918a",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bda191b881a1b93f5ffc8c7fe5a1",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bda67c6c81a193e34aeb564758c9",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bdafac6881a19346ed667aef84c5",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bdb4e87081a18b04ecd977d72797",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bdbaf78c81a18e53e50c143ae4a0",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bdcdb09481a1a3fd229c907ca184",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bdd043fc81a18ba573a4f9046699",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bddadecc81a1a5d6e25ae037ffcc",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_07b69152b71a72a5016996bdf5a36881a19bb58869356792f7",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          }
        ],
        "turn.completed": [
          {
            "type": "turn.completed",
            "usage": {
              "input_tokens": 136990,
              "cached_input_tokens": 33664,
              "output_tokens": 19330
            }
          }
        ]
      }
    },
    {
      "agent_name": "integrative-synthesizer",
      "system_prompt": "You are a senior medical director and translational medicine expert who bridges basic science and clinical practice. Your role is to synthesize complex multi-domain research into a coherent, comprehensive, and actionable clinical summary. You have access to web search to verify any details.",
      "user_prompt": "You have received comprehensive research from four domain experts:\n1. Genomics Specialist — mutation details and population genetics\n2. Molecular Biologist — protein function and DNA repair mechanisms\n3. Cancer Pathologist — risk profile and tumor characteristics\n4. Clinical Oncologist — prevention, surveillance, and treatment strategies\n\nYour task: Synthesize ALL of this into a single, well-structured comprehensive report that:\n- Connects the molecular mechanism (WHY the mutation causes cancer) to the clinical phenotype (WHAT cancers develop) to treatment rationale (HOW we treat)\n- Provides a clear decision framework for the patient\n- Highlights the most critical action items with their evidence levels\n- Notes any areas of uncertainty or evolving evidence\n- Is written at a level suitable for an informed patient or referring physician\n\nStructure the final report with clear sections and a brief executive summary at the top.",
      "full_prompt_sent": "You are: You are a senior medical director and translational medicine expert who bridges basic science and clinical practice. Your role is to synthesize complex multi-domain research into a coherent, comprehensive, and actionable clinical summary. You have access to web search to verify any details.\n\nContext from previous work:\n**Scope And Sources (As Of Feb 19, 2026)**  \nNCCN professional guidelines are paywalled; the most current publicly citable NCCN‑based content I can reference is from 2024–2025 secondary sources (e.g., peer‑reviewed summaries and ACOG’s evidence review that quotes NCCN BRCA management). I also used FDA, NCI, ACS, and clinicaltrials.gov for approvals and trials. ([academic.oup.com](https://academic.oup.com/jbi/article/7/6/636/8378424?searchresult=1&utm_source=openai))  \n\n**1. Molecular Genetics And DNA Repair**  \n`BRCA1 c.68_69delAG (185delAG)` causes a frameshift (p.Glu23Valfs*17) and premature stop, leading to loss of BRCA1 protein function; ClinVar classifies it as pathogenic and a common Ashkenazi founder variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV000034761/?utm_source=openai))  \nBRCA1 is central to homologous recombination (HR) DNA repair. Loss of function causes HR deficiency, making tumors more sensitive to DNA‑damaging agents (e.g., platinum) and PARP inhibitors. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \n\n**2. Cancer Risk Profile And Expected Pathology**  \nLifetime risks to age 80: breast cancer ~72% and ovarian/fallopian/peritoneal cancer ~44% for BRCA1 carriers; risk increases with family history (which is present here). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))  \nPancreatic cancer lifetime risk is ~2.2% for BRCA1 carriers (age 40–80). ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39611336/?utm_source=openai))  \nBRCA1‑associated breast tumors are frequently high‑grade, basal‑like and triple‑negative with basal cytokeratin expression; medullary‑like features are enriched. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6117459/?utm_source=openai))  \nBRCA1‑associated tubo‑ovarian cancers are predominantly high‑grade serous carcinoma; STIC in the fallopian tube is a recognized precursor and is found in ~40–60% of HGSOC. ([frontiersin.org](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.531790/full?utm_source=openai))  \n\n**3. Risk Reduction Recommendations (Actionable)**  \n**Risk‑reducing bilateral mastectomy**  \nRisk reduction is ~90–95% in BRCA1/2 carriers (not zero); strongest risk‑reduction option for breast cancer. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/14981104/?utm_source=openai))  \nGiven age 35 and early‑onset family history, this is reasonable to discuss now with reconstruction and quality‑of‑life counseling. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/14981104/?utm_source=openai))  \n\n**Risk‑reducing salpingo‑oophorectomy (RRSO)**  \nNCCN‑quoted guidance recommends RRSO for BRCA1 between ages 35–40 after completion of childbearing. ([journals.lww.com](https://journals.lww.com/greenjournal/fulltext/2023/07000/executive_summary_of_the_ovarian_cancer_evidence.22.aspx?utm_source=openai))  \nRRSO reduces ovarian/fallopian tube cancer risk by ~80% and lowers ovarian‑cancer mortality; it also lowers breast‑cancer risk (HR ~0.63 for BRCA1 in meta‑analysis). ([academic.oup.com](https://academic.oup.com/jnci/article/101/2/69/1208825?utm_source=openai))  \n\n**If deferring RRSO**  \nEarly salpingectomy with delayed oophorectomy is investigational; a clinical trials example is TUBectomy with delayed oophorectomy (NCT04294927). ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04294927?utm_source=openai))  \n\n**Chemoprevention**  \nTamoxifen/raloxifene are FDA‑approved for breast‑risk reduction in high‑risk women, but benefit in BRCA1 carriers is uncertain; tamoxifen may help contralateral risk and ER‑positive disease (more evident in BRCA2). ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \nNo PARP inhibitor is FDA‑approved for primary prevention in unaffected BRCA carriers; PARP use is in treatment/maintenance settings. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer?utm_source=openai))  \n\n**Ovarian risk reduction with OCPs**  \nOral contraceptives are associated with ~50% lower ovarian cancer risk even in BRCA carriers, with potential tradeoffs to discuss. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \n\n**4. Surveillance (NCCN‑Based Where Publicly Citable)**  \n**Breast**  \nNCCN‑based guidance for BRCA1: breast awareness from 18; clinical breast exam every 6–12 months from 25; annual MRI at 25–29; add annual mammography starting 30. Alternating MRI and mammography every 6 months is commonly used. ([academic.oup.com](https://academic.oup.com/jbi/article/7/6/636/8378424?searchresult=1&utm_source=openai))  \n\n**Ovarian**  \nCA‑125 and transvaginal ultrasound have not shown mortality benefit and have significant false‑positive harms; if RRSO is deferred, screening can be offered only with explicit counseling about limitations. ([uspreventiveservicestaskforce.org](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/ovarian-cancer-screening?utm_source=openai))  \n\n**Pancreatic**  \nCAPS consensus: BRCA1 carriers with at least one first‑degree relative with pancreatic cancer should start surveillance at age 50 or 10 years earlier than the youngest affected relative, using MRI/MRCP and/or EUS. Without that family history, routine pancreatic screening is not recommended. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/?utm_source=openai))  \n\n**Emerging screening (ctDNA / MCD tests)**  \nMulti‑cancer early detection blood tests are not FDA‑approved and are not recommended for routine screening; they do not replace standard imaging‑based screening. ([cancer.org](https://www.cancer.org/cancer/screening/multi-cancer-early-detection-tests.html?utm_source=openai))  \n\n**5. Treatment If Cancer Develops (FDA‑Approved Options + Key Evidence)**  \n\n**Breast (HER2‑negative, gBRCA)**  \nAdjuvant olaparib for high‑risk early‑stage HER2‑negative gBRCA breast cancer after (neo)adjuvant chemotherapy and local therapy (OlympiA) is FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer?utm_source=openai))  \nMetastatic HER2‑negative gBRCA breast cancer: olaparib (OlympiAD) and talazoparib (EMBRACA) are FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer?utm_source=openai))  \nPlatinum‑based chemotherapy is rational given HR‑deficiency. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \n\n**Immunotherapy**  \nPembrolizumab is FDA‑approved with chemotherapy for high‑risk early‑stage TNBC (neoadjuvant + adjuvant) and for PD‑L1‑positive metastatic TNBC. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer?utm_source=openai))  \nAtezolizumab’s TNBC indication was withdrawn in the U.S. ([roche.com](https://www.roche.com/media/releases/med-cor-2021-08-27?utm_source=openai))  \n\n**Antibody‑Drug Conjugates (ADCs)**  \nSacituzumab govitecan is FDA‑approved for metastatic TNBC after ≥2 prior lines (at least one in metastatic setting). ([gilead.com](https://www.gilead.com/news/news-details/2021/fda-approves-trodelvy-the-first-treatment-for-metastatic-triple-negative-breast-cancer-shown-to-improve-progression-free-survival-and-overall-survival?utm_source=openai))  \nTrastuzumab deruxtecan (Enhertu) is FDA‑approved for HR‑positive, HER2‑low/ultralow metastatic breast cancer after prior endocrine therapy; applicable if a future tumor is HER2‑low. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2?utm_source=openai))  \n\n**Ovarian/Fallopian/Peritoneal**  \nPARP maintenance after response to platinum: olaparib (recurrent maintenance), niraparib (first‑line maintenance), olaparib + bevacizumab for HRD‑positive, and rucaparib maintenance are FDA‑approved in relevant settings. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer?utm_source=openai))  \nFRα‑positive, platinum‑resistant disease: mirvetuximab soravtansine (Elahere) is FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian?utm_source=openai))  \n\n**Pancreatic**  \nOlaparib is FDA‑approved as maintenance after ≥16 weeks of platinum for gBRCA metastatic pancreatic cancer (POLO). ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-gbrcam-metastatic-pancreatic-adenocarcinoma?utm_source=openai))  \n\n**6. Family Implications**  \nInheritance is autosomal dominant: each child has a 50% chance of inheriting the BRCA1 variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/sites/books/NBK1247/?utm_source=openai))  \nCascade testing is recommended, starting with first‑degree relatives; genetic counselors can assist communication and testing strategy. ([cdc.gov](https://www.cdc.gov/cascade-testing/index.html?utm_source=openai))  \nReproductive options: PGT‑M is an accepted option for hereditary breast/ovarian cancer syndrome; it is optional and should be offered non‑directively with counseling. ([asrm.org](https://www.asrm.org/practice-guidance/practice-committee-documents/indications-and-management-of-preimplantation-genetic-testing-for-monogenic-conditions-a-committee-opinion-2023/?utm_source=openai))  \n\n---\n\n**Suggested Clinical Plan For This 35‑Year‑Old BRCA1 Carrier**  \n1. Continue annual breast MRI and annual mammography now; consider alternating every 6 months; clinical breast exam every 6–12 months. ([academic.oup.com](https://academic.oup.com/jbi/article/7/6/636/8378424?searchresult=1&utm_source=openai))  \n2. Discuss risk‑reducing bilateral mastectomy (90–95% risk reduction) and reconstruction timing. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/14981104/?utm_source=openai))  \n3. If childbearing is complete, proceed with RRSO between ages 35–40; if not, discuss fertility goals, timing, and investigational salpingectomy‑with‑delayed‑oophorectomy trials. ([journals.lww.com](https://journals.lww.com/greenjournal/fulltext/2023/07000/executive_summary_of_the_ovarian_cancer_evidence.22.aspx?utm_source=openai))  \n4. Review chemoprevention: tamoxifen/raloxifene have uncertain benefit in BRCA1 and are not a substitute for surgery; oral contraceptives can reduce ovarian cancer risk with known tradeoffs. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet))  \n5. Pancreatic screening only if a first‑degree relative has pancreatic cancer; otherwise, routine screening is not advised. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/?utm_source=openai))  \n6. Implement cascade testing for first‑degree relatives and offer genetic counseling; discuss PGT‑M if family planning is desired. ([cdc.gov](https://www.cdc.gov/cascade-testing/index.html?utm_source=openai))  \n\nIf you want, I can convert this into a clinician‑facing one‑page decision summary or a patient‑facing counseling handout tailored to her reproductive plans and risk‑tolerance profile.\n\nMain question:\nA 35-year-old woman of Ashkenazi Jewish descent, with a family history of breast cancer (mother diagnosed at 42, maternal aunt at 38), undergoes genetic testing and is found to carry a pathogenic BRCA1 c.68_69delAG (185delAG) founder mutation. She currently has no signs of cancer.\n\nWe need a comprehensive analysis covering:\n1. The molecular genetics of this specific mutation\n2. How the resulting protein defect disrupts DNA repair\n3. The cancer risk profile and expected tumor pathology\n4. Evidence-based prevention, surveillance, and treatment strategies\n\nYour specific assignment:\nYou have received comprehensive research from four domain experts:\n1. Genomics Specialist — mutation details and population genetics\n2. Molecular Biologist — protein function and DNA repair mechanisms\n3. Cancer Pathologist — risk profile and tumor characteristics\n4. Clinical Oncologist — prevention, surveillance, and treatment strategies\n\nYour task: Synthesize ALL of this into a single, well-structured comprehensive report that:\n- Connects the molecular mechanism (WHY the mutation causes cancer) to the clinical phenotype (WHAT cancers develop) to treatment rationale (HOW we treat)\n- Provides a clear decision framework for the patient\n- Highlights the most critical action items with their evidence levels\n- Notes any areas of uncertainty or evolving evidence\n- Is written at a level suitable for an informed patient or referring physician\n\nStructure the final report with clear sections and a brief executive summary at the top.",
      "reasoning": [
        "**Confirming web-search skill use**\n\nI'm verifying that the web-search skill is appropriate for providing up-to-date citations and will read the SKILL.md file to confirm usage details.",
        "**Noting missing skill file**",
        "**Deciding to use web.run for up-to-date data**\n\nDue to network restrictions and skill instructions, I'll rely on web.run to fetch current sources on BRCA1 and relevant 2026 guidelines and approvals, ensuring to cite these updated web references properly.",
        "**Planning multi-call web.run searches for comprehensive citations**\n\nI'll perform multiple web.run calls with targeted queries to gather diverse, high-quality sources covering BRCA mutation details, risk estimates, surveillance guidelines, and up-to-date FDA approvals, ensuring thorough citations without exceeding source limits.",
        "**Planning authoritative source search**\n\nI'm preparing to find key authoritative sources like the NCI BRCA fact sheet, USPSTF ovarian screening guidelines, CAPS pancreatic recommendations, ACS MCED info, FDA approvals, and pathology features for basal-like triple-negative cases to enrich the evidence base.",
        "**Planning to gather pathology sources**\n\nI'm looking for review articles on triple-negative, basal-like, medullary, and HGSOC STIC pathology to support the research.",
        "**Searching for BRCA1 breast cancer path features**",
        "**Searching for authoritative triple-negative sources**\n\nI'm looking at the NCI fact sheet's triple-negative link as a potential source but need additional info on basal-like high-grade medullary features, so I'll search for a relevant review on PMC.",
        "**Searching for FDA approval pages**",
        "**Searching FDA for olaparib approvals**",
        "**Searching for FDA page on olaparib adjuvant**\n\nI'm not finding a specific FDA page for olaparib adjuvant but found an FDA press release mentioning it; I'll search further to confirm its official presence.",
        "**Listing FDA approvals to verify**\n\nI need to verify FDA approvals for olaparib and rucaparib maintenance in ovarian cancer, mirvetuximab approvals in 2022/2024, and olaparib maintenance in pancreatic cancer (POLO). Next, I’ll search to confirm these dates.",
        "**Searching for FDA page on olaparib maintenance ovarian**",
        "**Searching for FDA approval of olaparib in early breast cancer**",
        "**Outlining key ovarian maintenance and screening references**\n\nI'm compiling ovarian maintenance options including FDA-approved drugs and NCI sources, plus surveillance guidelines from NCCN and StatPearls. I'll also cover genetic prevalence, pathogenic variant details, and treatment rationales citing authoritative sources like NCI, ACOG, CAPS, ClinVar, and Nature Communications.",
        "**Summarizing risk features and prevention evidence**\n\nI'm detailing BRCA1 tumor traits, mastectomy risk reduction stats, and RRSO timing and effect with ACOG sources. I'll note ovarian cancer risk reduction by contraceptives, screening limitations from USPSTF, MCED test status, pancreatic screening consensus, and family inheritance from GeneReviews.",
        "**Refining source selection and key recommendations**\n\nFocusing on high-quality sources like NCI, CDC, GeneReviews, and FDA; planning to reference CDC for cascade testing and family implications optionally, with GeneReviews for risk stats and counseling. Deciding to include RRSO age recommendation from ACOG and note investigational early salpingectomy citing clinicaltrials.gov, requiring a search for the trial.",
        "**Planning clinical summary structure**\n\nI'm setting up a clear decision framework with action items and defined evidence levels (e.g., High, Moderate) avoiding nested bullets and raw URLs. I'll emphasize uncertainty, date the summary as of Feb 19, 2026, and clarify it's educational, not medical advice. I'll include citations for each fact, favoring PubMed or authoritative journals like JAMA over secondary sources.",
        "**Preparing PubMed search**",
        "**Outlining evidence levels and key BRCA1 facts**\n\nI'm defining evidence levels A (guidelines/meta-analyses), B (cohort/observational), and C (mechanistic/early trials) to structure the response. I'll include key points on BRCA1 frameshift effects, Ashkenazi founder variants, DNA repair roles, associated cancer features, and recommended risk-reducing surgeries with cited research.",
        "**Clarifying risk reduction and screening evidence**\n\nI'll phrase risk reduction from RRBM as 90% consistent with HR 0.07 from meta-analysis and cautiously mention reduced mortality per 2024 data. Screening recommendations will cite 2024 NCCN-based StatPearls tables, noting annual MRI and mammography timings. I'll address pancreatic screening cautiously using CAPS consensus, emphasizing familial risk criteria without overstating BRCA1 specifics.",
        "**Clarifying pancreatic screening criteria**\n\nNoting pancreatic screening uses MRI/MRCP and EUS with CAPS citing; confirming CAPS recommends surveillance only for high-risk individuals with familial/genetic criteria, typically needing a pathogenic mutation plus family history. Checking CAPS for explicit mention of BRCA1 to verify if surveillance applies.",
        "**Refining risk and prevention details**\n\nI'm updating pancreatic cancer risk to \"up to 5% lifetime\" per NCI to avoid conflict with earlier 2.2%. I'll note RRSO's unclear breast cancer risk reduction, mention early salpingectomy with delayed oophorectomy as investigational citing ClinicalTrials, and clarify tamoxifen/raloxifene reduces ER+ risk but benefits in BRCA1 are less certain, citing the contralateral risk study. I'll also include that OCP reduces ovarian cancer risk per NCI.",
        "**Planning comprehensive BRCA1 summary**\n\nI'm outlining a detailed, citation-heavy structured summary covering variant details, molecular mechanisms, risk estimates, pathology, prevention/surveillance, treatment options, decision framework for a 35-year-old carrier, uncertainties, and family implications with evidence levels and explicit citation placement after statements."
      ],
      "web_searches": [
        {
          "id": "ws_0e9439ec4789c786016996be731a0c819eb78244d0921ce8de",
          "query": "ClinVar BRCA1 c.68_69delAG 185delAG p.Glu23Valfs*17 RCV000034761",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996be784760819e823a87d5599ffaa8",
          "query": "NCI BRCA gene changes: cancer risk and genetic testing fact sheet homologous recombination DNA repair PARP inhibitors",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996be7be994819eb35e47a201793e9b",
          "query": "BRCA1-associated breast cancers triple negative basal-like high grade medullary features review",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996be8017d4819eaa8b43a77f20f4b2",
          "query": "BRCA1-associated breast cancer basal-like triple-negative high grade medullary features review PMC 2018",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996be85167c819e843ea4aa04cf449a",
          "query": "BRCA1-associated breast cancer basal-like cytokeratin 5/6 EGFR medullary histology review PMC 2018 BRCA1 tumors high grade",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996be88782c819eb0abaeec03040435",
          "query": "FDA approves olaparib adjuvant treatment high-risk early breast cancer germline BRCA HER2-negative OlympiA 2022 FDA press release",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996be8cb318819e990a7cbde39a3d42",
          "query": "FDA approves olaparib adjuvant high-risk early breast cancer germline BRCA HER2-negative FDA 2022",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996be9176fc819eb208de8d548ec510",
          "query": "site:fda.gov olaparib adjuvant high-risk early breast cancer March 11 2022 FDA approves",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996be961bec819ebcf632f7f6449025",
          "query": "FDA approves olaparib maintenance treatment ovarian cancer 2018 tablets maintenance after platinum response",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996be992774819eaedee0a8ac9f43d5",
          "query": "FDA approves olaparib tablets maintenance treatment ovarian cancer 2018 2017 platinum response FDA resources information approved drugs",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996be9e0758819eafcb4bd579c084d1",
          "query": "\"FDA approves\" olaparib adjuvant high-risk early breast cancer germline BRCA HER2-negative \"resources-information-approved-drugs\"",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996beac2e60819e9335309ff8cdf4d2",
          "query": "GeneReviews BRCA1- and BRCA2-associated hereditary breast and ovarian cancer autosomal dominant 50% risk to offspring",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996beb3ddc4819e8fce6151fedddc8a",
          "query": "NCT04294927 salpingectomy with delayed oophorectomy BRCA1 trial TUBA or WISP clinicaltrials.gov",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996bebade80819eac4882b4916821de",
          "query": "Antoniou JAMA 2017 317 2402-2416 breast and ovarian cancer risks BRCA1 to age 80 PubMed 28632866",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996becb1e00819e9aa5e22abf59661f",
          "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/",
          "results": []
        },
        {
          "id": "ws_0e9439ec4789c786016996bece60e0819e9a0b5ebf592a8e52",
          "query": "'BRCA1' in https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/",
          "results": []
        }
      ],
      "command_executions": [
        {
          "id": "item_1",
          "command": "/bin/zsh -lc ls",
          "output": "README.md\nexamples\noutput\npyproject.toml\nsrc\n",
          "exit_code": 0
        },
        {
          "id": "item_3",
          "command": "/bin/zsh -lc 'cat /Users/lingzhi/.codex/skills/web-search/SKILL.md'",
          "output": "---\nname: web-search\ndescription: Search and browse the public web from Codex CLI (联网搜索/查网页/找资料/给链接/带出处). Use when you need up-to-date info or answers that must cite web sources.\n---\n\n# Web Search (联网搜索)\n\nThis skill provides a repeatable workflow to search the web, optionally fetch page text, and answer with sources.\n\n## Quick start\n\n- Search:\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --format md`\n- Search + fetch page text (for evidence):\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --fetch --format md`\n\n## Providers (auto)\n\nThe script picks the first available provider:\n\n- **Tavily**: set `TAVILY_API_KEY`\n- **Serper**: set `SERPER_API_KEY`\n- **Brave**: set `BRAVE_API_KEY` (or `BRAVE_SEARCH_API_KEY`)\n- **Fallback**: DuckDuckGo HTML scrape (best-effort; may break)\n\n## Workflow\n\n- Clarify what must be looked up and what must be cited.\n- Run the search script; pick 3–5 sources.\n- If a claim is important/controversial, re-run with `--fetch` and quote specific lines from sources.\n- In the final answer:\n  - Include a **Sources** list with URLs.\n  - Never invent citations; if evidence is missing, say so.\n\n## Notes\n\n- This skill uses network access. In restricted network/sandbox modes, request escalation before running the script.\n",
          "exit_code": 0
        }
      ],
      "final_output": "**Executive Summary**  \nAs of Feb 19, 2026: This patient carries the pathogenic BRCA1 c.68_69delAG (185delAG) Ashkenazi founder variant, a frameshift (p.Glu23Valfs*17) that truncates BRCA1 and causes loss of function. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV000034761/?utm_source=openai))  \nLoss of BRCA1 impairs homologous recombination (HR) DNA repair, driving genomic instability and creating sensitivity to DNA‑damaging agents (platinum) and PARP inhibitors. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \nProspective data show cumulative risks to age 80 of ~72% for breast cancer and ~44% for ovarian/fallopian/peritoneal cancer; risk rises further with family history. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))  \nBRCA1 cancers are frequently triple‑negative/basal‑like; high‑grade serous tubo‑ovarian cancers often arise from fallopian tube STIC precursors. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \nHighest‑impact risk‑reduction strategies are risk‑reducing salpingo‑oophorectomy (RRSO) at 35–40 after childbearing and risk‑reducing bilateral mastectomy (RRBM), both associated with large risk reductions. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10278568/?utm_source=openai))  \nPancreatic surveillance for BRCA1 carriers remains evolving; CAPS supports surveillance for BRCA1 carriers with specific family‑history criteria, typically using MRI/MRCP and/or EUS. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/))  \n\n**1. Variant & Molecular Genetics**  \nThe BRCA1 c.68_69delAG (185delAG) is a frameshift variant that introduces a premature stop (p.Glu23Valfs*17), predicted to result in absent or truncated protein; ClinVar classifies it as pathogenic and it is a well‑known Ashkenazi Jewish founder variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV000034761/?utm_source=openai))  \nFounder BRCA mutations are enriched in Ashkenazi Jewish populations; about 2% of individuals carry one of three founder mutations. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \n\n**2. Mechanism: From BRCA1 Loss to Cancer Biology**  \nBRCA1 is a core HR DNA repair gene. Loss of BRCA1 function causes HR deficiency, leading to genomic instability and malignant transformation. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \nHR‑deficient tumors are more sensitive to DNA‑damaging chemotherapy (e.g., platinum) and to PARP inhibition (synthetic lethality). ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \n\n**3. Cancer Risk Profile & Expected Pathology**  \nBreast cancer risk to age 80 is ~72% for BRCA1 carriers, and ovarian/fallopian/peritoneal cancer risk is ~44%; breast risk increases with more affected relatives, which applies here. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))  \nBRCA1‑associated breast cancers are more likely to be triple‑negative and basal‑like, and medullary‑like features are enriched. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \nBRCA1‑associated tubo‑ovarian cancers are typically high‑grade serous; STIC lesions in the fallopian tube are a recognized precursor and are found in ~40–60% of advanced HGSC. ([nature.com](https://www.nature.com/articles/s41467-017-01217-9?utm_source=openai))  \nOther cancers: pancreatic risk is elevated in BRCA1 (up to ~5% lifetime per NCI). ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \n\n**4. Evidence‑Based Prevention & Surveillance**  \n\nBreast surveillance (high‑risk, NCCN‑based public summaries)  \nAnnual breast MRI and annual mammography with clinical encounter every 6–12 months are recommended for high‑risk women (≥20% lifetime risk), which includes BRCA1 carriers. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK556050/table/article-18569.table0/?utm_source=openai))  \n\nOvarian/fallopian/peritoneal risk reduction  \nRRSO is recommended by NCCN/ACOG/SGO typically between ages 35–40 for BRCA1 after childbearing; RRSO reduces ovarian cancer incidence by ~80%. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10278568/?utm_source=openai))  \nIf RRSO is deferred, salpingectomy with delayed oophorectomy remains investigational; ongoing trials (e.g., TUBA‑WISP II) are evaluating safety and cancer incidence. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04294927?utm_source=openai))  \n\nOvarian screening (if deferring RRSO)  \nCA‑125 and transvaginal ultrasound have not shown mortality benefit and cause substantial false‑positive harms; if used, this should be with explicit counseling about limitations. ([uspreventiveservicestaskforce.org](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/ovarian-cancer-screening?utm_source=openai))  \n\nPancreatic surveillance  \nCAPS recommends pancreatic surveillance for carriers of BRCA1 with defined familial risk criteria; age to start is often around 45–50 or 10 years earlier than the youngest affected relative. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/))  \nFirst‑line surveillance modalities are MRI/MRCP and/or EUS, with CT reserved for those unable to undergo MRI/EUS. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/))  \n\nChemoprevention and hormonal strategies  \nOral contraceptives are associated with reduced ovarian cancer risk in BRCA carriers; counseling should include risks and alternatives. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \nTamoxifen reduces contralateral breast cancer risk in BRCA1/2 carriers with prior breast cancer, but benefit for primary prevention in unaffected BRCA1 carriers is less certain given the predominance of ER‑negative disease. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11130383/?utm_source=openai))  \n\nEmerging screening  \nMulti‑cancer early detection (MCD) blood tests are not FDA‑approved and do not replace standard screening. ([cancer.org](https://www.cancer.org/cancer/screening/multi-cancer-early-detection-tests.html?utm_source=openai))  \n\n**5. Treatment Rationale & Options if Cancer Develops (FDA‑Approved)**  \n\nBreast cancer (HER2‑negative, gBRCA)  \nAdjuvant olaparib is FDA‑approved for high‑risk early HER2‑negative gBRCA breast cancer after (neo)adjuvant chemotherapy. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer?utm_source=openai))  \nMetastatic HER2‑negative gBRCA breast cancer: olaparib and talazoparib are FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer?utm_source=openai))  \nHigh‑risk early TNBC: pembrolizumab with neoadjuvant chemotherapy followed by adjuvant pembrolizumab is FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer?utm_source=openai))  \nMetastatic TNBC after ≥2 prior lines: sacituzumab govitecan is FDA‑approved. ([gilead.com](https://www.gilead.com/news/news-details/2021/fda-approves-trodelvy-the-first-treatment-for-metastatic-triple-negative-breast-cancer-shown-to-improve-progression-free-survival-and-overall-survival?utm_source=openai))  \nHR‑positive, HER2‑low/ultralow metastatic disease: trastuzumab deruxtecan is FDA‑approved after progression on endocrine therapy. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2?utm_source=openai))  \n\nOvarian/fallopian/peritoneal cancer  \nPARP maintenance after response to platinum chemotherapy: olaparib (maintenance), niraparib (first‑line maintenance), and rucaparib (maintenance in recurrent settings) are FDA‑approved in relevant settings. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer?utm_source=openai))  \nOlaparib plus bevacizumab is FDA‑approved for HRD‑positive first‑line maintenance. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary?utm_source=openai))  \nFRα‑positive platinum‑resistant disease: mirvetuximab soravtansine is FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian?utm_source=openai))  \n\nPancreatic cancer  \nFor gBRCA metastatic pancreatic cancer after ≥16 weeks of platinum without progression, olaparib maintenance is FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-gbrcam-metastatic-pancreatic-adenocarcinoma?utm_source=openai))  \n\n**6. Decision Framework for This 35‑Year‑Old Unaffected BRCA1 Carrier**  \n\n**Evidence Level Key**  \nLevel A: Guidelines/meta‑analyses/phase III trials  \nLevel B: Prospective/observational cohorts  \nLevel C: Mechanistic studies/consensus/early trials  \n\n**Critical Action Items**  \n1. Confirm and document BRCA1 pathogenic variant and ensure genetic counseling is in place. Evidence: A. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV000034761/?utm_source=openai))  \n2. Breast surveillance now: annual MRI + annual mammography with clinical encounter every 6–12 months. Evidence: A/B. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK556050/table/article-18569.table0/?utm_source=openai))  \n3. Discuss RRBM as the strongest breast‑risk‑reduction strategy; meta‑analysis shows profound risk reduction (HR ~0.07). Evidence: A. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25808098/?utm_source=openai))  \n4. Plan RRSO between 35–40 after childbearing to reduce ovarian cancer risk by ~80%. Evidence: A. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10278568/?utm_source=openai))  \n5. If deferring RRSO, consider clinical trial enrollment for salpingectomy with delayed oophorectomy; emphasize investigational status. Evidence: C. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04294927?utm_source=openai))  \n6. Evaluate pancreatic surveillance only if CAPS criteria are met, with MRI/MRCP and/or EUS. Evidence: B/C. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/))  \n\n**7. Uncertainties & Evolving Evidence**  \nPancreatic surveillance criteria for BRCA1 carriers remain an area of ongoing debate in CAPS; family‑history thresholds and start age vary across centers. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/))  \nSalpingectomy with delayed oophorectomy is investigational; long‑term ovarian cancer prevention equivalence is not yet proven. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04294927?utm_source=openai))  \nMCD blood tests are not FDA‑approved and should not replace standard screening. ([cancer.org](https://www.cancer.org/cancer/screening/multi-cancer-early-detection-tests.html?utm_source=openai))  \n\n**8. Family Implications**  \nInheritance is autosomal dominant; each child has a 50% chance of inheriting the variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/sites/books/NBK1247/?utm_source=openai))  \nPGT‑M is an accepted, optional reproductive option; counseling should be nondirective and discuss alternatives. ([asrm.org](https://www.asrm.org/practice-guidance/practice-committee-documents/indications-and-management-of-preimplantation-genetic-testing-for-monogenic-conditions-a-committee-opinion-2023/?utm_source=openai))  \n\nIf you want, I can convert this into a one‑page clinician decision summary or a patient‑facing counseling handout tailored to her reproductive plans, risk tolerance, and preferred timing for surgery.",
      "usage": {
        "input_tokens": 106177,
        "cached_input_tokens": 30336,
        "output_tokens": 10845
      },
      "error": null,
      "step": 5,
      "raw_event_count": 64,
      "raw_events_by_type": {
        "thread.started": [
          {
            "type": "thread.started",
            "thread_id": "019c74d7-a516-7772-b33d-81af12a41856"
          }
        ],
        "turn.started": [
          {
            "type": "turn.started"
          }
        ],
        "item.completed": [
          {
            "type": "item.completed",
            "item": {
              "id": "item_0",
              "type": "reasoning",
              "text": "**Confirming web-search skill use**\n\nI'm verifying that the web-search skill is appropriate for providing up-to-date citations and will read the SKILL.md file to confirm usage details."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_1",
              "type": "command_execution",
              "command": "/bin/zsh -lc ls",
              "aggregated_output": "README.md\nexamples\noutput\npyproject.toml\nsrc\n",
              "exit_code": 0,
              "status": "completed"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_2",
              "type": "reasoning",
              "text": "**Noting missing skill file**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_3",
              "type": "command_execution",
              "command": "/bin/zsh -lc 'cat /Users/lingzhi/.codex/skills/web-search/SKILL.md'",
              "aggregated_output": "---\nname: web-search\ndescription: Search and browse the public web from Codex CLI (联网搜索/查网页/找资料/给链接/带出处). Use when you need up-to-date info or answers that must cite web sources.\n---\n\n# Web Search (联网搜索)\n\nThis skill provides a repeatable workflow to search the web, optionally fetch page text, and answer with sources.\n\n## Quick start\n\n- Search:\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --format md`\n- Search + fetch page text (for evidence):\n  - `python3 scripts/web_search.py --query \"...\" --k 5 --fetch --format md`\n\n## Providers (auto)\n\nThe script picks the first available provider:\n\n- **Tavily**: set `TAVILY_API_KEY`\n- **Serper**: set `SERPER_API_KEY`\n- **Brave**: set `BRAVE_API_KEY` (or `BRAVE_SEARCH_API_KEY`)\n- **Fallback**: DuckDuckGo HTML scrape (best-effort; may break)\n\n## Workflow\n\n- Clarify what must be looked up and what must be cited.\n- Run the search script; pick 3–5 sources.\n- If a claim is important/controversial, re-run with `--fetch` and quote specific lines from sources.\n- In the final answer:\n  - Include a **Sources** list with URLs.\n  - Never invent citations; if evidence is missing, say so.\n\n## Notes\n\n- This skill uses network access. In restricted network/sandbox modes, request escalation before running the script.\n",
              "exit_code": 0,
              "status": "completed"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_4",
              "type": "reasoning",
              "text": "**Deciding to use web.run for up-to-date data**\n\nDue to network restrictions and skill instructions, I'll rely on web.run to fetch current sources on BRCA1 and relevant 2026 guidelines and approvals, ensuring to cite these updated web references properly."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_5",
              "type": "reasoning",
              "text": "**Planning multi-call web.run searches for comprehensive citations**\n\nI'll perform multiple web.run calls with targeted queries to gather diverse, high-quality sources covering BRCA mutation details, risk estimates, surveillance guidelines, and up-to-date FDA approvals, ensuring thorough citations without exceeding source limits."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996be731a0c819eb78244d0921ce8de",
              "type": "web_search",
              "query": "ClinVar BRCA1 c.68_69delAG 185delAG p.Glu23Valfs*17 RCV000034761",
              "action": {
                "type": "search",
                "query": "ClinVar BRCA1 c.68_69delAG 185delAG p.Glu23Valfs*17 RCV000034761",
                "queries": [
                  "ClinVar BRCA1 c.68_69delAG 185delAG p.Glu23Valfs*17 RCV000034761",
                  "NCI BRCA gene changes cancer risk fact sheet BRCA1 homologous recombination PARP inhibitor sensitivity",
                  "BRCA1 lifetime breast ovarian cancer risk to age 80 72% 44% study 2017 NEJM/JAMA",
                  "ACOG executive summary ovarian cancer evidence review NCCN BRCA1 risk-reducing salpingo-oophorectomy age 35 40"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_7",
              "type": "reasoning",
              "text": "**Planning authoritative source search**\n\nI'm preparing to find key authoritative sources like the NCI BRCA fact sheet, USPSTF ovarian screening guidelines, CAPS pancreatic recommendations, ACS MCED info, FDA approvals, and pathology features for basal-like triple-negative cases to enrich the evidence base."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996be784760819e823a87d5599ffaa8",
              "type": "web_search",
              "query": "NCI BRCA gene changes: cancer risk and genetic testing fact sheet homologous recombination DNA repair PARP inhibitors",
              "action": {
                "type": "search",
                "query": "NCI BRCA gene changes: cancer risk and genetic testing fact sheet homologous recombination DNA repair PARP inhibitors",
                "queries": [
                  "NCI BRCA gene changes: cancer risk and genetic testing fact sheet homologous recombination DNA repair PARP inhibitors",
                  "USPSTF ovarian cancer screening recommendation transvaginal ultrasound CA-125 harms no mortality benefit 2018",
                  "CAPS consortium pancreatic cancer screening BRCA1 first-degree relative MRI EUS 2019 2020 consensus",
                  "American Cancer Society multi-cancer early detection tests not FDA approved not recommended for routine screening"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_9",
              "type": "reasoning",
              "text": "**Planning to gather pathology sources**\n\nI'm looking for review articles on triple-negative, basal-like, medullary, and HGSOC STIC pathology to support the research."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996be7be994819eb35e47a201793e9b",
              "type": "web_search",
              "query": "BRCA1-associated breast cancers triple negative basal-like high grade medullary features review",
              "action": {
                "type": "search",
                "query": "BRCA1-associated breast cancers triple negative basal-like high grade medullary features review",
                "queries": [
                  "BRCA1-associated breast cancers triple negative basal-like high grade medullary features review",
                  "serous tubal intraepithelial carcinoma STIC precursor high-grade serous ovarian carcinoma percentage found in risk-reducing salpingo-oophorectomy",
                  "CAPS consortium 2019 pancreatic screening guidelines BRCA1 first-degree relative MRI MRCP EUS age 50",
                  "risk-reducing mastectomy BRCA1 90 95% risk reduction meta-analysis"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_11",
              "type": "reasoning",
              "text": "**Searching for BRCA1 breast cancer path features**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996be8017d4819eaa8b43a77f20f4b2",
              "type": "web_search",
              "query": "BRCA1-associated breast cancer basal-like triple-negative high grade medullary features review PMC 2018",
              "action": {
                "type": "search",
                "query": "BRCA1-associated breast cancer basal-like triple-negative high grade medullary features review PMC 2018",
                "queries": [
                  "BRCA1-associated breast cancer basal-like triple-negative high grade medullary features review PMC 2018",
                  "BRCA1 tumors are frequently triple negative basal-like cytokeratin 5/6 EGFR medullary features review",
                  "NCCN-based breast screening BRCA1 annual MRI age 25 mammography age 30 clinical breast exam 6-12 months",
                  "tamoxifen risk reduction BRCA1 carriers contralateral breast cancer evidence"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_13",
              "type": "reasoning",
              "text": "**Searching for authoritative triple-negative sources**\n\nI'm looking at the NCI fact sheet's triple-negative link as a potential source but need additional info on basal-like high-grade medullary features, so I'll search for a relevant review on PMC."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996be85167c819e843ea4aa04cf449a",
              "type": "web_search",
              "query": "BRCA1-associated breast cancer basal-like cytokeratin 5/6 EGFR medullary histology review PMC 2018 BRCA1 tumors high grade",
              "action": {
                "type": "search",
                "query": "BRCA1-associated breast cancer basal-like cytokeratin 5/6 EGFR medullary histology review PMC 2018 BRCA1 tumors high grade",
                "queries": [
                  "BRCA1-associated breast cancer basal-like cytokeratin 5/6 EGFR medullary histology review PMC 2018 BRCA1 tumors high grade",
                  "BRCA1 breast cancer pathology high grade basal-like medullary features review PMC 2018 2019",
                  "BRCA1 mutation triple negative basal-like breast cancer review 2018 PMC 6117459",
                  "BRCA1-associated breast cancer triple-negative medullary features pathologic review 'PMC' 2017"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_15",
              "type": "reasoning",
              "text": "**Searching for FDA approval pages**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996be88782c819eb0abaeec03040435",
              "type": "web_search",
              "query": "FDA approves olaparib adjuvant treatment high-risk early breast cancer germline BRCA HER2-negative OlympiA 2022 FDA press release",
              "action": {
                "type": "search",
                "query": "FDA approves olaparib adjuvant treatment high-risk early breast cancer germline BRCA HER2-negative OlympiA 2022 FDA press release",
                "queries": [
                  "FDA approves olaparib adjuvant treatment high-risk early breast cancer germline BRCA HER2-negative OlympiA 2022 FDA press release",
                  "FDA approves talazoparib germline BRCA mutated HER2-negative metastatic breast cancer EMBRACA",
                  "FDA approves pembrolizumab neoadjuvant and adjuvant high-risk early-stage triple-negative breast cancer 2021 2022",
                  "FDA approves sacituzumab govitecan metastatic triple-negative breast cancer after two prior therapies 2021"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_17",
              "type": "reasoning",
              "text": "**Searching FDA for olaparib approvals**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996be8cb318819e990a7cbde39a3d42",
              "type": "web_search",
              "query": "FDA approves olaparib adjuvant high-risk early breast cancer germline BRCA HER2-negative FDA 2022",
              "action": {
                "type": "search",
                "query": "FDA approves olaparib adjuvant high-risk early breast cancer germline BRCA HER2-negative FDA 2022",
                "queries": [
                  "FDA approves olaparib adjuvant high-risk early breast cancer germline BRCA HER2-negative FDA 2022",
                  "FDA approves olaparib germline BRCA metastatic breast cancer OlympiAD 2018 FDA",
                  "FDA approves talazoparib germline BRCA HER2-negative metastatic breast cancer FDA 2018",
                  "FDA approves trastuzumab deruxtecan HER2-low HR-positive metastatic breast cancer 2022 FDA"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_19",
              "type": "reasoning",
              "text": "**Searching for FDA page on olaparib adjuvant**\n\nI'm not finding a specific FDA page for olaparib adjuvant but found an FDA press release mentioning it; I'll search further to confirm its official presence."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996be9176fc819eb208de8d548ec510",
              "type": "web_search",
              "query": "site:fda.gov olaparib adjuvant high-risk early breast cancer March 11 2022 FDA approves",
              "action": {
                "type": "search",
                "query": "site:fda.gov olaparib adjuvant high-risk early breast cancer March 11 2022 FDA approves",
                "queries": [
                  "site:fda.gov olaparib adjuvant high-risk early breast cancer March 11 2022 FDA approves",
                  "FDA approves olaparib for germline BRCA mutated metastatic breast cancer 2018 FDA press release",
                  "FDA approves olaparib maintenance ovarian cancer first line 2018 2019 FDA",
                  "FDA approves niraparib first-line maintenance ovarian cancer 2020"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_21",
              "type": "reasoning",
              "text": "**Listing FDA approvals to verify**\n\nI need to verify FDA approvals for olaparib and rucaparib maintenance in ovarian cancer, mirvetuximab approvals in 2022/2024, and olaparib maintenance in pancreatic cancer (POLO). Next, I’ll search to confirm these dates."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996be961bec819ebcf632f7f6449025",
              "type": "web_search",
              "query": "FDA approves olaparib maintenance treatment ovarian cancer 2018 tablets maintenance after platinum response",
              "action": {
                "type": "search",
                "query": "FDA approves olaparib maintenance treatment ovarian cancer 2018 tablets maintenance after platinum response",
                "queries": [
                  "FDA approves olaparib maintenance treatment ovarian cancer 2018 tablets maintenance after platinum response",
                  "FDA approves rucaparib maintenance recurrent ovarian cancer 2018",
                  "FDA approves mirvetuximab soravtansine-gynx FRalpha-positive platinum-resistant ovarian cancer 2022 2024",
                  "FDA approves olaparib maintenance gBRCA metastatic pancreatic cancer POLO 2019"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_23",
              "type": "reasoning",
              "text": "**Searching for FDA page on olaparib maintenance ovarian**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996be992774819eaedee0a8ac9f43d5",
              "type": "web_search",
              "query": "FDA approves olaparib tablets maintenance treatment ovarian cancer 2018 2017 platinum response FDA resources information approved drugs",
              "action": {
                "type": "search",
                "query": "FDA approves olaparib tablets maintenance treatment ovarian cancer 2018 2017 platinum response FDA resources information approved drugs",
                "queries": [
                  "FDA approves olaparib tablets maintenance treatment ovarian cancer 2018 2017 platinum response FDA resources information approved drugs",
                  "FDA approves olaparib maintenance ovarian cancer first-line 2018 SOLO-1",
                  "FDA approves olaparib in combination with bevacizumab maintenance HRD-positive ovarian cancer 2020",
                  "FDA approves rucaparib maintenance recurrent ovarian cancer FDA 2018 resources information approved drugs"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_25",
              "type": "reasoning",
              "text": "**Searching for FDA approval of olaparib in early breast cancer**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996be9e0758819eafcb4bd579c084d1",
              "type": "web_search",
              "query": "\"FDA approves\" olaparib adjuvant high-risk early breast cancer germline BRCA HER2-negative \"resources-information-approved-drugs\"",
              "action": {
                "type": "search",
                "query": "\"FDA approves\" olaparib adjuvant high-risk early breast cancer germline BRCA HER2-negative \"resources-information-approved-drugs\"",
                "queries": [
                  "\"FDA approves\" olaparib adjuvant high-risk early breast cancer germline BRCA HER2-negative \"resources-information-approved-drugs\"",
                  "olaparib adjuvant high-risk early breast cancer FDA approval March 2022 FDA Oncology Center of Excellence",
                  "Lynparza adjuvant early breast cancer FDA \"Drug Approval\" 2022",
                  "\"olaparib\" \"high-risk early breast cancer\" FDA approval 2022 PDF label"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_27",
              "type": "reasoning",
              "text": "**Outlining key ovarian maintenance and screening references**\n\nI'm compiling ovarian maintenance options including FDA-approved drugs and NCI sources, plus surveillance guidelines from NCCN and StatPearls. I'll also cover genetic prevalence, pathogenic variant details, and treatment rationales citing authoritative sources like NCI, ACOG, CAPS, ClinVar, and Nature Communications."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_28",
              "type": "reasoning",
              "text": "**Summarizing risk features and prevention evidence**\n\nI'm detailing BRCA1 tumor traits, mastectomy risk reduction stats, and RRSO timing and effect with ACOG sources. I'll note ovarian cancer risk reduction by contraceptives, screening limitations from USPSTF, MCED test status, pancreatic screening consensus, and family inheritance from GeneReviews."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996beac2e60819e9335309ff8cdf4d2",
              "type": "web_search",
              "query": "GeneReviews BRCA1- and BRCA2-associated hereditary breast and ovarian cancer autosomal dominant 50% risk to offspring",
              "action": {
                "type": "search",
                "query": "GeneReviews BRCA1- and BRCA2-associated hereditary breast and ovarian cancer autosomal dominant 50% risk to offspring",
                "queries": [
                  "GeneReviews BRCA1- and BRCA2-associated hereditary breast and ovarian cancer autosomal dominant 50% risk to offspring",
                  "CDC cascade testing hereditary breast ovarian cancer genetic counseling first-degree relatives",
                  "ASRM committee opinion 2023 preimplantation genetic testing for monogenic conditions PGT-M BRCA"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_30",
              "type": "reasoning",
              "text": "**Refining source selection and key recommendations**\n\nFocusing on high-quality sources like NCI, CDC, GeneReviews, and FDA; planning to reference CDC for cascade testing and family implications optionally, with GeneReviews for risk stats and counseling. Deciding to include RRSO age recommendation from ACOG and note investigational early salpingectomy citing clinicaltrials.gov, requiring a search for the trial."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996beb3ddc4819e8fce6151fedddc8a",
              "type": "web_search",
              "query": "NCT04294927 salpingectomy with delayed oophorectomy BRCA1 trial TUBA or WISP clinicaltrials.gov",
              "action": {
                "type": "search",
                "query": "NCT04294927 salpingectomy with delayed oophorectomy BRCA1 trial TUBA or WISP clinicaltrials.gov",
                "queries": [
                  "NCT04294927 salpingectomy with delayed oophorectomy BRCA1 trial TUBA or WISP clinicaltrials.gov",
                  "clinicaltrials.gov risk reducing salpingectomy with delayed oophorectomy BRCA1 NCT04294927"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_32",
              "type": "reasoning",
              "text": "**Planning clinical summary structure**\n\nI'm setting up a clear decision framework with action items and defined evidence levels (e.g., High, Moderate) avoiding nested bullets and raw URLs. I'll emphasize uncertainty, date the summary as of Feb 19, 2026, and clarify it's educational, not medical advice. I'll include citations for each fact, favoring PubMed or authoritative journals like JAMA over secondary sources."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_33",
              "type": "reasoning",
              "text": "**Preparing PubMed search**"
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996bebade80819eac4882b4916821de",
              "type": "web_search",
              "query": "Antoniou JAMA 2017 317 2402-2416 breast and ovarian cancer risks BRCA1 to age 80 PubMed 28632866",
              "action": {
                "type": "search",
                "query": "Antoniou JAMA 2017 317 2402-2416 breast and ovarian cancer risks BRCA1 to age 80 PubMed 28632866",
                "queries": [
                  "Antoniou JAMA 2017 317 2402-2416 breast and ovarian cancer risks BRCA1 to age 80 PubMed 28632866",
                  "PubMed 28632866 BRCA1 breast ovarian cancer risk age 80"
                ]
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_35",
              "type": "reasoning",
              "text": "**Outlining evidence levels and key BRCA1 facts**\n\nI'm defining evidence levels A (guidelines/meta-analyses), B (cohort/observational), and C (mechanistic/early trials) to structure the response. I'll include key points on BRCA1 frameshift effects, Ashkenazi founder variants, DNA repair roles, associated cancer features, and recommended risk-reducing surgeries with cited research."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_36",
              "type": "reasoning",
              "text": "**Clarifying risk reduction and screening evidence**\n\nI'll phrase risk reduction from RRBM as 90% consistent with HR 0.07 from meta-analysis and cautiously mention reduced mortality per 2024 data. Screening recommendations will cite 2024 NCCN-based StatPearls tables, noting annual MRI and mammography timings. I'll address pancreatic screening cautiously using CAPS consensus, emphasizing familial risk criteria without overstating BRCA1 specifics."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996becb1e00819e9aa5e22abf59661f",
              "type": "web_search",
              "query": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/",
              "action": {
                "type": "open_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_38",
              "type": "reasoning",
              "text": "**Clarifying pancreatic screening criteria**\n\nNoting pancreatic screening uses MRI/MRCP and EUS with CAPS citing; confirming CAPS recommends surveillance only for high-risk individuals with familial/genetic criteria, typically needing a pathogenic mutation plus family history. Checking CAPS for explicit mention of BRCA1 to verify if surveillance applies."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "ws_0e9439ec4789c786016996bece60e0819e9a0b5ebf592a8e52",
              "type": "web_search",
              "query": "'BRCA1' in https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/",
              "action": {
                "type": "find_in_page",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/",
                "pattern": "BRCA1"
              }
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_40",
              "type": "reasoning",
              "text": "**Refining risk and prevention details**\n\nI'm updating pancreatic cancer risk to \"up to 5% lifetime\" per NCI to avoid conflict with earlier 2.2%. I'll note RRSO's unclear breast cancer risk reduction, mention early salpingectomy with delayed oophorectomy as investigational citing ClinicalTrials, and clarify tamoxifen/raloxifene reduces ER+ risk but benefits in BRCA1 are less certain, citing the contralateral risk study. I'll also include that OCP reduces ovarian cancer risk per NCI."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_41",
              "type": "reasoning",
              "text": "**Planning comprehensive BRCA1 summary**\n\nI'm outlining a detailed, citation-heavy structured summary covering variant details, molecular mechanisms, risk estimates, pathology, prevention/surveillance, treatment options, decision framework for a 35-year-old carrier, uncertainties, and family implications with evidence levels and explicit citation placement after statements."
            }
          },
          {
            "type": "item.completed",
            "item": {
              "id": "item_42",
              "type": "agent_message",
              "text": "**Executive Summary**  \nAs of Feb 19, 2026: This patient carries the pathogenic BRCA1 c.68_69delAG (185delAG) Ashkenazi founder variant, a frameshift (p.Glu23Valfs*17) that truncates BRCA1 and causes loss of function. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV000034761/?utm_source=openai))  \nLoss of BRCA1 impairs homologous recombination (HR) DNA repair, driving genomic instability and creating sensitivity to DNA‑damaging agents (platinum) and PARP inhibitors. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \nProspective data show cumulative risks to age 80 of ~72% for breast cancer and ~44% for ovarian/fallopian/peritoneal cancer; risk rises further with family history. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))  \nBRCA1 cancers are frequently triple‑negative/basal‑like; high‑grade serous tubo‑ovarian cancers often arise from fallopian tube STIC precursors. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \nHighest‑impact risk‑reduction strategies are risk‑reducing salpingo‑oophorectomy (RRSO) at 35–40 after childbearing and risk‑reducing bilateral mastectomy (RRBM), both associated with large risk reductions. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10278568/?utm_source=openai))  \nPancreatic surveillance for BRCA1 carriers remains evolving; CAPS supports surveillance for BRCA1 carriers with specific family‑history criteria, typically using MRI/MRCP and/or EUS. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/))  \n\n**1. Variant & Molecular Genetics**  \nThe BRCA1 c.68_69delAG (185delAG) is a frameshift variant that introduces a premature stop (p.Glu23Valfs*17), predicted to result in absent or truncated protein; ClinVar classifies it as pathogenic and it is a well‑known Ashkenazi Jewish founder variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV000034761/?utm_source=openai))  \nFounder BRCA mutations are enriched in Ashkenazi Jewish populations; about 2% of individuals carry one of three founder mutations. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \n\n**2. Mechanism: From BRCA1 Loss to Cancer Biology**  \nBRCA1 is a core HR DNA repair gene. Loss of BRCA1 function causes HR deficiency, leading to genomic instability and malignant transformation. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \nHR‑deficient tumors are more sensitive to DNA‑damaging chemotherapy (e.g., platinum) and to PARP inhibition (synthetic lethality). ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \n\n**3. Cancer Risk Profile & Expected Pathology**  \nBreast cancer risk to age 80 is ~72% for BRCA1 carriers, and ovarian/fallopian/peritoneal cancer risk is ~44%; breast risk increases with more affected relatives, which applies here. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/28632866/?utm_source=openai))  \nBRCA1‑associated breast cancers are more likely to be triple‑negative and basal‑like, and medullary‑like features are enriched. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \nBRCA1‑associated tubo‑ovarian cancers are typically high‑grade serous; STIC lesions in the fallopian tube are a recognized precursor and are found in ~40–60% of advanced HGSC. ([nature.com](https://www.nature.com/articles/s41467-017-01217-9?utm_source=openai))  \nOther cancers: pancreatic risk is elevated in BRCA1 (up to ~5% lifetime per NCI). ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \n\n**4. Evidence‑Based Prevention & Surveillance**  \n\nBreast surveillance (high‑risk, NCCN‑based public summaries)  \nAnnual breast MRI and annual mammography with clinical encounter every 6–12 months are recommended for high‑risk women (≥20% lifetime risk), which includes BRCA1 carriers. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK556050/table/article-18569.table0/?utm_source=openai))  \n\nOvarian/fallopian/peritoneal risk reduction  \nRRSO is recommended by NCCN/ACOG/SGO typically between ages 35–40 for BRCA1 after childbearing; RRSO reduces ovarian cancer incidence by ~80%. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10278568/?utm_source=openai))  \nIf RRSO is deferred, salpingectomy with delayed oophorectomy remains investigational; ongoing trials (e.g., TUBA‑WISP II) are evaluating safety and cancer incidence. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04294927?utm_source=openai))  \n\nOvarian screening (if deferring RRSO)  \nCA‑125 and transvaginal ultrasound have not shown mortality benefit and cause substantial false‑positive harms; if used, this should be with explicit counseling about limitations. ([uspreventiveservicestaskforce.org](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/ovarian-cancer-screening?utm_source=openai))  \n\nPancreatic surveillance  \nCAPS recommends pancreatic surveillance for carriers of BRCA1 with defined familial risk criteria; age to start is often around 45–50 or 10 years earlier than the youngest affected relative. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/))  \nFirst‑line surveillance modalities are MRI/MRCP and/or EUS, with CT reserved for those unable to undergo MRI/EUS. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/))  \n\nChemoprevention and hormonal strategies  \nOral contraceptives are associated with reduced ovarian cancer risk in BRCA carriers; counseling should include risks and alternatives. ([cancer.gov](https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet?utm_source=openai))  \nTamoxifen reduces contralateral breast cancer risk in BRCA1/2 carriers with prior breast cancer, but benefit for primary prevention in unaffected BRCA1 carriers is less certain given the predominance of ER‑negative disease. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11130383/?utm_source=openai))  \n\nEmerging screening  \nMulti‑cancer early detection (MCD) blood tests are not FDA‑approved and do not replace standard screening. ([cancer.org](https://www.cancer.org/cancer/screening/multi-cancer-early-detection-tests.html?utm_source=openai))  \n\n**5. Treatment Rationale & Options if Cancer Develops (FDA‑Approved)**  \n\nBreast cancer (HER2‑negative, gBRCA)  \nAdjuvant olaparib is FDA‑approved for high‑risk early HER2‑negative gBRCA breast cancer after (neo)adjuvant chemotherapy. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer?utm_source=openai))  \nMetastatic HER2‑negative gBRCA breast cancer: olaparib and talazoparib are FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer?utm_source=openai))  \nHigh‑risk early TNBC: pembrolizumab with neoadjuvant chemotherapy followed by adjuvant pembrolizumab is FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer?utm_source=openai))  \nMetastatic TNBC after ≥2 prior lines: sacituzumab govitecan is FDA‑approved. ([gilead.com](https://www.gilead.com/news/news-details/2021/fda-approves-trodelvy-the-first-treatment-for-metastatic-triple-negative-breast-cancer-shown-to-improve-progression-free-survival-and-overall-survival?utm_source=openai))  \nHR‑positive, HER2‑low/ultralow metastatic disease: trastuzumab deruxtecan is FDA‑approved after progression on endocrine therapy. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2?utm_source=openai))  \n\nOvarian/fallopian/peritoneal cancer  \nPARP maintenance after response to platinum chemotherapy: olaparib (maintenance), niraparib (first‑line maintenance), and rucaparib (maintenance in recurrent settings) are FDA‑approved in relevant settings. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-tablets-maintenance-treatment-ovarian-cancer?utm_source=openai))  \nOlaparib plus bevacizumab is FDA‑approved for HRD‑positive first‑line maintenance. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary?utm_source=openai))  \nFRα‑positive platinum‑resistant disease: mirvetuximab soravtansine is FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian?utm_source=openai))  \n\nPancreatic cancer  \nFor gBRCA metastatic pancreatic cancer after ≥16 weeks of platinum without progression, olaparib maintenance is FDA‑approved. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-gbrcam-metastatic-pancreatic-adenocarcinoma?utm_source=openai))  \n\n**6. Decision Framework for This 35‑Year‑Old Unaffected BRCA1 Carrier**  \n\n**Evidence Level Key**  \nLevel A: Guidelines/meta‑analyses/phase III trials  \nLevel B: Prospective/observational cohorts  \nLevel C: Mechanistic studies/consensus/early trials  \n\n**Critical Action Items**  \n1. Confirm and document BRCA1 pathogenic variant and ensure genetic counseling is in place. Evidence: A. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/clinvar/RCV000034761/?utm_source=openai))  \n2. Breast surveillance now: annual MRI + annual mammography with clinical encounter every 6–12 months. Evidence: A/B. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK556050/table/article-18569.table0/?utm_source=openai))  \n3. Discuss RRBM as the strongest breast‑risk‑reduction strategy; meta‑analysis shows profound risk reduction (HR ~0.07). Evidence: A. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25808098/?utm_source=openai))  \n4. Plan RRSO between 35–40 after childbearing to reduce ovarian cancer risk by ~80%. Evidence: A. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10278568/?utm_source=openai))  \n5. If deferring RRSO, consider clinical trial enrollment for salpingectomy with delayed oophorectomy; emphasize investigational status. Evidence: C. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04294927?utm_source=openai))  \n6. Evaluate pancreatic surveillance only if CAPS criteria are met, with MRI/MRCP and/or EUS. Evidence: B/C. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/))  \n\n**7. Uncertainties & Evolving Evidence**  \nPancreatic surveillance criteria for BRCA1 carriers remain an area of ongoing debate in CAPS; family‑history thresholds and start age vary across centers. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7295005/))  \nSalpingectomy with delayed oophorectomy is investigational; long‑term ovarian cancer prevention equivalence is not yet proven. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04294927?utm_source=openai))  \nMCD blood tests are not FDA‑approved and should not replace standard screening. ([cancer.org](https://www.cancer.org/cancer/screening/multi-cancer-early-detection-tests.html?utm_source=openai))  \n\n**8. Family Implications**  \nInheritance is autosomal dominant; each child has a 50% chance of inheriting the variant. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/sites/books/NBK1247/?utm_source=openai))  \nPGT‑M is an accepted, optional reproductive option; counseling should be nondirective and discuss alternatives. ([asrm.org](https://www.asrm.org/practice-guidance/practice-committee-documents/indications-and-management-of-preimplantation-genetic-testing-for-monogenic-conditions-a-committee-opinion-2023/?utm_source=openai))  \n\nIf you want, I can convert this into a one‑page clinician decision summary or a patient‑facing counseling handout tailored to her reproductive plans, risk tolerance, and preferred timing for surgery."
            }
          }
        ],
        "item.started": [
          {
            "type": "item.started",
            "item": {
              "id": "item_1",
              "type": "command_execution",
              "command": "/bin/zsh -lc ls",
              "aggregated_output": "",
              "exit_code": null,
              "status": "in_progress"
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "item_3",
              "type": "command_execution",
              "command": "/bin/zsh -lc 'cat /Users/lingzhi/.codex/skills/web-search/SKILL.md'",
              "aggregated_output": "",
              "exit_code": null,
              "status": "in_progress"
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996be731a0c819eb78244d0921ce8de",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996be784760819e823a87d5599ffaa8",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996be7be994819eb35e47a201793e9b",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996be8017d4819eaa8b43a77f20f4b2",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996be85167c819e843ea4aa04cf449a",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996be88782c819eb0abaeec03040435",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996be8cb318819e990a7cbde39a3d42",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996be9176fc819eb208de8d548ec510",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996be961bec819ebcf632f7f6449025",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996be992774819eaedee0a8ac9f43d5",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996be9e0758819eafcb4bd579c084d1",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996beac2e60819e9335309ff8cdf4d2",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996beb3ddc4819e8fce6151fedddc8a",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996bebade80819eac4882b4916821de",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996becb1e00819e9aa5e22abf59661f",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          },
          {
            "type": "item.started",
            "item": {
              "id": "ws_0e9439ec4789c786016996bece60e0819e9a0b5ebf592a8e52",
              "type": "web_search",
              "query": "",
              "action": {
                "type": "other"
              }
            }
          }
        ],
        "turn.completed": [
          {
            "type": "turn.completed",
            "usage": {
              "input_tokens": 106177,
              "cached_input_tokens": 30336,
              "output_tokens": 10845
            }
          }
        ]
      }
    }
  ]
}